- Annual and Transition Report (foreign private issuer) (20-F)

Name	Symbol	Market	Type
Citigroup Prfd C	NYSE:CPC	NYSE	Preference Share

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.00	0.00%	8.00				0	01:00:00

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 20-F

(Mark One)

¨	Registration statement pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934

x	Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the fiscal year ended December 31, 2010

¨	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

¨	Shell company report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of event requiring this shell company report

Commission file number 001-34368

Chemspec International Limited

(Exact Name of Registrant as Specified in Its Charter)

Cayman Islands

(Jurisdiction of Incorporation or Organization)

No. 200, Wu Wei Road, Shanghai 200331, People’s Republic of China

(Address of Principal Executive Offices)

Jianhua Yang

No. 200, Wu Wei Road, Shanghai 200331,

People’s Republic of China

Tel: +86 (21) 6363-9090

Fax: +86 (21) 6363-6993

(Name, Telephone, email and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of Each Class

Name of Each Exchange on Which Registered

Ordinary Shares, par value HK$0.01 per share

American Depositary Shares, as evidenced by American Depositary

Receipts, each representing 60 Ordinary Shares

New York Stock Exchange*

Securities registered or to be registered pursuant to Section 12(g) of the Act:

None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

None

Indicate the number of outstanding shares of each of the Issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

2,163,190,740 Ordinary Shares

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ¨ No x

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer ¨		Accelerated filer ¨		Non-accelerated filer x

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP x International Financial Reporting Standards as issued by the International Accounting Standards Board ¨ Other ¨

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ¨ Item 18 ¨

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes ¨ No x

(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12,13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ¨ No ¨

CHEMSPEC INTERNATIONAL LIMITED

FORM 20-F ANNUAL REPORT

FISCAL YEAR ENDED DECEMBER 31, 2010

TABLE OF CONTENTS


			Page
CONVENTIONS THAT APPLY TO THIS ANNUAL REPORT ON FORM 20-F				1

PART I				1

	ITEM 1.	IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS		1

	ITEM 2.	OFFER STATISTICS AND EXPECTED TIMETABLE		1

	ITEM 3.	KEY INFORMATION		1

	ITEM 4.	INFORMATION ON THE COMPANY		34

	ITEM 4A.	UNRESOLVED STAFF COMMENTS		50

	ITEM 5.	OPERATING AND FINANCIAL REVIEW AND PROSPECTS		50

	ITEM 6.	DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES		75

	ITEM 7.	MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS		83

	ITEM 8.	FINANCIAL INFORMATION		85

	ITEM 9.	THE OFFER AND LISTING		86

	ITEM 10.	ADDITIONAL INFORMATION		87

	ITEM 11.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK		95

	ITEM 12.	DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES		96

PART II				98

	ITEM 13.	DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES		98

	ITEM 14.	MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS		98

	ITEM 15.	CONTROLS AND PROCEDURES		98

	ITEM 16A.	AUDIT COMMITTEE FINANCIAL EXPERT		100

	ITEM 16B.	CODE OF ETHICS		100

	ITEM 16C.	PRINCIPAL ACCOUNTANT FEES AND SERVICES		101

	ITEM 16D.	EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES		101

	ITEM 16E.	PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS		101

	ITEM 16F.	CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT		102

	ITEM 16G.	CORPORATE GOVERNANCE		102

PART III				102

	ITEM 17.	FINANCIAL STATEMENTS		102

	ITEM 18.	FINANCIAL STATEMENTS		103

	ITEM 19.	EXHIBITS		103

SIGNATURES				104

CONVENTIONS THAT APPLY TO THIS ANNUAL REPORT ON FORM 20-F

Unless otherwise indicated, references in this annual report on Form 20-F to:

•

“US$” and “U.S. dollars” are to the legal currency of the United States;

•

“ADRs” are to the American depositary receipts, which, if issued, evidence our ADSs;

•

“ADSs” are to our American depositary shares, each of which represents 60 ordinary shares;

•

“CAGR” are to compound annual growth rate;

•

“China” and the “PRC” are to the People’s Republic of China, excluding, for the purposes of annual report only, Taiwan and the special administrative regions of Hong Kong and Macau;

•

“Euro” are to the legal currency of the European Union;

•

“HK$” are to the legal currency of Hong Kong;

•

“ordinary shares” are to our ordinary shares, par value HK$0.01 per share;

•

“RMB” and “Renminbi” are to the legal currency of China;

•

“we,” “us,” “our company” and “our” are to Chemspec International Limited, its predecessor entities and its consolidated subsidiaries; and

•

“TFT-LCD” are to thin film transistor liquid crystal displays.

This annual report includes our audited consolidated financial statements for the years ended December 31, 2008, 2009 and 2010 and as of December 31, 2009 and 2010.

Our ADSs are listed on the New York Stock Exchange under the symbol “CPC.”

PART I

ITEM 1.

IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

Not applicable.

ITEM 2.

OFFER STATISTICS AND EXPECTED TIMETABLE

Not applicable.

ITEM 3.

KEY INFORMATION

A. Selected Financial Data

The following selected consolidated statement of income data (except per ADS data) for the years ended December 31, 2008, 2009 and 2010 and selected consolidated balance sheet data as of December 31, 2009 and 2010 have been derived from our audited consolidated financial statements included elsewhere in this annual report. The following selected consolidated statement of income data for the years ended December 31, 2006 and 2007 and selected consolidated balance sheet data as of December 31, 2006, 2007 and 2008 have been derived from our audited consolidated financial statements, which are not included in this annual report. You should read the selected consolidated financial data in conjunction with our consolidated financial statements included in this annual report and “Item 5. Operating and Financial Review and Prospects.” Our consolidated financial statements are prepared and presented in accordance with United States generally accepted accounting principles, or U.S. GAAP. Our historical results are not necessarily indicative of our results expected for any future periods.


	Year Ended December 31,
	2006			2007			2008(4)			2009			2010			2010
	RMB			RMB			RMB			RMB			RMB			US$
	(in thousands, except share, per share and per ADS data)
Selected Consolidated Statements of Income Data
Sales		580,747			589,349			942,487			820,295			1,082,031			163,944
Gross profit		328,549			332,493			393,944			324,711			417,240			63,218
Selling expenses		(8,798	)		(10,234	)		(11,898	)		(11,245	)		(11,130	)		(1,686	)
General and administrative expenses		(22,714	)		(30,934	)		(58,947	)		(69,871	)		(77,768	)		(11,783	)
Research and development expenses		(18,648	)		(18,169	)		(27,483	)		(30,913	)		(65,679	)		(9,951	)
Income from operations		281,682			273,138			294,490			207,461			266,703			40,410
Foreign currency exchange loss, net		(1,951	)		(2,036	)		(9,514	)		(1,961	)		(3,249	)		(492	)
Earnings before income taxes		279,929			271,615			284,428			205,990			265,225			40,186
Income tax (expense) benefit		(43,902	)		(37,443	)		32,240			(28,838	)		(38,999	)		(5,909	)
Net income		236,027			234,172			316,668			177,152			226,226			34,277
Net (income) loss attributable to noncontrolling interests		519			(132	)		(4,307	)		(4,721	)		(685	)		(104	)
Net income attributable to Chemspec International Limited(1)		236,546			234,040			312,361			172,431			225,541			34,173
Basic earnings per share(1)(2)		RMB 0.13			RMB 0.13			RMB 0.17			RMB 0.09			RMB 0.10			USD 0.02
Diluted earnings per share(1)(2)		RMB 0.13			RMB 0.13			RMB 0.17			RMB 0.09			RMB 0.10			USD 0.02
Basic income per ADS		RMB 7.88			RMB 7.80			RMB 10.41			RMB 5.18			RMB 6.24			USD 0.95
Diluted income per ADS		RMB 7.88			RMB 7.80			RMB 10.40			RMB 5.18			RMB 6.24			USD 0.95
Ordinary shares used in computation:(2)(3)
Basic		1,800,000,000			1,800,000,000			1,800,000,000			1,997,606,762			2,168,517,722			2,168,517,722
Diluted		1,800,000,000			1,800,000,000			1,802,742,035			1,997,606,762			2,169,629,356			2,169,629,356
Cash dividends declared per ordinary share		RMB 0.16			RMB 0.00			—			—			RMB 0.02			USD 0.00
Cash dividends declared per ADS		RMB 9.31			RMB 0.07			—			—			RMB 1.23			USD 0.19
Share-based compensation expense during the relevant period included in:
Selling expenses		—			—			12,210			11,796			150			23
General and administrative expenses		—			—			1,210			483			(1,635	)		(248	)
Research and development expenses		—			—			4,497			3,164			2,984			452

(1)

We have been entitled to certain tax holidays and tax refunds in the past. Without applicable tax holidays, net income attributable to our Company for the years ended December 31, 2008, 2009 and 2010 would have been reduced by RMB104.4 million, RMB26.0 million and RMB 35.5 million (US$5.4 million), respectively, and our basic and fully diluted earnings per share for the years ended December 31, 2008, 2009 and 2010 would have been reduced by RMB0.06, RMB0.01 and RMB 0.02 (US$0.00), respectively. The details of tax refunds we received are as follows:


	Year Ended December 31,
	2006			2007			2008(4)			2009			2010			2010
	RMB			RMB			RMB			RMB			RMB			US$
	(in thousands, except share, per share and per ADS data)
Income tax expense excluding tax refunds		(43,902	)		(37,443	)		(26,527	)		(28,838	)		(38,999	)		(5,909	)
Income tax refunds		—			—			58,767			—			—			—

Income tax (expense) benefit		(43,902	)		(37,443	)		32,240			(28,838	)		(38,999	)		(5,909	)

(2)	All share and per share data have been presented to give retrospective effect to our reorganization.

(3)

Our company issued 1,800,000,000 ordinary shares in August 2006 in connection with our reorganization in 2006. For the purposes of calculating basic and diluted earnings per ordinary share, the number of ordinary shares used in the calculation reflects the issuance of ordinary shares as if the reorganization took place as of the beginning of the earliest period presented.

(4)

In November 2009, we acquired 100% equity interest of Jiangsu Kangpeng Nong Hua Limited, or Kangpeng Nong Hua, for RMB25 million (US$3.7 million) in cash. As our Chairman and CEO, Dr. Yang held more than 50% voting ownership interest of both the Company and Kangpeng Nong Hua at the date of the acquisition, it was considered a transaction between entities under common control. Therefore, our consolidated financial statements have been retroactively adjusted to reflect the combined entities for the periods during which the entities were under common control.


	As of December 31,
	2006		2007		2008(4)		2009		2010		2010
	RMB		RMB		RMB		RMB		RMB		US$
	(in thousands, except share, per share and per ADS data)
Selected Consolidated Balance Sheet Data
Cash		37,633		56,929		180,602		351,097		98,719		14,957
Accounts receivable, net		81,370		86,749		136,664		94,154		137,873		20,890
Inventories		61,446		111,117		218,263		271,434		470,432		71,278
Total current assets.		203,590		311,237		584,506		798,157		844,788		127,998
Property, plant and equipment, net		131,802		216,824		405,180		699,181		871,398		132,030
Total assets		370,183		563,527		1,063,457		1,575,283		1,796,356		272,175
Short-term bank borrowings		40,000		40,000		65,000		—		20,000		3,030
Long-term bank borrowings, current portion		—		—		—		—		5,000		758
Accounts payable		23,043		43,127		81,382		81,870		142,319		21,564
Amounts due to related parties		65,638		40,366		51,246		23,659		5,559		842
Total current liabilities		210,489		168,893		296,998		339,831		405,079		61,376
Long-term bank borrowings		—		—		—		10,000		—		—
Total liabilities		210,489		168,893		318,244		383,023		429,876		65,133
Ordinary shares(1)		18,446		18,446		18,446		21,686		21,649		3,280
Our shareholders’ equity		152,213		387,021		730,133		1,186,252		1,360,822		206,185
Noncontrolling interests		7,481		7,613		15,080		6,008		5,658		857
Total equity		159,694		394,634		745,213		1,192,260		1,366,480		207,042

(1)

We were incorporated on May 30, 2006 and as part of a series of reorganization activities, became a holding company of our subsidiaries in August 2006. Our financial results are presented as though the reorganization were completed at the beginning of the earliest period presented, or January 1, 2006.

Currency Translations and Exchange Rates

This annual report on Form 20-F contains translations of certain RMB amounts into U.S. dollar amounts at specified rates. Unless otherwise noted, all translations from Renminbi to U.S. dollars and from U.S. dollars to Renminbi in this annual report were made at a rate of RMB6.6000 to US$1.00, the noon buying rate in the City of New York for cable transfers in RMB per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York, or the noon buying rate, in effect as of December 31, 2010. We make no representation that the RMB or U.S. dollar amounts referred to in this annual report could have been or could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all. See “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—Fluctuations in the exchange rates of the Renminbi may have a material adverse effect on your investment” and “—Governmental control of currency conversion may affect the value of your investment” for discussions of the effects of fluctuating exchange rates and currency control on the value of our ADSs. On June 10, 2011, the noon buying rate was RMB6.4801 to US$1.00.

The following table sets forth information concerning exchange rates between the RMB and the U.S. dollar for the periods indicated.


	RMB per U.S. Dollar Exchange Rate(1)
Period	Period End		Average(2)		Low		High
	(RMB per US$1.00)
2005		8.0702		8.1826		8.2765		8.0702
2006		7.8041		7.9579		8.0702		7.8041
2007		7.2946		7.6072		7.8127		7.2946
2008		6.8225		6.9477		7.2946		6.7800
2009		6.8259		6.8307		6.8470		6.8176
2010		6.6000		6.7696		6.8330		6.6000
2010
November		6.6670		6.6358		6.6892		6.6630
December		6.6000		6.6497		6.6745		6.6600
2011
January		6.6017		6.5964		6.6364		6.5809
February		6.5713		6.5761		6.5965		6.5520
March		6.5483		6.5645		6.5743		6.5483
April		6.4900		6.5267		6.5477		6.4900
May		6.4786		6.4957		6.5073		6.4786
June (through June 10)		6.4801		6.4790		6.4824		6.4754

(1)

For all periods prior to January 1, 2009, the exchange rate refers to the noon buying rate as reported by the Federal Reserve Bank of New York. For periods beginning on or after January 1, 2009, the exchange rate refers to the exchange rate as set forth in the H.10 statistical release of the Federal Reserve Board.

(2)	Annual averages are calculated from month-end rates. Monthly averages are calculated using the average of the daily rates during the relevant period.

B. Capitalization and Indebtedness

Not applicable.

C. Reasons for the Offer and Use of Proceeds

Not applicable.

D. Risk Factors

Our business and operations are subject to various risks, many of which are beyond our control. If any of the risks described below actually occurs, our business, financial condition or results of operations could be seriously harmed.

Risks Related to Our Company and Our Industry

If we are unable to manage our growth effectively, our business, financial condition and operating results could be harmed.

We have experienced rapid growth, especially since 2003, which has required us to expand our operations and make increasing investments in our management, administrative, operational and financial infrastructure. For example, the number of our employees increased from 118 as of January 1, 2003 to 1,794 as of December 31, 2010. Furthermore, our sales increased from RMB68.9 million in 2003 to RMB1,082.0 million (US$163.9 million) in 2010. Rapid expansion has placed strain on our management resources and may have led to inefficiencies in our administrative systems or business operations, some of which we have not yet discovered or addressed. It has also placed a strain on our ability to expand manufacturing facilities that can satisfy the increasing number of orders we receive. While our customers typically give us an estimated production plan for a period of two to twelve months, those estimates are not binding. Typically, it takes two to three years from the time that we acquire the land for a production facility for that production facility to begin operations. The relatively short lead-time and non-binding nature of the production estimates that we receive from our customers and the relatively long and capital-intensive process involved in creating new production capacity have made it difficult to anticipate needed production capacity. For example, the lack of growth of our revenues and our net income from 2006 to 2007 resulted in part from the fact that we were producing at or near maximum capacity and were not rolling out our new production facility until late in 2007. In addition, the decline of our revenues in 2009 from 2008 resulted mainly from the impact of the global financial crisis and economic recession. Despite the temporary decline we experienced in 2009, we expect our business to continue to expand significantly as the global economy continues to recover and demand for specialty chemicals in our industry increases. While we increased our production capacity when we opened our new production facilities since late 2007 and through our acquisition of Jiangsu Wei Er in February 2008, we may in the future face periods of increasing demand in which we are unable to address increasing orders. Our future prospects will depend in part on the ability of our senior management to successfully manage our operations so that we are able to capitalize on any growth opportunities that arise. In order to be positioned to take advantage of any future growth opportunities that may arise, we must take, among other actions, some or all of the following actions:

•

increase production capacity and further renovate our production facilities, either at our existing facilities or through the construction or purchase of additional facilities;

•

keep up with evolving industry standards, technologies and market developments, expand research and development capabilities and continue to improve our engineering and manufacturing processes;

•

improve our existing, or implement additional, operational and financial systems, procedures and controls;

•

increase awareness of our brand name, protect our reputation and expand our sales and marketing network and capability in order to further deepen and broaden our business scale and scope;

•

attract, train and retain qualified research and development and operational employees and manage our rapidly growing employee base;

•

retain our key relationships with government agencies, obtain and maintain any governmental approvals required for our business, including current and future product offerings, and respond to changes in the regulatory and policy environment; and

•

integrate any acquired businesses into our operations and realize the potential benefit of our acquisitions.

Furthermore, we need to maintain, expand and diversify our relationships with our existing and new customers, suppliers and other third parties. If our current and planned operations, personnel, systems, internal procedures and controls are not adequate to support our recent and future growth, then our business and financial condition could be adversely affected. In addition, the success of our growth strategy depends on a number of internal and external factors, such as raw material costs, our ability to increase production capacity and output

and our ability to develop and commercialize new products together with our customers and end users. If we are unable to manage our growth effectively, we may not be able to take advantage of market opportunities, execute our business strategies or respond to competitive pressures.

Our operating history with our current scale and product mix may not serve as an adequate basis to judge our future prospects and results of operations.

Our product mix varies frequently from year to year in accordance with the specific demands and industry of the end users of our products. This in turn can lead to fluctuations in our sales. We had sales of RMB942.5 million, RMB820.3 million and RMB1,082.0 million (US$163.9 million) and net income attributable to our shareholders of RMB312.4 million, RMB172.4 million and RMB225.5 million (US$34.2 million) in 2008, 2009 and 2010, respectively. In the event that we are unable to expand our business and increase our sales, we may not achieve similar results in future periods. Accordingly, you should not rely on our past results or historical growth rate as an indication of our current or future business, financial performance and prospects.

Among other factors and limitations, you should consider our future prospects in light of the risks and uncertainties experienced by a specialty chemicals company, which is based in China. These risks include, among others, the risk that we will be unable to:

•

retain existing customers and obtain new customers;

•

diversify our revenue sources by successfully identifying market opportunities, developing technologies and processes, achieving economies of scale and commercializing our pipeline products;

•

expand our business and effectively manage our business as it expands;

•

anticipate and respond in a successful and timely way to changes in technology, market developments and regulatory environment;

•

obtain on commercially reasonable terms the licenses required to operate and expand our business;

•

protect our intellectual property and our customers’ intellectual property and manage risks associated with intellectual property rights;

•

maintain effective control of our costs and expenses;

•

raise sufficient capital to sustain and expand our business; and

•

attract, retain and motivate qualified personnel.

If we are unsuccessful in addressing any of these risks and uncertainties, our prospects, business, financial condition, results of operations and future growth would be adversely affected.

If the end markets for our specialty chemicals decline or do not grow as quickly as we anticipate, or if our customers do not succeed in increasing their market shares in those markets, our business prospects and results of operations could be harmed.

Demand for our products is dependent on demand for the end products that incorporate our products. Most of those end users are in the electronics, pharmaceuticals and agrochemicals industries. While some of our sales are to direct end users, a significant percentage of our sales are made to trading companies that act as middlemen and sell our products to end users for multiple industry applications. Due to this sales model, there is a degree of uncertainty about the identity of the ultimate end users of some of our products, the industries in which our products are used and our estimates of the approximate percentages of sales derived from each end market into which we sell our products. The largest percentage of our sales has historically been derived from products used in the electronics industry, particularly in the manufacture of TFT-LCDs. Historically, the second largest percentage of our sales has been derived from products used in the pharmaceuticals industry and this sector has been increasing in importance to our business. Although it has historically been the smallest source of sales of

our products, the agrochemicals industry has also been increasing in importance to our business over time, except in the second half of 2009 because the global agrochemical business deteriorates as a result of the global economic recession and unfavorable weather patterns in some major farming markets. Our future success depends on the continued growth of these markets as well as the growth, viability and financial stability of our customers and end users and the end-market demand for our customers’ products. If the end markets for our specialty chemicals decline or do not grow as quickly as we anticipate, just like what we experienced in the first quarter of 2009 for the electronics chemical market and the second half of 2009 for the agrochemical market, or if our customers do not succeed in increasing their market shares in those markets, our business prospects, financial condition and results of operations could be harmed. In particular, the end markets for our products, the electronics, pharmaceutical and agrochemical industries, are characterized by rapid technological changes, short product life cycles, vigorous competition, consolidation and/or pricing and margin pressures. Significant decreases in demand for consumer electronics, beginning in the second half of 2008 brought on by the global economic downturn resulted in decreases in demand for our specialty chemicals used in the manufacture of TFT-LCDs in 2009, particularly in the first quarter of 2009. In addition, significant decreases in demand for agrochemicals beginning in the second half of 2009 brought on by the global economic recession resulted in decreases in demand for our specialty chemicals used in the agrochemical market in the second half of 2009. Therefore, although we had seen a strong recovery in demand for our products in 2010, especially in the electronics chemical market, the increase in sales of our products resulting from anticipated growth in these industries may be less than expected or may fail to materialize altogether if the global economic condition changes. If anticipated growth occurs at a slower rate than expected or fails to occur at all, our strategy to expand our business by continuing to expand into these end markets may not be successful, which could have a material adverse effect on our business. If any of these risks materialize, we may not grow or our growth may slow and our business, financial condition and operating results could be materially harmed.

We may prove unsuccessful in our ability to manage increased manufacturing capacity and increased research and development capability and we may not realize the anticipated benefits from either or both of these expansions.

We manufacture all of our products and conduct our research and development activities in our facilities in China. We have built a new research and development center and head office building in Shanghai that significantly increased our research and development capabilities. We also have expanded, and continue to expand our manufacturing capacity at our existing facilities and through the addition of new facilities. As of December 31, 2010, we owned and operated six major production facilities with a total maximum production capacity of 2.3 million liters of reactor volume. We must continue to devote significant resources to the expansion of our manufacturing capacity. These planned expansions will be expensive, will require a significant amount of management’s time that could otherwise be used in other aspects of our business and may disrupt our operations. We will incur these costs, which may be higher than we anticipate, as well as continuing costs of maintenance and operations for these facilities, even if we are unable to utilize the increased capacity and capability due to decreases in demand for our products, reduced sales volumes or otherwise.

Additional risks associated with increasing our manufacturing capacity and research and development capabilities include:

•

inability to attract and retain manufacturing personnel and research and development engineers or shortages of such personnel;

•

difficulties in achieving adequate yields or quality control from new or expanded manufacturing facilities;

•

inability to quickly implement an adequate set of financial controls to track the increased scale of our business;

•

lack of trained personnel to manage the operations and customer contracts appropriately;

•

wage inflation and unfavorable exchange rates;

•

maintaining customer, supplier and other favorable business relationships;

•

effective training of staff to manage new customers and products;

•

unanticipated disruptions in our operations which may impact our ability to make timely deliveries to our customers, produce quality products and ensure overall customer satisfaction;

•

delays in commencing operations at our new and expanded facilities; and

•

costs required to procure all necessary equipment for these projects and expansion, which may be higher than anticipated.

In the event that we are unsuccessful in our ability to manage and utilize this increased capacity and capability, or if the delays, disruption, or costs related to these projects are greater than we anticipate, our business, financial condition and operating results could be harmed.

Our products, in particular our commercialized projects, may be subject to decreasing pricing trends and reduced margins in the future. If we are unable to successfully replace these products subject to those trends with newer, more profitable products, our sales and future results of operations could be harmed.

Many specialty chemicals, including those that we manufacture, are subject to price declines over time due to competitive forces, while manufacturing and material costs may remain constant or increase. In particular, our average selling price of our commercialized products decreased from RMB444, 000 per metric ton in 2008 to RMB308, 000 per metric ton in 2009. Although the average selling price of our commercialized products increased to RMB 424,000 (US$64,171) per metric ton in 2010, as some of our products enter into a later stage in their lifecycles, the average selling prices of those products may decrease.

In addition, many of the raw materials we use, particularly petroleum-based chemicals and solvents, fluorine and hydrofluoric acid, have been subject to significant price fluctuations in recent years. As a result of the decline in average selling prices for our commercialized products and the fluctuations in the cost of the raw materials that we use to produce those products, margins for some of our specialty chemicals have declined and may continue to decline over time. We must continuously transition our product range to newer, more advanced specialty chemicals to command higher margins to maintain our growth and profitability and to offset rising raw material costs. Our profitability also depends on our ability to successfully control costs during the manufacturing process by continuing to increase the efficiency of our manufacturing processes, reduce raw material consumption and increase production yields. In addition, changes in our product mix or production of products with lower average selling prices by new or acquired facilities may negatively affect our overall average selling prices. If we are unable to successfully design, manufacture and market new products that command higher average selling prices, or if we fail to effectively increase the efficiency of our manufacturing processes, continue to control manufacturing costs or shift new or acquired facilities to higher value-added products, our business, financial condition and operating results could be harmed.

Our operating results may fluctuate considerably on a quarterly basis. These fluctuations could have an adverse effect on the price of our shares and ADSs.

Our results of operations have fluctuated in the past and may continue to fluctuate significantly on a quarterly basis as a result of a number of factors, many of which are beyond our control. Although many companies may encounter fluctuations in their results of operations, these fluctuations are particularly relevant to us as a result of our current reliance on a limited number of customers, our reliance on purchase orders rather than long-term contracts with our customers, our relatively small size, our limited operating history and the dynamics of operating a business in China. Factors that could cause our results of operations to fluctuate include, among others:

•

seasonal or periodic fluctuations in our customers’ and end users’ businesses, which could cause the timing of their purchases of our products to vary;

•

the timing of purchases made by our customers, which are tied to the needs of such customers and subject to any seasonal or periodic fluctuation in their businesses;

•

the average selling prices of our products;

•

delivery delays, price fluctuations and shortages with respect to raw materials that we acquire from suppliers, outsourced manufacturers, and other third parties;

•

the rate and cost at which are able to expand our internal manufacturing capacity to meet customer demand and the timeliness and success of these expansion efforts;

•

timing and changes by our end users in the commercializing their products;

•

unpredictable volume and timing of customer orders, most of which are determined not on a fixed contractual basis but rather on a discretionary purchase-order basis;

•

the loss of one or more key customers or the significant reduction or postponement of orders from these customers;

•

unplanned expenses incurred to address contingencies such as manufacturing failures, defects or downtime;

•

costs relating to acquisitions and investments;

•

the effects of the global economic downturn, which have led to decreases in demand for our products, including those used in the manufacture of electronics, especially TFT-LCDs in 2009, and those used in the manufacture of agrochemicals in the second half of 2009;

•

geopolitical turmoil within any of the countries in which we operate or sell products;

•

foreign currency fluctuations, particularly fluctuations in the exchange rates of the Euro, U.S. dollar and Renminbi;

•

our success in maintaining, establishing and expanding customer relationships;

•

changes in our manufacturing costs;

•

changes in the relative sales mix of our products;

•

our ability to successfully develop, introduce and sell new or enhanced products in a timely manner, and the amount and timing of related research and development costs;

•

the timing of new product or technology announcements or introductions by our competitors and other developments in our competitive environment;

•

litigation involving intellectual property; and

•

international or China-specific economic downturns.

A number of these effects are most noticeable in the first quarter of a non-recession business year, which is when we generally experience lower demand for our products, in particular commercialized products, than in other quarters.

In addition, as we generally do not enter into long-term contracts with our customers, any decision by one or more of them to reduce or terminate orders during a certain period of time could have an adverse effect on our sales for those periods. We base our planned operating expenses in part on our expectations of future revenue, and as a result, a significant portion of our expenses will be fixed in the short term. If revenue for a particular quarter is lower than we expect, we likely will be unable to proportionately reduce our operating expenses for that quarter, which would have a material adverse effect on our operating results for that quarter. You should not rely on our results from any quarter as an indication of future performance. Quarterly variations in our operations could result in significant volatility in the market for our ADSs, and the market price for our ADSs might fall.

Furthermore, the occurrence of any of the risks described above could result in harm to our business, financial condition and operating results, especially if it continues for a period of time or is not mitigated in subsequent periods.

Our current dependence on a limited number of customers may cause significant fluctuations or declines in our revenues.

We currently derive the substantial majority of our sales from a limited number of customers. Our customers consist of the actual end users of our products as well as trading companies that sell our specialty chemicals to third parties. In 2008, 2009 and 2010, aggregate sales to our three largest customers represented approximately 65%, 61% and 65% of our total sales, respectively. Our three largest customers in 2008, 2009 and 2010, each individually accounted for more than 7% of our sales, while our single largest customer accounted for 35%, 24% and 33% of our total sales in 2008, 2009 and 2010, respectively. In addition, some of our end users purchase our products indirectly through one or more of our customers that are trading companies. We are unable to fully assess the exact amount of such indirect sales although we are aware of the occurrence of these situations based on various discussions with certain of our end users and customers. Based on the assessments of the amount of sales to our single largest end user, including both direct purchases from us and indirect purchases through trading companies, the percentage of sales accounted for by that end user is larger than the figures indicated above for our single largest customer. Due to the concentration of our business and dependence on a limited number of customers and end users, any one or more of the following events, among others, some of which we experienced in 2010, may cause material fluctuations or declines in our revenues and have a material adverse effect on our financial condition, results of operations and prospects:

•

reduction, delay or cancellation of orders or contracts from one or more of our significant customers, and our failure to identify additional or replacement customers;

•

reduction, delay or cancellation of orders to our customers from one or more of the companies to which they sell our products, due to a reduction in their customers’ product sales or otherwise;

•

the decision by one or more of our significant customers to select one or more of our competitors to supply their specialty chemicals needs;

•

loss of one or more of our significant customers and our failure to obtain additional or replacement customers that can replace the lost sales volume at satisfactory pricing, production and other terms;

•

reduction in the price that one or more of our significant customers is willing to pay for our products;

•

any adverse change in the bilateral or multilateral trade relationships among China, the United States, Japan and European countries that could cause us to lose access to certain customers or make such access more difficult; and

•

the failure or inability of any of our significant customers to make timely payment for our products.

We anticipate that our dependence on a limited number of customers will continue in the foreseeable future although we have been doing our best in recent years to diversify our customer base. In addition, as we generally do not enter into long-term contracts with customers, but receive purchase orders based on the specific needs of our customers, we are frequently subject to the renegotiation of pricing and other terms. We have and may continue to be required to reduce our average selling price in response to competitive pricing pressures. We also do not typically obtain firm purchase orders or commitments from our customers for extended periods. These factors may result in a lack of certainty and predictability about our sales, which may fluctuate unpredictably depending on customer demand and orders. Although we have historically retained many of our largest customers for extended periods, we cannot be certain whether these customer relationships will continue to develop or if these customers will continue to generate significant revenue for us in the future.

In addition, while we work closely with our customers to develop forecasts for periods of up to one year, these forecasts are not binding and may be unreliable. Customers may cancel their orders, change production

quantities from forecasted volumes or delay production for a number of reasons beyond our control, which could materially and adversely affect our sales and results of operations. The short-term nature of our customers’ commitments and the possibility of rapid changes in demand for their products also reduce our ability to accurately estimate the future requirements of our customers. The difficultly of forecasting the level of customer orders with certainty makes it difficult to schedule production, order appropriate levels of materials and maximize the utilization of our manufacturing capacity. This could also lead to an inability to meet production demands, which could harm our business, financial condition and operating results.

Our current business and future growth depend in part upon the level of regulatory and commercial success of the end products incorporating our specialty chemicals. If those end products experience regulatory or commercial setbacks, related expenditures and development activities may fall short of our expectations and our business, financial condition and results of operations may be harmed.

Many of the orders we receive are for specialty chemicals used in products still in the development stage or at an early stage of marketing, some of which are subject to regulatory review and approval. Whether those products receive such required approvals and ultimately pass through the test stage and reach a level of commercial production will significantly affect our future sales as we continue to provide specialty chemicals to those customers and end users. In particular, certain of our specialty chemicals are used as intermediates for the research and development of new pharmaceutical and agrochemical compounds. As pharmaceutical and agrochemical companies seek to develop new drugs and agrochemical products that will be successful in the marketplace, they conduct extensive research and development. We supply pharmaceutical and agrochemical companies with pilot quantities of novel specialty chemicals for use in their research for commercial production and clinical development. If those products prove effective, obtain governmental approval and achieve marketing success in the future, we may be able to supply them with larger quantities of specialty chemicals. However, if the products which use our specialty chemicals do not prove effective, fail to receive regulatory approval or fail to achieve commercial success, we will not be able to increase our sales of those specialty chemicals, which could materially and adversely affect our growth prospects.

If the companies that use our products change their production processes, demand for our specialty chemicals could decline, and our business, financial condition and results of operations could be harmed.

Our specialty chemicals are used in a range of applications. Changes in the production processes used by our customers or the companies that purchase their products could reduce or eliminate demand for the specialty chemicals that we produce or make our specialty chemicals unnecessary. Companies that use our specialty chemicals may also decide to produce or purchase alternative materials or use production processes that no longer require our products. If such a change were to occur, whether due to price, performance or other considerations, we might not be able to supply specialty chemicals that meet those new requirements. For example, the markets for electronics and pharmaceuticals, where many of our specialty chemicals have been used in recent years, are rapidly evolving and demand for our specialty chemicals that are used in these markets could change quickly. Our business, results of operations, and financial condition could be materially and adversely affected if we were unable to successfully adapt to such changes in a timely or cost-effective manner.

Our business and prospects depend on our ability to successfully identify market opportunities for new products, develop new technologies and develop and implement manufacturing processes for commercial production of the new products. If we are not successful in expanding our sales into new product lines, our business, financial condition and results of operations could be harmed.

Our business model depends on our ability to successfully identify specialty chemicals with significant market opportunities for end users, develop new technologies and develop and implement manufacturing processes for commercial production. The manufacture of new and technologically advanced products involves complex and uncertain processes requiring highly skilled engineering and development personnel. If we are unable to successfully develop these products or processes or if the benefits from developing them prove to be

less than anticipated, our growth may slow or stall, and we may incur costs that are not offset by sales from the new specialty chemicals. Even if we correctly identify specialty chemicals that offer significant market opportunities, we may be unable to produce new products in a commercially viable manner, if at all.

The applications for specialty chemicals are characterized by rapid technological advances. Our technologies, processes and products may become uncompetitive or obsolete if we are less successful at adapting to new technologies, new processes, new products, changes in customer demand or changes in customer requirements than our competitors. In order to keep pace with technological advances and to retain our competitive position, we will need to invest substantial financial resources to improve our technologies and production processes. If we fail to commercialize our research and development results or to improve our technologies and production processes, we may become less competitive and our results of operations may be negatively affected.

A payment failure or cancellation of purchase orders at a late stage by any of our large customers could significantly harm our cash flows and results of operations.

Consistent with industry practice, under many of our purchase orders with our customers, we offer 30 to 120 days sales credit terms to our customers, unless we receive collateral for the payment obligations. Historically, we have not experienced any significant delay, refusal or inability of our major customers to make timely payments to us, but payment problems may arise in the future. If any of our customers fails to make timely payments, we could experience delays in our cash receivables, incur costs to collect overdue payments, write off accounts receivable or increase provisions made against our accounts receivable, which could adversely affect our cash flows and results of operations.

In the event that we are unable to obtain raw materials in a timely manner and at reasonable prices, our business, financial condition and results of operations would be harmed.

Raw materials accounted for 86.8%, 77.0% and 74.1% of our cost of sales in 2008, 2009 and 2010, respectively. In addition, raw material costs accounted for 50.5%, 46.5% and 45.5% of our sales in those periods, respectively. While the factors affecting the prices of our raw materials are difficult to predict, changes in the price of raw materials may have a significant impact on our cost of sales. In recent years, the prices of fluorine, hydrofluoric acid, petroleum-based solvents and many of the other raw materials we use have fluctuated significantly. We expect raw material prices to continue to increase as the global economy recovers. In the event that raw material prices increase above certain levels, the continued production of our products may become uneconomical. Our inability to fully offset the effects of higher raw material costs or to obtain such raw materials on pricing and other terms satisfactory to us could have a material and adverse effect on our financial condition and results of operations.

If we are unable to secure adequate amounts of necessary raw materials, it may limit or prevent us from delivering our specialty chemicals in a timely manner to our customers in the required quantities and at competitive prices, which could result in order cancellations, decreased revenue and loss of market share. We have not entered into any long-term agreements with our suppliers. If we fail to maintain our relationships with our current suppliers or develop relationships with our suppliers on pricing and other terms that are satisfactory to us, or if a supplier fails to supply raw materials that meet our quality, quantity and cost requirements, we may be unable to fill our customers’ orders on a timely and cost-effective basis, which could result in order cancellations, decreased revenue, loss of market share and damage to our reputation.

In the event that the third parties who supply chemical components for our specialty chemicals are unable to deliver those chemical components in a timely manner and at a sufficient quality level, our business, reputation and results of operations could be harmed.

Some of the chemical building blocks involved in the manufacture of specialty chemicals we produce are commodity chemicals, the manufacture of which does not require advanced process or manufacturing

expertise. In order to focus on our core competencies, we outsource some of the less advanced production to third-party manufacturers who provide us with components for use in our manufacturing processes. We believe this arrangement is more efficient and economical than producing these chemicals ourselves. While we monitor the quality of the chemical components we receive and carefully select our vendors, we cannot guarantee the quality or timely delivery of the chemical components produced by those vendors. If our vendors fail to timely deliver those chemical components, or if those components are of inadequate quality, our own production could be delayed. While we generally have not experienced problems with quality or timeliness in delivery by these third-party suppliers, we cannot ensure that such problems or delays will not occur in the future. If we experience problems with the quality of outsourced chemical components we purchase or delays in the delivery by these third-party suppliers, our ability to produce and deliver satisfactory quality products in a timely way using those chemicals could be compromised, which could harm our reputation, business and results of operations.

We have limited insurance coverage.

The insurance industry in China is still at an early stage of development. Insurance companies in China offer limited insurance products. As of December 31, 2010, we carried approximately RMB891.7 million (US$135.1 million) of insurance coverage, which includes coverage for certain of our property, plant and equipment and inventory and for employee injury and third-party liability for all of our operations. We also have a directors and officers, or D&O, insurance with US$10 million coverage. We do not have insurance coverage on our other assets and we do not have insurance to cover our business or interruption of our business, other types of litigation or product liability. We have determined that the costs of insuring for these risks and the difficulties associated with acquiring such insurance on commercially reasonable terms make it impractical for us to have such insurance. Any uninsured occurrence of loss or damage to property, litigation or business disruption may result in our incurring substantial costs and the diversion of resources, which could have an adverse effect on our operating results and financial condition.

We face risks associated with the marketing and sale of our specialty chemicals internationally, and the failure to effectively manage these risks could materially and adversely affect our business, prospects, financial condition and results of operations.

In 2008, 2009 and 2010, sales to customers outside of China represented approximately 48.7%, 55.8% and 51.0% of our sales, respectively. These figures include sales made to Japan, which constituted 36.1%, 51.0% and 60.4% of our sales made outside of China and 17.6%, 28.5% and 31.2% of our total sales in 2008, 2009 and 2010, respectively. The majority of our products sold to China-based trading companies, which we account for as domestic sales, are ultimately sold to end users in international markets such as Japan, the United States and Europe. We anticipate that revenues derived internationally will continue to be significant to our sales in the near future. The marketing and sale of our products in the international market expose us to a number of risks, including, among others, the following:

•

increases in trade barriers such as export requirements, tariffs, taxes and other restrictions and expenses, which could increase the prices of our products and make us less competitive in some countries;

•

trade disputes between China and other jurisdictions such as Japan, the United States and Europe;

•

fluctuations in currency exchange rates;

•

increased costs associated with maintaining marketing and selling efforts in various countries;

•

increased shipping costs; and

•

difficulties and costs related to compliance with the different commercial, environmental and other legal requirements in the various international markets in which we sell our products.

Furthermore, the geographic concentration of our sales in Japan heightens these risks with respect to that region. If any of these risks materialize with respect to Japan, or if economic conditions generally worsen there, or in the event of a natural disaster there, our results may be disproportionately affected and our business may be harmed and we may experience losses. In March 2011, Japan was struck by a 9.0-magnitude earthquake. Although the earthquake together with the resulting tsunami and radiation leak at the Fukushima nuclear power plant have not had an immediate direct impact on our operations, we cannot assure you that these events will not have any subsequent adverse effect on our industry. The extent of existing and potential future radiation release from the Fukushima nuclear power plant is still in flux and coupled with potential aftershocks from the earthquake, may result in future additional adverse effects on the operations of our customers. Our customers with facilities and operations in Japan or who have business dealings with Japan that have been affected by these events may suffer from a slowdown resulting in reduced demand for our services and we can make no assurances that our results of operations will not be adversely affected.

The occurrence of one or more of these risks could materially and adversely affect our business, prospects, financial condition and results of operations.

If we are unable to compete successfully against our current and future competitors, many of which have greater name recognition, resources, experience and larger customer bases than we do, our business, financial condition and results of operations could be harmed.

We compete against a number of Chinese specialty chemicals producers, such as WuXi PharmaTech Co., Ltd., Asymchem Laboratories Co., Ltd., Xi’an Ruilian Modern Electronic Chemicals Co., Ltd., Yantai Valiant Fine Chemicals Co., Ltd., and Zhejiang Yongtai Chemical Co., Ltd., and foreign specialty chemicals producers, such as Lonza Group Ltd., Evonik Degussa GmbH, Lanxess AG, Balchem Corporation, Rohm and Haas Company, and Sigma-Aldrich Corporation. We face competition based on a number of factors, including quality, timeliness, good manufacturing practices, depth of customer relationships, pricing, geography and ability to protect confidential information and intellectual property. Many of our competitors have longer operating histories, economies of scale, greater name recognition, larger customer bases and significantly greater financial, sales and marketing, production, distribution, technical and other resources and experience than we do. Our competitors’ greater size in some cases provides them with greater pricing flexibility and a competitive advantage with respect to production costs due to greater economies of scale and their ability to purchase raw materials and utilities at lower prices. In addition, our competitors may be able to devote greater resources to the research and development of technologies, processes and products that are more effective than ours, and that may render our technologies, processes or products obsolete or uneconomical. They may also adapt more quickly to new or emerging technologies and changes in customer demand and requirements. In addition, new competitors or alliances among our competitors could emerge and rapidly acquire significant market share. Our failure to maintain a competitive position with respect to technological advances, adapt to changing market conditions or otherwise compete successfully with existing or new competitors could have a material and adverse effect on our business, financial condition and results of operations. In addition, as more Chinese and international chemical manufacturers continue to invest in China and take advantage of lower production and labor costs in China, we may face increasing pricing pressure and decreasing demand for our products and services as well as increasing competition for qualified personnel, which could have a material and adverse effect on our business, financial condition and results of operations.

We also expect increasing competition as new companies enter the market and more advanced technologies become available. Our products and expertise may be rendered obsolete or uneconomical by technological advances or new approaches. The current or future technologies used or developed by our competitors may be more effective or advanced than those used and developed by us. Furthermore, increasing competition increases pricing pressure for our products, which can reduce our profit margins on the products we sell and have a material and adverse effect on our business, financial condition and results of operations.

Our use, production and disposal of hazardous materials subject us to stringent environmental, health and safety regulations. Any actual or alleged violation of these regulations could result in significant regulatory actions, fines and other penalties, including suspending production or ceasing operations, substantial civil or criminal claims resulting in potentially significant monetary damages, adverse publicity, and other negative consequences to our business.

Because we use, produce and dispose of hazardous materials and our production processes generate noise, waste water, gaseous and other industrial wastes, we are required to comply with national and local environmental, health and safety regulations applicable to us. We believe that we have instituted environmental, health and safety procedures and measures that meet or exceed the standards prescribed by national, provincial and local regulations in China. However, we cannot completely eliminate the environmental, health and safety risks associated with our use, production and disposal of hazardous materials and we have experienced environmental, health and safety incidents at our facilities in the past, including fires, leakages and other accidents, which have resulted in regulatory actions requiring us to take corrective actions and subjected us to fines and other penalties. In some cases, we have been required to temporarily suspend production or cease operations while we performed corrective actions. We believe we are currently in compliance with applicable environmental, health and safety regulations in all material aspects and have all necessary environmental, health and safety permits to operate our business as it is presently conducted. However, if more stringent regulations are adopted in the future, the costs of compliance with these new regulations could be substantial. If we fail to comply with present or future environmental, health and safety regulations, we may be subject to significant regulatory actions, fines and other penalties, including suspending production or ceasing operations, substantial civil or criminal claims resulting in potentially significant monetary damages, adverse publicity, and other negative consequences to our business, all of which could have a material adverse affect on our business, reputation, financial condition and results of operations.

Our operations are subject to various risks associated with our use, handling, storage and disposal of hazardous materials, many of which are toxic and flammable. If we are found liable for contamination, injury to employees or others, or other harms related to our use, handling, storage and disposal of hazardous materials, our business, reputation, financial condition and results of operations may be adversely affected.

We use, handle, store and dispose of hazardous materials in our operations, many of which are toxic and flammable. We believe that we have been diligent in designing and implementing procedures and measures to promote occupational health and safety in compliance with the standards prescribed by national, provincial and local regulations in China. However, we cannot completely eliminate the risks of contamination, injury to employees or others, or other harms related to our use, handling, storage and disposal of hazardous materials. We have experienced incidents in the past, including fires, leakages and other accidents, and there can be no assurance that such incidents will not occur in the future. In the event of future incidents, we could be liable for any damages that result, including potentially significant monetary damages for any civil litigation or government proceedings related to a personal injury claim, as well as other fines, penalties and other consequences, including suspension or revocation of our licenses or permits or suspending production or ceasing operations at our research and manufacturing facilities, all of which could have a material adverse affect on our business, reputation, financial condition and results of operations. Furthermore, we currently do not carry any insurance coverage for potential liabilities relating to the release of hazardous materials and any release of hazardous materials could cause us further harm.

Our failure to obtain and maintain permits, licenses and registrations necessary to conduct our business could materially harm our business and prospects.

We use hazardous chemicals that are subject to regulation by many national, provincial and local governmental authorities in China. As we grow, we may become subject to additional regulation or higher compliance standards.

In order to obtain regulatory approval of certain new products and production processes, we must, among other things, demonstrate to the relevant authorities that the product is safe for its intended uses and that we are capable of manufacturing the product in accordance with applicable regulations. The process of seeking approvals can be time consuming and subject to unanticipated and significant delays. Approvals may not be granted to us on a timely basis, or at all. Any delay in obtaining, or any failure to obtain or maintain, these approvals would adversely affect our ability to introduce new products and to generate revenue from those products. In addition, some of these licenses and permits are subject to periodic renewal. Failure to obtain or maintain any of these permits and licenses could have a material adverse effect on our business and prospects. New laws and regulations may be introduced in the future that could result in additional compliance costs, seizures, confiscation, recall or monetary fines, any of which could prevent or inhibit the development, distribution and sale of our products.

Our business and operations are subject to business interruption risks due to the actions of third parties, which could have a material adverse effect on our business, reputation, financial condition and results of operations.

Due to the nature of our business, we are at risk of business interruption due to the actions of third parties. For example, many of our vendors and subcontractors have operations that are also subject to environmental, health and safety risks associated with the use of hazardous materials. Some of our vendors and subcontractors are, or have been related parties to us, and have experienced environmental, health and safety incidents in the past that have impacted us, including an explosion at a third party facility that resulted in the death of one of our employees in 2007. In addition, we may be adversely impacted by incidents at unrelated facilities. For example, Jiangsu Wei Er was ordered to shut down following an accident at an unrelated facility located in the same industrial park while local authorities investigated the accident in 2008. Any future environmental, health and safety incidents affecting our vendors and subcontractors may result in significant regulatory actions, fines and other penalties, including restrictions, prohibitions or sanctions on their operations, and could impair their ability to perform their contracts with us or could otherwise subject us to liability, all of which could have a material adverse affect on our business, reputation, financial condition and results of operations. In addition, there can be no assurance that we will not be adversely affected by incidents at unrelated facilities. Furthermore, we currently do not carry any business disruption insurance coverage and any business disruption could cause us further harm.

Any failure by us to satisfy our end users’ reviews and inspections could harm our reputation and our business, financial condition, results of operations and prospects.

Several end users of our products, including several leading international pharmaceutical companies, routinely audit and inspect our facilities, processes and practices to ensure that our services meet their internal standards and the regulatory standards applicable to them. The internal standards and regulatory standards applicable to these end users may change at any time, which may cause us to incur additional expenditure in order to comply with these standards, and any inability to comply may result in a loss of business. Any failure to complete these audits or inspections to these end users’ satisfaction in the future could significantly harm our reputation and materially and adversely affect our business, financial condition, results of operations and prospects.

If we are unsuccessful at expanding into new product lines, our business and results of operations may suffer. In addition, our business and prospects depend on our ability to successfully identify market opportunities for new products, develop new technologies and develop and implement manufacturing processes for commercial production of the new products.

Our business model depends on our ability to successfully identify specialty chemicals with significant market opportunities for end users, develop new technologies and develop and implement manufacturing processes for commercial production. The manufacture of new and technologically advanced products involves a complex and uncertain process requiring highly-skilled engineering and development personnel. We may be unable to produce new products in a commercially viable manner, or at all. In addition, as specialty chemicals are characterized by

rapid technological advances, our technologies, processes and products may become uncompetitive or obsolete if our competitors adapt more quickly or cost effectively than we do to new technologies, processes and products or changes in customer demand or requirements. In order to keep pace with technological advances and to retain our competitive position, we will need to invest substantial financial resources to improve our technologies and production processes. If we fail to commercialize our research and development results or to improve our technologies and production processes, we may become less competitive and our results of operations may be negatively affected. Furthermore, we cannot assure you that products, technologies and processes that we have developed will permit cost effective commercial production on a larger scale.

Our production activities are and will continue to be conducted in concentrated locations. Damage to or disruptions at our production or research and development facilities could materially and adversely affect our business, financial condition and results of operations, especially since we do not have any business interruption insurance.

Our six operating production facilities are located in Shanghai and in Jiangsu and Zhejiang provinces, making our operations particularly vulnerable to natural and other disasters that may occur in those provinces. Operating hazards, natural disasters or other unanticipated or catastrophic events, including power interruptions, water shortages, storms, typhoons, fires, explosions, earthquakes, terrorist attacks, wars, and labor disputes in and around these provinces could cause damage to or destroy our facilities or equipment therein. Any of these or similar events could significantly impair our ability to operate our business, as well as delay our research and development activities and commercial production. Our facilities and equipment are expensive and potentially difficult and time-consuming to repair or replace. Catastrophic events may also result in damage to or the destruction of inventory located in our production facilities. In addition, we do not carry any business interruption or other insurance that would compensate us in the event of a loss of this type. The occurrence of such an event could result in substantial costs and diversion of resources, and our business, financial condition and results of operations may be materially and adversely affected.

Our business depends substantially on the continuing efforts of our executive officers, and our business may be severely disrupted if we lose their services.

Our future success depends substantially on the continuing service of our executive officers. In particular, we depend on the services of Dr. Jianhua Yang, our founder, chairman of our board of directors and chief executive officer, and other members of our senior management team. We do not currently maintain key employee life insurance for Dr. Yang or for any of our other employees. If one or more of our executive officers is unable or unwilling to continue serving in his or her present position, we may not be able to find a suitable replacement. As a result, our business may be severely disrupted, and we may incur additional expenses to recruit and retain new executive officers.

If our business grows rapidly, we may not be able to train and integrate new executive officers and operations staff into our operations in a timely manner to cope with the growing demands of our business. In addition, if any of our executives or other key employees joins a competitor or forms a competing company, we may lose some of our customers and our trade secrets could be compromised. Since our executive officers reside and hold most of their assets in the PRC, disputes that arise between us and our executive officers will most likely be resolved through the PRC legal system. Given the uncertainties associated with the PRC legal system, we may be unable to enforce employment agreements in that jurisdiction. See “—Risks Related to Doing Business in China—Uncertainties with respect to the PRC legal system could have a material adverse effect on us.”

Because competition for highly skilled employees is intense, we may not be able to attract and retain the highly skilled employees we need to support our business and our expected growth.

Due to the specialized and technical nature of our business and our reliance on proprietary manufacturing technologies, processes, patents and trade secrets, our future performance is largely dependent on the continued

service of, and on our ability to attract and retain, qualified scientific, technical, marketing and support personnel. Approximately 20% of our employees are production managers, engineers, technicians or research scientists, who have specialized experience and education. We compete with competitors and other employers, including chemical and engineering companies, for these qualified and experienced science and technology professionals. Without sufficient numbers of skilled employees, our operations would suffer from, among other things, deteriorating production standards and decreasing capacity utilization. Competition for such skilled personnel is intense, and replacing qualified employees is difficult. In order to effectively hire and retain a sufficient number of employees with the skills, experience and education that we require to operate and expand our business, we may be required to offer higher compensation and other benefits, which could materially and adversely affect our business, financial condition and results of operations. If we are unable to attract, retain and motivate our scientific, technical, marketing and support personnel, our business and prospects could be materially and adversely affected. Furthermore, we may not be able to hire sufficient numbers of skilled and experienced employees to replace those who leave, and we may be unable to redeploy and retrain our professionals to keep pace with continuing changes in technology, evolving standards and changing customer demands, which could adversely affect our business and prospects.

Our patents and other intellectual property are important assets to us, and if we are unable to protect them, our business, financial condition and results of operations may be harmed.

Our commercial success will depend in part on our ability to obtain and enforce trade secret and patent protection for our technologies, know-how, processes and products against third-party challenges. We will only be able to protect our technologies, processes and products from unauthorized use by third parties to the extent that we obtain valid and enforceable intellectual property rights with respect to them. Furthermore, the degree of future protection of our proprietary rights is uncertain because legal means may only provide limited protection and may not adequately protect our exclusive proprietary interest or permit us to gain or keep our competitive advantage.

Because most of our technologies and production methods or processes involve unpatented, proprietary technology, processes, know-how and data, we primarily rely on trade secret protection and contractual restrictions to safeguard our interests. However, trade secrets are difficult to protect. While we use reasonable efforts to protect our trade secrets, including requiring our employees, consultants, contractors or scientific and other advisors to enter into confidentiality agreements with us and endeavoring to induce the parties with whom we collaborate on research projects including the end users of our products, enter into confidentiality agreements, such persons may still disclose our information to competitors in violation of their agreements. In addition, confidentiality agreements may not be enforceable or provide an adequate remedy in the event of unauthorized use or disclosure. It may be difficult to prove or enforce a claim that a third party had illegally obtained and used our trade secrets. Our enforcement efforts would be expensive and time-consuming and the outcome would be unpredictable. In addition, our competitors may independently develop technologies that are equivalent to our trade secrets, in which case we would not be entitled to enforce our trade secrets and our business and prospects could be harmed.

As of the date of this annual report, we hold sixteen patents and have nineteen patent applications pending in China. We do not hold any patents and have not submitted any applications for any patents outside of China. The process of obtaining patent protection is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at reasonable costs or in a timely manner. Despite efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. Changes in either the patent laws or in interpretations of patent laws in China or other countries may diminish the value of our intellectual property. Accordingly, there is a risk that we will be unable to fully enforce our patents because we may not be able to claim protection for all the necessary components of our patents.

In addition, we have sold, and expect to continue to sell, a substantial portion of our products outside of China, where we currently have no patent protection. In these jurisdictions, others may independently develop

substantially equivalent technologies or processes, or otherwise gain access to our proprietary technologies or processes, and obtain patents for such intellectual properties, including in countries where we sell our products, which could allow those patent holders to prevent us from selling any of our products that infringe those foreign patents in those countries.

If we are not able to protect our trade secrets and obtain and defend our patents, we will not be able to exclude competitors from developing or producing competing products using the relevant technologies or processes, thereby adversely affecting our competitiveness which may materially and adversely affect our business, financial condition, results of operations and prospects.

In the event that our patents are challenged, invalidated or held unenforceable or we are found to infringe third party rights, our business, financial conditions and results of operations could be harmed.

The existence of a patent may not necessarily protect us from competition, as any issued patent may be challenged, invalidated or held unenforceable. Competitors may successfully challenge our patents, produce similar products using processes that do not infringe our patents or produce products in countries where we do not have patents. In addition, it is possible that competitors could, under PRC patent law, apply for and obtain a compulsory license to our patents should we refuse to grant a license under those patents on reasonable terms. The occurrence of any of these events could hurt our competitive position and decrease our revenues from product sales.

Furthermore, the existence of a patent does not provide assurance that the production, sale or use of our products does not infringe the patent rights of another. Third parties may also have blocking patents that could be used to prevent us from marketing products utilizing our patented technologies or processes. In addition, it takes many years for patent applications to go through the approval process and become issued patents, so it is possible that our technologies, processes or products may infringe patents that have not yet been issued. Specifically, in China and many other jurisdictions, the term of patent protection starts from the date the application is first filed. Therefore, our attempt to enforce any PRC patents may be defeated by third-party patents issued on a later date if the applications for those patents were filed before ours and the technologies or processes underlying such patents are the same or substantially similar to ours. In such a case, a third party with an earlier application could force us to pay to license its patented technology, sue us for patent infringement and challenge the validity of our patents. If a third party were to sue us for infringement, the litigation would divert substantial management time and resources, regardless of whether we were ultimately successful. Further, we could be liable for monetary damages and forced to redesign, which might prove impracticable, impossible or too costly our technology to avoid the infringement.

In addition, as we currently have no patent protection outside of China, if any third party successfully obtains patents in any of our markets outside of China covering technologies or processes that we use and enforce their patents against us, we may be prevented from selling products produced from the allegedly infringing technologies in those markets, which may materially and adversely affect our business, results of operations and prospects.

If we fail to protect the intellectual property rights of our customers, we may be subject to liability for breach of contract and our reputation may be damaged.

Protection of intellectual property associated with our production, particularly the production of intermediates used in pharmaceuticals, is critical to our customers. In manufacturing specialty chemicals used in pharmaceuticals, our customers often provide us with confidential information and intellectual property, which we have a contractual duty to protect. As a result, our success depends in substantial part on our ability to protect the proprietary rights of our customers. Protecting the intellectual property of our customers is particularly important to us given we are located in China, and Chinese companies and the Chinese legal system traditionally have not protected intellectual property to the same extent as their counterparts in the United States and other

jurisdictions. Despite measures we take to protect our and our customers’ intellectual property, unauthorized parties may attempt to obtain and use information that we regard as proprietary. Any unauthorized disclosure of our customers’ proprietary information could subject us to liability for breach of contract, as well as significant damage to our reputation, which could materially harm our business, financial condition, results of operations and prospects.

Litigation involving our intellectual property rights could prove costly, and either those costs or an adverse result in an intellectual property dispute could materially and adversely affect our business, financial condition and results of operations.

We may become a party to future litigation by third parties based on claims that our technologies, processes or products infringe the intellectual property rights of others or that we have misappropriated the trade secrets of others. We may also initiate lawsuits to defend the ownership or inventorship of our inventions and our trade secrets. Notably, enforcement of intellectual property rights may be more difficult and/or less effective in China when compared to other jurisdictions, such as the United States, that have a longer history of recognizing and enforcing intellectual property rights. Litigation relating to intellectual property rights is costly and diverts technical and management personnel from their normal responsibilities. Furthermore, we may not prevail in any such litigation or proceeding. A determination in an intellectual property litigation or proceeding that results in a finding of non-infringement by others to our intellectual property or an invalidation of our patents may result in the use by competitors of our technologies or processes and sale by competitors of products that resemble our products. In addition, a determination that we have infringed on the intellectual property rights of another may require us to do one or more of the following:

•

pay monetary damages to the other parties to compensate for their loss, which could adversely affect our financial condition and results of operations;

•

cease selling any of our infringing products, which could adversely affect our revenues;

•

cease use of infringing production processes, which could make our products less competitive;

•

obtain a license from the holder of the infringed intellectual property right, which might be costly or might not be available on reasonable terms, or at all, and such license may be non-exclusive and allow one or more of our competitors to have access to the same technology licensed to us; or

•

redesign our technologies, processes or products to make them non-infringing, which would be costly and time-consuming, or may not be possible at all.

Any adverse outcome from such litigation, or the time and cost of the proceedings themselves, could materially and adversely affect our business, financial condition and results of operations. In addition, there is a risk that some of our confidential information could be compromised by disclosure during intellectual property litigation.

Fluctuations in exchange rates could adversely affect our business and your investment.

Our sales are currently denominated in U.S. dollars, Euros and Renminbi, and our costs and expenses are primarily denominated in Renminbi. Fluctuations in currency exchange rates could have a significant effect on our financial stability due to a mismatch among various foreign-currency-denominated assets and liabilities. Fluctuations in exchange rates, particularly among the U.S. dollar, the Japanese Yen, the Euro and the Renminbi, affect our net profit margins and result in foreign-currency-exchange gains and losses on the corresponding assets and liabilities. For example, we incurred a total net foreign currency loss of RMB4.8 million (US$0.7 million) in 2010 including a net foreign currency exchange loss of RMB3.2 million (US$0.5 million) recognized in our statement of income and a foreign currency translation adjustment of RMB1.6 million (USD$0.2 million) through other comprehensive income as a component of equity. We cannot predict the impact of future exchange rate fluctuations on our results of operations and may incur material net foreign currency losses in the future.

In addition, the change in value of the Renminbi against the U.S. dollar and other currencies is affected by, among other things, changes in China’s political and economic conditions. The conversion of Renminbi into foreign currencies, including U.S. dollars, is based on rates set by the People’s Bank of China. The PRC government allowed the Renminbi to appreciate by more than 20% against the U.S. dollar between July 2005 and July 2008. Between July 2008 and June 2010, this appreciation halted and the exchange rate between the Renminbi and the U.S. dollar remained within a narrow band. Since June 2010, the PRC government has allowed the Renminbi to appreciate slowly against the U.S. dollar again. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the Renminbi against the U.S. dollar in the future. Because we rely on dividends paid to us by our operating subsidiaries, any significant revaluation of the Renminbi may have a material adverse effect on the value of, and any dividends payable on, our ADSs in foreign currency terms. For example, to the extent that we need to convert U.S. dollars we receive from our initial public offering into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount we would receive from the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar against the Renminbi would have a negative effect on the U.S. dollar amount available to us. Consequently, appreciation or depreciation in the value of the Renminbi relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms without giving effect to any underlying change in our business or results of operations.

In addition, an appreciation in the value of the Renminbi against foreign currencies could make our products more expensive for our international customers, which could adversely affect our international sales. Appreciation of the Renminbi could also reduce the competitiveness of the products of our PRC customers in the international market, which may potentially lead to a reduction in their orders from us and negatively affect our sales and results of operations. Furthermore, many of our competitors are foreign companies that could benefit from such currency appreciation, making it more difficult for us to compete against these companies. On the other hand, depreciation in the value of the Renminbi against foreign currencies could increase the costs of the raw materials we purchase from foreign suppliers.

Our future growth depends in part on our ability to make strategic acquisitions and investments and to establish and maintain strategic relationships, and the failure to do so could have a material adverse effect on our market penetration, revenue growth and prospects.

As part of our plan to sustain business growth, we intend to make strategic acquisitions and investments and to establish and maintain joint ventures and strategic relationships with third parties. We may engage in such activities to gain expertise in performing certain process design and development, production and logistical activities, access to raw materials, equipment and facilities or support our marketing and sales activities. In addition, we may enter into strategic relationships with third parties to gain access to capital or funding for research and development programs, process development programs and commercialization activities, or to reduce the risk of developing and scaling-up for commercial production of pipeline products.

Our strategic acquisitions, investments, joint ventures and strategic relationships with third parties may not be beneficial for our business. Furthermore, exploration into these transactions, whether or not actually consummated, could require us to incur significant expenses and could divert significant management time and attention from our existing business operations, which could harm the effective management of our business. This could have a material adverse effect on our market penetration, revenues growth and results of operations.

In addition, strategic acquisitions, investments and relationships with third parties could subject us to a number of risks, including:

•

our inability to integrate new operations, products, personnel, services or technologies;

•

unforeseen or hidden liabilities, including exposure to lawsuits associated with newly acquired companies;

•

the diversion of resources from our existing businesses;

•

disagreement with joint venture or strategic relationship partners;

•

our inability to generate sufficient revenues to offset the costs and expenses of strategic acquisitions, investments, joint venture formations, or other strategic relationships; and

•

potential loss of, or harm to, employees or customer relationships.

Any one or more of these events could impair our ability to manage our business, result in our failure to derive the intended benefits of the strategic acquisitions, investments, joint ventures or strategic relationships, result in us being unable to recover our investment in such initiatives or otherwise have a material adverse effect on our business, financial condition and results of operations.

Our future liquidity needs are uncertain and we may need to raise additional funds in the future.

We may need to raise additional funds within the foreseeable future if our expenditures exceed our current expectations. This could occur for a number of reasons, including, for example, if we decide to devote a significant amount of financial resources to the research and development of projects that we believe to have significant commercial potential. Our ability to raise additional funds in the future is subject to a variety of uncertainties, including:

•

our future financial condition, results of operations and cash flows;

•

general market conditions for capital-raising activities by early stage China-based companies; and

•

economic, political and other conditions in China and elsewhere.

If our revenues are not sufficient to meet our operational needs and capital requirements or if we have future liquidity needs or other business reasons, we may need (or we may elect) to sell additional equity or debt securities or borrow funds to raise capital. The sale of additional equity or equity-linked securities could result in additional dilution to our shareholders. The incurrence of additional debt would result in increased debt service obligations and could result in operating and financing covenants that would restrict our operations or our ability to pay dividends.

Our largest shareholder, who holds a significant portion of our outstanding equity, may have substantial influence over our company and his interests may not be aligned with the interests of our other shareholders.

Dr. Jianhua Yang, our founder, chief executive officer and chairman of our board of directors, beneficially owns approximately 55.8% of our outstanding share capital as of the date of this annual report. As such, Dr. Jianhua Yang has substantial influence over our business, including decisions regarding mergers, consolidations and the sale of all or substantially all of our assets, election of directors and other significant corporate actions. This concentration of ownership may discourage, delay or prevent a change in control of our company, which could deprive our shareholders of an opportunity to receive a premium for their shares as part of a sale of our company and might negatively impact the price of our ADSs. These actions may be taken even if they are opposed by our other shareholders.

Our grant of employee share options, restricted shares or other share-based compensation and any future such grants could have an adverse effect on our net income.

We adopted our share incentive plan in 2008 and modified it in 2010. We have granted share options under this share incentive plan. We recognize share-based compensation as compensation expense in the statement of operations based on the fair value of equity awards on the date of the grant, with the compensation expense recognized over the period in which the recipient is required to provide service in exchange for the equity award. We adopt a fair value-based method for measuring the compensation expense related to share-based compensation. The additional expenses associated with share-based compensation may reduce the attractiveness of issuing share options or restricted shares under our share incentive plan. However, if we do not grant share

options or restricted shares, or reduce the number of share options or restricted shares that we grant, we may not be able to attract and retain key personnel. If we grant more share options or restricted shares to attract and retain key personnel, the expenses associated with share-based compensation may adversely affect our net income.

Current or worsening economic conditions could adversely impact our business.

Since early 2008, there has been a significant deterioration in the U.S. and global economy and thus liquidity has contracted significantly. In light of the recent European debt crisis, the global economy is still uncertain and may continue to deteriorate in the future. There were, and could be in the future, domino effects from such turmoil on our business. Like other players in the market, we face risks attendant to changes in consumer demand for products that incorporate our specialty chemicals, economic environments, changes in interest rates and instability in securities markets around the world, among other factors. In particular, the worsening economic climate had resulted in decreased industrial output and decreased consumer demand for products including consumer electronics, which beginning in early 2009 had resulted in decreased demand for our specialty chemicals used in the manufacture of TFT-LCDs in 2009. In addition, we had been unfavorably impacted by the decreased demand in the global agrochemical market beginning in the second half of 2009. In 2010, we saw a strong recovery in demand for our specialty chemicals used in the electronics market and some mild recovery in demand for our specialty chemicals used in the agrochemical market. But we cannot assure you that these resumed growths will continue in the near future as there are many other contingencies and the global economy may further deteriorate. Any systemic economic or financial crisis could cause revenues for our industry as a whole to decline dramatically and could materially and adversely affect our results of operations.

Climate change, other environmental concerns and green initiatives present commercial challenges, economic risks and physical risks that could harm our results of operations or affect the manner in which we conduct our business

Increasing climate change and environmental concerns could affect the results of our operations if any of our customers would request us to exceed any standards set for environmentally compliant products. If we are unable to offer such products, we may lose market share to our competitors.

Further, energy costs in general could increase significantly due to climate change regulations. Therefore, our energy costs may increase significantly if utility or power companies pass on their costs, fully or partially, such as those associated with carbon taxes, emission cap and carbon credit trading programs.

In addition, more frequent droughts and floods, extreme weather conditions and rising sea levels could occur due to climate change. The impact of such changes could be significant. For instance, our sales to the agrochemical end-market was negatively impacted by the bad weather pattern in the second half of 2009. For example, transportation suspension caused by extreme weather conditions could harm the delivery of our supplies and the distribution of our products. We cannot predict the economic impact, if any, of disasters or climate change.

Risks Related to Doing Business in China

Substantially all of our operations are conducted in China. Accordingly, to a significant extent, our business, financial condition, results of operations and prospects are subject, to economic, political and legal developments in China.

We face risks related to natural disasters and health epidemics in China, which could have a material adverse effect on our business and results of operations.

Our business could be materially and adversely affected by natural disasters or the outbreak of health epidemics in China. For example, in May 2008, Sichuan Province suffered a strong earthquake measuring

approximately 8.0 on the Richter scale that caused widespread damage and casualties. In addition, in the last decade, the PRC has suffered health epidemics related to the outbreak of avian influenza and severe acute respiratory syndrome, or SARS. In April 2009, an outbreak of the H1N1 virus, also commonly referred to as “swine flu”, occurred in Mexico and has spread to other countries. Cases of swine flu have been reported in Hong Kong and mainland China. If the outbreak of swine flu were to become widespread in China or increase in severity, it could have an adverse effect on economic activity in China, and our business and operations could be adversely affected. Any future natural disasters or health epidemics in the PRC could also have a material adverse effect on our business and results of operations.

Uncertainties with respect to the PRC legal system could have a material adverse effect on us.

The PRC legal system is a civil law system based on written statutes. Unlike common law systems, prior court decisions may be cited for reference but have limited precedential value. In 1979, the PRC government began to promulgate a comprehensive system of laws and regulations governing economic matters in general. The overall effect of legislation since then has been to significantly enhance the protections afforded to various forms of foreign investments in China. We conduct the majority of our business through our subsidiaries established in China. These subsidiaries are generally subject to laws and regulations applicable to foreign investment in China and, in particular, laws applicable to wholly foreign-owned enterprises. However, since these laws and regulations are relatively new and the PRC legal system continues to rapidly evolve, the interpretations of many laws, regulations and rules are not always uniform and enforcement of these laws, regulations and rules involves uncertainties, which may limit legal protections available to us. In addition, some regulatory requirements issued by certain PRC government authorities may not be consistently applied by other government authorities (including local government authorities), thus making strict compliance with all regulatory requirements impractical, or in some circumstances, impossible. For example, we may have to resort to administrative and court proceedings to enforce the legal protection that we enjoy either by law or contract. However, since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. These uncertainties may impede our ability to enforce the contracts we have entered into with our business partners, customers and suppliers. By way of further example, although required by PRC law, many foreign-invested enterprises, including our PRC subsidiaries, have not historically obtained approvals from the National Development and Reform Commission, or NDRC, or its counterparts before receiving the approval from the Ministry of Commerce or its counterparts for their establishment. However, the legal consequence for failure to obtain the NDRC approval by those foreign-invested enterprises, including our PRC subsidiaries, is not prescribed under the current PRC law. In addition, such uncertainties, including the inability to enforce our contracts, together with any development or interpretation of PRC law that is adverse to us, could materially and adversely affect our business and operations. Furthermore, intellectual property rights and confidentiality protections in China may not be as effective as in the United States or other countries. Accordingly, we cannot predict the effect of future developments in the PRC legal system, including the promulgation of new laws, changes to existing laws or the interpretation or enforcement thereof, or the preemption of local regulations by national laws. These uncertainties could limit the legal protections available to us and other foreign investors, including you. In addition, any litigation in China may be protracted and result in substantial costs and diversion of our resources and management attention.

Unauthorized use of our intellectual property by third parties and the expenses we might need to incur in protecting our intellectual property rights, may adversely affect our business.

Our patents, trade secrets and other intellectual property are important to our success. In particular, our proprietary manufacturing processes, many of which we protect as trade secrets, are important to our business and we believe are one of our competitive advantages. Unauthorized use of any of our intellectual property may adversely affect our business and reputation. We rely on patent law, trade secret protection and confidentiality agreements with our employees, clients, business partners and others to protect our intellectual property rights. Nevertheless, it may be possible for third parties to obtain and use our intellectual property without authorization.

The unauthorized use of intellectual property is common and widespread in China and enforcement of intellectual property rights by Chinese regulatory agencies is inconsistent. Moreover, litigation may be necessary in the future to enforce our intellectual property rights. Future litigation could result in substantial costs and diversion of our management’s attention and resources, and could disrupt our business, as well as have a material adverse effect on our financial condition and results of operations. Given the relative unpredictability of China’s legal system and potential difficulties enforcing a court judgment in China, we may be unable to halt the unauthorized use of our intellectual property through litigation, which could adversely affect our competitive position, our ability to attract customers, and our results of operations.

Adverse changes in political and economic policies of the PRC government could have a material adverse effect on the overall economic growth of China, which could reduce the demand for our products and materially and adversely affect our results of operations and competitive position.

Substantially all of our business operations are conducted in China with some of our sales made in China. Accordingly, our business, financial condition, results of operations and prospects are affected significantly by economic, political and legal developments in China. The Chinese economy differs from the economies of most developed countries in many respects, including:

•

the degree of government involvement;

•

the level of development;

•

the growth rate;

•

the control of foreign exchange;

•

access to financing; and

•

the allocation of resources.

While the Chinese economy has grown significantly in the past 30 years, the growth has been uneven, both geographically and among various sectors of the economy. The PRC government has implemented various measures to encourage, but also to control economic growth and guide the allocation of resources. Some of these measures benefit the overall Chinese economy but may also have a negative effect on us. For example, our financial condition and results of operations may be adversely affected by government control over capital investments or changes in tax regulations that are applicable to us.

The Chinese economy has been transitioning from a planned economy to a more market-oriented economy since the late 1970s. Although in recent years the PRC government has implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive assets and the establishment of sound corporate governance in business enterprises, a substantial portion of the productive assets in China is still owned by the PRC government. The continued control of these assets and other aspects of the national economy by the PRC government could materially and adversely affect our business. The PRC government also exercises significant control over China’s economic growth through the allocation of resources, controlling payment of foreign-currency-denominated obligations, setting monetary policy and providing preferential treatment to particular industries or companies. Since late 2003, the PRC government implemented a number of measures, such as raising bank reserves against deposit rates to place additional limitations on the ability of commercial banks to make loans and raise interest rates, in order to control the pace of economic growth. These actions, as well as future actions and policies of the PRC government, could cause decreased economic activity in China and could materially affect our business, liquidity, access to capital, results of operations and financial condition.

China’s social and political conditions are also not as stable as those of the United States and other developed countries. Any sudden changes to China’s political system or the occurrence of widespread social unrest could have negative effects on our business and results of operations. In addition, China has contentious

relations with some of its neighbors, most notably Taiwan. A significant further deterioration in such relations could have negative effects on the Chinese economy and lead to changes in governmental policies that would be adverse to our business interests.

We rely on dividends paid by our consolidated subsidiaries for our cash needs, and any limitation on the ability of our subsidiaries to make payments to us could have a material adverse effect on our ability to conduct our business.

We conduct all of our business through our consolidated subsidiaries incorporated in China. We rely on dividends paid by these consolidated subsidiaries for our cash needs, including the funds necessary to pay any dividends and other cash distributions to our shareholders, to service any debt we may incur and to pay our operating expenses. The payment of dividends by entities established in China is subject to limitations. Regulations in China currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China. Each of our PRC subsidiaries, including wholly foreign-owned enterprises, or WFOEs, and joint venture enterprises is also required to set aside at least 10% of its after-tax profit based on PRC accounting standards each year to its general reserves or statutory capital reserve fund until the aggregate amount of such reserves reaches 50% of its respective registered capital. Our statutory reserves are not distributable as loans, advances or cash dividends. In addition, if any of our PRC subsidiaries incurs debt on its own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us. As of December 31, 2010, our PRC subsidiaries had allocated RMB85.8 million (US$13.0 million) to these reserves. Any limitations on the ability of our PRC subsidiaries to transfer funds to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends and otherwise fund and conduct our business.

In addition, the newly enacted PRC Enterprise Income Tax Law, or the EIT Law, and its relevant regulations also impose a withholding tax at 10%, unless reduced by a tax treaty, for dividend distributions out of earnings accumulated beginning on January 1, 2008. Undistributed earnings generated prior to January 1, 2008 are exempt from such withholding tax. Under the Arrangement between the PRC and the Hong Kong Special Administrative Region on the Avoidance of Double Taxation and Prevention of Fiscal Evasion, or the China-Hong Kong tax arrangement, a qualified Hong Kong tax resident which is the “beneficial owner” and holds 25% or more of the equity interest in a PRC-resident enterprise is entitled to a reduced withholding rate of 5%. We are actively monitoring the withholding tax and are evaluating appropriate organizational changes to minimize the corresponding tax impact.

PRC regulation of loans and direct investment by offshore holding companies to PRC entities may delay or prevent us from making loans or additional capital contributions to our PRC operating subsidiaries and affiliated entities, which could materially and adversely affect our liquidity and our ability to fund and expand our business.

As an offshore holding company of our PRC operating subsidiaries and affiliates, we may make loans to our PRC subsidiaries and consolidated PRC affiliated entities, or we may make additional capital contributions to our PRC subsidiaries. Any loans to our PRC subsidiaries are subject to PRC regulations and approvals. For example, loans by us to our wholly owned subsidiaries in China that are foreign-invested enterprises to finance their activities cannot exceed statutory limits and must be registered with the State Administration of Foreign Exchange in China, or the SAFE, or its local branch.

We may also decide to finance our wholly owned subsidiaries by means of capital contributions. These capital contributions must be approved by the Ministry of Commerce in China or its local counterpart. We cannot assure you that we will be able to complete these government registrations or obtain the government approvals on a timely basis, if at all, with respect to future loans or capital contributions by us to our subsidiaries or any of their respective subsidiaries. If we fail to complete these registrations or obtain the approvals, our ability to capitalize our PRC operations may be negatively affected, which could adversely and materially affect our liquidity and our ability to fund and expand our business.

The approval of the Chinese Securities Regulatory Commission, or the CSRC, might have been required in connection with our initial public offering, and, if required, we could be subject to sanction, fines and other penalties.

On August 8, 2006, six PRC regulatory agencies, including the CSRC, promulgated the “Provisions Regarding Mergers and Acquisitions of Domestic Enterprises by Foreign Investors,” or the new M&A rule, which took effect on September 8, 2006, to more effectively regulate foreign investment in PRC domestic enterprises. The new M&A rule also contains a provision requiring offshore special purpose vehicles, or SPVs, formed for overseas listing purposes and controlled by PRC individuals to obtain the approval of the CSRC prior to publicly listing their securities on an overseas stock exchange.

The application of this new M&A rule is currently unclear. However, our PRC counsel, Jin Mao PRC Lawyers, has advised us that based on its understanding of the current PRC laws, rules and regulations and the new M&A rule, the new M&A rule does not require that we obtain prior CSRC approval for the listing and trading of our ADSs on the NYSE, because our acquisition of the equity interest in our PRC subsidiaries is not subject to the new M&A rule due to the fact that each of them was already a foreign-invested enterprise before September 8, 2006, the effective date of the new M&A rule.

Jin Mao PRC Lawyers has further advised us that their opinions summarized above are subject to the timing and content of any new laws, rules and regulations or clear implementations and interpretations from the CSRC in any form relating to the new M&A rule.

However, if the CSRC or another PRC regulatory agency subsequently determines CSRC prior approval was required, we may face regulatory actions or other sanctions from the CSRC or other PRC regulatory agencies. These regulatory agencies may impose fines and penalties on our operations, limit our operating privileges, delay or restrict the repatriation of the proceeds from the initial public offering of our ADSs into China or payment or distribution of dividends by our PRC subsidiaries, or take other actions that could have a material adverse effect on our business, financial condition, results of operations, reputation and prospects, as well as the trading price of our ADSs. Also, if the CSRC later requires that we obtain its approval, we may be unable to obtain a waiver of the CSRC approval requirements, if and when procedures are established to obtain such a waiver. Any uncertainties or negative publicity regarding this CSRC approval requirement could have a material adverse effect on the trading price of our ADSs.

We cannot predict when the CSRC may promulgate additional implementing rules or other guidance, if at all. Moreover, implementing rules or guidance, to the extent issued, may fail to resolve current ambiguities under this new PRC regulation. Uncertainties and/or negative publicity regarding this new PRC regulation could have a material adverse effect on the trading price of our ADSs.

The new M&A rule establishes more complex procedures for some acquisitions of Chinese companies by foreign investors, which could make it more difficult for us to pursue growth through acquisitions in China.

The new M&A rule establishes additional procedures and requirements that could make some acquisitions of Chinese companies by foreign investors more time-consuming and complex, including requirements in some instances that the Ministry of Commerce be notified in advance of any change-of-control transaction in which a foreign investor takes control of a Chinese domestic enterprise. In the future, we may grow our business in part by acquiring complementary businesses, although we do not have any plans to do so at this time. Complying with the requirements of the new M&A rule to complete such transactions could be time-consuming, and any required approval processes, including obtaining approval from the Ministry of Commerce, may delay or inhibit our ability to complete such transactions, which could affect our ability to expand our business or maintain our market share.

Recent PRC regulations relating to the establishment of offshore special purpose companies by PRC residents may subject our PRC resident shareholders or our PRC subsidiaries to penalties, limit our ability to distribute capital to our PRC subsidiaries, limit our PRC subsidiaries’ ability to distribute funds to us, or otherwise adversely affect us.

The SAFE issued a public notice in October 2005, or the SAFE Circular No. 75, requiring PRC residents to register with the local SAFE branch before establishing or controlling any company outside of China for the purpose of capital financing with assets or equities of PRC companies, referred to in the SAFE Circular No. 75 as SPVs. PRC residents who are shareholders of SPVs established before November 1, 2005 were required to register with the local SAFE branch before March 31, 2006. Further, PRC residents are required to file amendments to their registrations with the local SAFE branch if their SPVs undergo a material event involving changes in capital, such as changes in share capital, mergers and acquisitions, share transfers or exchanges, spin-off transactions or long-term equity or debt investments. On May 29, 2007, the SAFE issued guidance to its local branches for the implementation of the SAFE Circular No. 75. This guidance standardizes more specific and stringent supervision on the registration requirement relating to the SAFE Circular No. 75 and further requests PRC residents holding any equity interests or options in SPVs, directly or indirectly, controlling or nominal, to make overseas investment foreign exchange registration with the SAFE. Our current beneficial owners have made the registration successfully. However, any failure by beneficial owners of our ordinary shares to amend their registration or the failure of future beneficial owners of our company who are PRC residents to comply with the registration procedures set forth in the SAFE Circular No. 75 could subject such beneficial owners and our PRC subsidiaries to fines and legal sanctions. See “Item 4. Information on the Company—B. Business Overview—Regulation—Foreign Exchange Regulation.”

Under the Implementation Rules of the Administration Measure for Individual Foreign Exchange, or the Individual Foreign Exchange Rule, and an implementation guidance on the rule, issued in January and March 2007, respectively, by the SAFE, PRC citizens who are granted share options by an overseas publicly-listed company are required, through a PRC agent who may be the PRC subsidiary of such overseas publicly-listed company, to register with the SAFE and complete certain other procedures related to the share options. We and our PRC citizen employees who have been granted share options, or PRC optionees, are subject to these regulations as our company is now an overseas publicly-listed company. If we or our PRC optionees fail to comply with these regulations, we or our PRC optionees may be subject to fines and legal sanctions. However, as these rules were only recently promulgated, it is currently unclear as to how they will be interpreted and implemented. See “Item 4. Information on the Company—B. Business Overview—Regulation—Regulations Relating to Employee Share Options.”

Dividends we receive from our operating subsidiaries located in the PRC may be subject to PRC withholding tax.

The EIT Law and the implementation regulations for the EIT Law issued by the PRC State Council, became effective as of January 1, 2008. The EIT Law provides that a maximum income tax rate of 20% may be applicable to dividends payable to non-PRC investors that are “non-resident enterprises,” to the extent such dividends are derived from sources within the PRC, and the State Council has reduced such rate to 10% through the implementation regulations. According to the China- Hong Kong tax arrangement, dividends paid to enterprises incorporated in Hong Kong are subject to a withholding tax of 5%. We are a Cayman Islands holding company and substantially all of our income may be derived from dividends we receive from our operating subsidiaries located in the PRC. Thus, dividends paid to us through our Hong Kong subsidiary by our subsidiaries in China may be subject to the 5% income tax if we are considered as a “non-resident enterprise” under the EIT Law. If we are required under the EIT Law to pay income tax for any dividends we receive from our subsidiaries, it will materially and adversely affect the amount of dividends, if any, we may pay to our shareholders and ADS holders.

We may be classified as a “resident enterprise” for PRC enterprise income tax purposes, which could result in unfavorable tax consequences to us and our non-PRC shareholders.

The Enterprise Income Tax Law provides that enterprises established outside of China whose “de facto management bodies” are located in China are considered “resident enterprises” and are generally subject to the uniform 25% enterprise income tax rate on their worldwide income. In addition, a circular issued by the State Administration of Taxation regarding the standards used to classify certain Chinese-invested enterprises controlled by Chinese enterprises or Chinese group enterprises and established outside of China as “resident enterprises” clarified that dividends and other income paid by such “resident enterprises” will be considered to be PRC source income, subject to PRC withholding tax, currently at a rate of 10%, when recognized by non-PRC shareholders. This recent circular also subjects such “resident enterprises” to various reporting requirements with the PRC tax authorities. Under the implementation regulations to the enterprise income tax, a “de facto management body” is defined as a body that has material and overall management and control over the manufacturing and business operations, personnel and human resources, finances and treasury, and acquisition and disposition of properties and other assets of an enterprise. In addition, the recent circular mentioned above details that certain Chinese-invested enterprises controlled by Chinese enterprises or Chinese group enterprises will be classified as “resident enterprises” if the following are located or resident in China: senior management personnel and departments that are responsible for daily production, operation and management; financial and personnel decision making bodies; key properties, accounting books, company seal, and minutes of board meetings and shareholders’ meetings; and half or more of the directors with voting rights or senior management. If the PRC tax authorities determine that we are a “resident enterprise,” we may be subject to enterprise income tax at a rate of 25% on our worldwide income and dividends paid by us to our non-PRC shareholders as well as capital gains recognized by them with respect to the sale of our stock may be subject to a PRC withholding tax. This will have an impact on our effective tax rate, a material adverse effect on our net income and results of operations, and may require us to withhold tax on our non-PRC shareholders.

Dividends payable by us to our foreign investors and gain on the sale of our ADSs or ordinary shares may become subject to taxes under PRC tax laws.

Under the EIT Law and implementation regulations issued by the State Council, PRC income tax at the rate of 10% is applicable to dividends payable to investors that are “non-resident enterprises,” which do not have an establishment or place of business in the PRC, or which have such establishment or place of business but the relevant income is not effectively connected with the establishment or place of business, to the extent such dividends have their sources within the PRC. Similarly, any gain realized on the transfer of ADSs or shares by such investors is also subject to 10% PRC income tax if such gain is regarded as income derived from sources within the PRC. According to the China-Hong Kong tax arrangement, dividends paid to enterprises incorporated in Hong Kong are subject to a withholding tax of 5%. If we are considered a PRC “resident enterprise,” it is unclear whether dividends we pay with respect to our ordinary shares or ADSs, or the gain you may realize from the transfer of our ordinary shares or ADSs, would be treated as income derived from sources within the PRC and be subject to PRC tax. If we are required under the EIT Law to withhold PRC income tax on dividends payable to our non-PRC investors that are “non-resident enterprises,” or if you are required to pay PRC income tax on the transfer of our ordinary shares or ADSs, the value of your investment in our ordinary shares or ADSs may be materially and adversely affected.

Governmental control of currency conversion may limit our ability to receive dividends from our subsidiaries in China.

Certain portions of our revenues and expenses are denominated in Renminbi. If our revenues denominated in Renminbi increase or expenses denominated in Renminbi decrease in the future, we may need to convert a portion of our revenues into other currencies to meet our foreign currency obligations, including, among others, debt service or payment of dividends declared, if any, in respect of our ordinary shares. Under China’s existing foreign exchange regulations, our PRC subsidiaries are allowed to pay dividends in foreign currencies, without

prior approval from the SAFE, by complying with certain procedural requirements. However, the PRC government may take further measures in the future to restrict access to foreign currencies for current account transactions.

Foreign exchange transactions by our subsidiaries under capital accounts continue to be subject to significant foreign exchange controls and require the approval of, or registration with, PRC governmental authorities. In particular, if one subsidiary borrows foreign currency loans from us or other foreign lenders, these loans must be registered with SAFE or its local counterparts, and if we finance such subsidiary by means of additional capital contributions, these capital contributions must be approved by certain government authorities including the Ministry of Commerce or its local counterparts. These limitations could affect the ability of our subsidiaries to obtain foreign exchange through debt or equity financing.

New labor laws in the PRC may adversely affect our results of operations.

On June 29, 2007, the PRC government promulgated a new labor law, namely, the Labor Contract Law of the PRC, or the New Labor Contract Law, which became effective on January 1, 2008. The New Labor Contract Law imposes greater liabilities on employers and significantly affects the cost of an employer’s decision to reduce its workforce. Further, it requires certain terminations be based upon seniority and not merit. In the event we decide to significantly change or decrease our workforce, the New Labor Contract Law could adversely affect our ability to enact such changes in a manner that is most advantageous to our business or in a timely and cost-effective manner, thus materially and adversely affecting our financial condition and results of operations.

If we are found to have failed to comply with applicable laws, we may incur additional expenditures or be subject to significant fines and penalties.

Our operations are subject to PRC laws and regulations applicable to us. However, many PRC laws and regulations are uncertain in their scope, and the implementation of such laws and regulations in different localities could have significant differences. In certain instances, local implementation rules and the actual implementation are not necessarily consistent with the regulations at the national level. Although we strive to comply with all the applicable PRC laws and regulations, we cannot assure you that the relevant PRC government authorities will not later determine that we have not been in compliance with certain laws or regulations. In particular, there is a PRC regulation requiring all employees to make contributions to a housing provident fund based on their salary level and their employers to match such contributions. However, some employees are reluctant to make such contributions as they do not perceive such contribution will benefit them, and this regulation generally has not been rigorously enforced. We have allowed our employees to make contributions on a voluntary basis and then match their contributions. However, we cannot assure you that in the future the PRC government will not start to enforce this regulation more rigorously. Although there are no material penalties stipulated in this regulation, if we are found to not be in compliance, we may be required to bring current any past deficiencies, which could adversely affect our financial condition and results of operations.

The continuation or worsening of recent trends toward price inflation in China could erode some of the advantages of operating in a relatively low-cost jurisdiction such as China, which could negatively affect our competitive advantages and our results of operations.

In recent years, inflation in China has increased. According to the China Statistics Bureau, consumer price inflation in China was 5.9%, -0.7% and 3.3% in 2008, 2009 and 2010, respectively. Because we purchase raw materials from suppliers in China, this price inflation has increased the costs of the raw materials we must purchase for production. This trend risks counteracting the competitive advantage we enjoy as a result of the relatively lower production costs we incur from operating in China. If inflationary trends continue in China, China could lose its competitive advantage as a low-cost manufacturing venue, including with respect to our products, which could in turn lessen any competitive and reputational advantages we gain through China-based manufacturing. Accordingly, continuing or increasing inflation in China may weaken our competitiveness in our markets and have a material adverse effect on our business and results of operations.

Risks Related to Ownership of Our Shares or ADSs

The market price for our ADSs may be volatile, which could result in substantial losses to you.

The market price for our ADSs is likely to be highly volatile and subject to wide fluctuations in response to factors, many of which are beyond our control and which may occur regardless of our actual operating performance, including the following:

•

announcements of technological or competitive developments;

•

regulatory developments in China affecting us, our customers or our competitors;

•

announcements regarding patent or other intellectual property litigation or the issuance of patents to us or our competitors or updates with respect to the enforceability of patents or other intellectual property rights generally in China or internationally;

•

actual or anticipated fluctuations in our quarterly operating results;

•

changes in financial estimates by securities research analysts;

•

changes in the economic performance or market valuations of other specialty chemicals companies;

•

addition or departure of our executive officers and key research personnel;

•

release or expiry of lock-up or other transfer restrictions on our outstanding ordinary shares or ADSs;

•

sales or perceived sales of additional ordinary shares or ADSs; and

•

Our board of directors’ decision to implement new share repurchase programs and to change dividend policies.

In addition, the securities market has, from time to time, experienced significant price and volume fluctuations that are not related to the operating performance of particular companies. Any of these factors could result in large and sudden changes in the volume and trading price of our ADSs and could cause holders of our ADSs to incur substantial losses. In the past, following periods of volatility in the market price of a company’s securities, shareholders have often instituted securities class action litigation against that company. If we were involved in a class action suit or other securities litigation, it would divert the attention of our senior management, require us to incur significant expense and, whether or not adversely determined, could have a material adverse effect on our business, financial condition, results of operations and prospects.

Substantial future sales of our ADSs or the anticipation of future sales of our ADSs in the public market could cause the price of our ADSs to decline.

Sales of our ADSs or common shares in the public market, or the perception that these sales could occur, could cause the market price of our ADSs to decline. As of December 31, 2010, we had 2,163,190,740 ordinary shares outstanding, including 545,746,140 ordinary shares represented by 9,095,769 ADSs. Sales of our ordinary shares or ADSs held by our significant shareholders or any other shareholder, or the availability of these securities for future sale, may have a negative effect on the market price of our ADSs.

In addition, certain holders of our ordinary shares or their transferees and assignees will have the right to cause us to register the sale of their shares under the Securities Act upon the occurrence of certain circumstances. Registration of these shares under the Securities Act would result in these shares becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. Sales of these registered shares in the public market could cause the price of our ADSs to decline.

Our articles of association contain anti-takeover provisions that could discourage a third party from acquiring us, which could limit our shareholders’ opportunity to sell their shares, including ordinary shares represented by our ADSs, at a premium.

Our memorandum and articles of association contain provisions which limit the ability of others to acquire control of our company or cause us to engage in change-of-control transactions. These provisions could have the

effect of depriving our shareholders of an opportunity to sell their shares at a premium over prevailing market prices by discouraging third parties from seeking to obtain control of our company in a tender offer or similar transaction. For example, our board of directors has the authority, without further action by our shareholders, to issue preferred shares. These preferred shares may have better voting rights than our ordinary shares, in the form of ADSs or otherwise, and could be issued quickly with terms calculated to delay or prevent a change in control of our company or make removal of management more difficult. If our board of directors decides to issue preferred shares, the price of our ADSs may fall and the voting rights of the holders of our ordinary shares and ADSs may be diluted.

Certain actions require the approval of a supermajority of at least two-thirds of the members of our board of directors which, among other things, would allow our non-independent directors to block a variety of actions or transactions, such as a merger, asset sale or other change of control, even if all of our independent directors unanimously voted in favor of such action, thereby further depriving our shareholders of an opportunity to sell their shares at a premium.

Holders of ADSs have fewer rights than shareholders and must act through the depositary to exercise their rights.

Holders of ADSs do not have the same rights of our shareholders and may only exercise voting rights with respect to the underlying ordinary shares in accordance with the provisions of the deposit agreement. Under our memorandum and articles of association, the minimum notice period required to convene a general meeting is twenty-one days. When a general meeting is convened, you may not receive sufficient notice of a shareholders’ meeting to permit you to withdraw your ordinary shares to allow you to cast your vote with respect to any specific matter. In addition, the depositary and its agents may not be able to send voting instructions to you or carry out your voting instructions in a timely manner. We will make all reasonable efforts to cause the depositary to extend voting rights to you in a timely manner, but we cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your ADSs. Furthermore, the depositary and its agents will not be responsible for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, you may not be able to exercise your right to vote and you may lack recourse if your ADSs are not voted as you requested. In addition, in your capacity as an ADS holder, you will not be able to call a shareholders’ meeting.

You may be subject to limitations on transfers of your ADSs.

Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deem it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason.

Your right to participate in any future rights offerings may be limited, which may cause dilution to your holdings and you may not receive cash dividends if it is impractical to make them available to you.

We may from time to time distribute rights to our shareholders, including rights to acquire our securities. However, we cannot make rights available to you in the United States unless we register the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. Also, under the deposit agreement, the depositary bank will not make rights available to you unless the distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, you may be unable to participate in our rights offerings and may experience dilution in your holdings.

In addition, the depositary of our ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. However, the depositary may, at its discretion, decide that it is not lawful or reasonably practicable to make a distribution available to any holders of ADSs. For example, the depositary may determine that it is not practicable to distribute certain property through the mail, or that the value of certain distributions may be less than the cost of mailing them. In these cases, the depositary may decide not to distribute such property and you will not receive such distribution.

We are a Cayman Islands company and, because judicial precedent regarding the rights of shareholders is more limited under Cayman Islands law than that under U.S. law, you may have less protection for your shareholder rights than you would under U.S. law.

Our corporate affairs are governed by our memorandum and articles of association, as amended and restated from time to time, the Cayman Islands Companies Law (as amended) and the common law of the Cayman Islands. The rights of shareholders to take action against the directors, actions by noncontrolling shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from English common law, which has persuasive, but not binding, authority on a court in the Cayman Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has a less developed body of securities laws than the United States. In addition, some U.S. states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate law than the Cayman Islands.

As a result of all of the above, public shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or controlling shareholders than they would as shareholders of a U.S. public company.

You may have difficulty enforcing judgments obtained against us.

We are a Cayman Islands company and substantially all of our assets are located outside of the United States. Substantially all of our current operations are conducted in the PRC. In addition, many of our directors and officers are nationals and residents of countries other than the United States. As a result, it may be difficult for you to effect service of process within the United States upon these persons. It may also be difficult for you to enforce in U.S. courts judgments obtained in U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us and our officers and directors, many of whom are not residents in the United States and the substantial majority of whose assets are located outside of the United States. In addition, there is uncertainty as to whether the courts of the Cayman Islands or the PRC would recognize or enforce judgments of U.S. courts against us or such persons predicated upon the civil liability provisions of the securities laws of the United States or any state and it is uncertain whether such Cayman Islands or PRC courts would be competent to hear original actions brought in the Cayman Islands or the PRC against us or such persons predicated upon the securities laws of the United States or any state.

We may be classified as a passive foreign investment company, which could result in adverse United States federal income tax consequences to U.S. holders.

Based on our financial statements, relevant market data and the projected composition of our income and valuation of our assets, including goodwill, we do not believe that we were a passive foreign investment company, or PFIC, for 2010, and we do not expect to be a PFIC in 2011 or to become one in the foreseeable future, although there can be no assurance in this regard. If, however, we become a PFIC, such characterization could result in adverse U.S. tax consequences to you if you are a U.S. investor. For example, if we become a PFIC, our U.S. investors will become subject to increased tax liabilities under U.S. tax laws and regulations and

will become subject to burdensome reporting requirements. The determination of whether or not we are a PFIC is made on an annual basis and depends on the composition of our income and assets from time to time. Specifically, we will be classified as a PFIC for U.S. tax purposes if either: (i) 75% or more of our gross income in a taxable year is passive income, or (ii) the average percentage of our assets (which include cash) by (determined on a quarterly average) value in a taxable year which produce or are held for the production of passive income (which includes cash) is at least 50%. The calculation of the value of our assets will be based, in part, on the then prevailing market value of our ADSs, which is subject to change. We cannot assure you that we will not be a PFIC for 2011 or any future taxable year. For more information on PFICs, see “Item 10.E Additional Information—Taxation—United States Federal Income Taxation.”

ITEM 4.

INFORMATION ON THE COMPANY

A. History and Development of the Company

Our legal and commercial name is Chemspec International Limited. We are a holding company incorporated in the Cayman Islands on May 30, 2006 to facilitate investment by foreign financial investors and as part of our restructuring conducted in 2006. We are a Cayman Islands exempted company with limited liability and our affairs are governed by our memorandum and articles of association, as amended and restated from time to time, and the Companies Law (as amended) of the Cayman Island. Our current operations are conducted through our subsidiaries organized and located in the PRC. Our ADSs have been listed on the New York Stock Exchange under the symbol “CPC” since June 24, 2009. Our principal executive offices are located at No. 200, Wu Wei Road, Shanghai 200331, People’s Republic of China, and our telephone number at this address is (86) 21-6363-9090. Our registered office in the Cayman Islands is at c/o Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. Our website address is http://www.chemspec.com.cn. The information on our website does not form a part of this annual report. Our agent for service of process in the United States is Law Debenture Corporate Services Inc., located at 400 Madison Avenue, Fourth Floor, New York, New York 10017.

Shanghai ChemSpec Corporation, or Shanghai ChemSpec, was founded in November 1996 by Dr. Jianhua Yang and Teng Zhou Rui Yuan Fragrance Factory, or Fragrance Factory. In April 2006, Wisecon Limited, or Wisecon, was incorporated in Hong Kong. The transfer of the equity interests in our operating subsidiaries to Wisecon was completed in July 2006 for the purpose of establishing a corporate structure to facilitate the raising of capital from investors outside of China. In February 2006, Stanley Space Limited, or Stanley Space, was incorporated in the British Virgin Islands as the holding company of Wisecon. The initial beneficial owner of Stanley Space was Dr. Jianhua Yang. Stanley Space Limited purchased all of the equity interests of Wisecon in April 2006 for HK$1.0. On May 30, 2006, to facilitate investments by foreign financial investors, Chemspec International Limited, or Chemspec, was incorporated in the Cayman Islands. In August 2006, we issued ordinary shares to existing shareholders of Stanley Space in exchange for the respective equity interest that these shareholders held in Stanley Space, and Chemspec International Limited became the ultimate holding company of our operating subsidiaries.

Shanghai ChemSpec Trading Co., Ltd., or Shanghai ChemSpec Trading, which was incorporated in June 1999 in the PRC as a wholly owned subsidiary of Shanghai ChemSpec Co., purchases raw materials and supplies from suppliers located in China for our core manufacturing business. In October 2007, we transferred all our interests in Shanghai ChemSpec Trading to a third party. In addition, we entered into a series of share transfer agreements to purchase 80% equity interests in Jiangsu Wei Er in January 2008. In March 2008, we acquired an additional 20% interest in Zhejiang Huajing Fluorochemical and Technology Company Limited, or Huajing Company, to increase our equity interest to 80%. Furthermore, we acquired the remaining 20% equity interest in Jiangsu Wei Er for cash consideration of RMB 41,000,000 on November 5, 2009 and 100% of the equity interest of Jiangsu Kangpeng Nong Hua Co., Ltd., or Kangpeng Nong Hua for cash consideration of RMB25,000,000 on November 9, 2009, respectively. On March 18, 2010, we also acquired the 8% minority equity interest of Binghai Kanjie Chemicals Co., Ltd., or Binhai Kangjie, from an independent third party for cash consideration of

RMB 2,800,000. As of the date of this annual report, we conduct substantially all of our operations through the following subsidiaries:

•

Shanghai ChemSpec, our wholly owned subsidiary incorporated in the PRC that (i) provides overall management and operational planning for all of our subsidiaries and (ii) engages in research and development, the design, manufacture and sale of complex fluorine-based specialty chemicals;

•

Taixing ChemSpec, our wholly owned subsidiary incorporated in the PRC that engages in the manufacture of the full range of our products;

•

Shanghai Qi Yue, our wholly owned subsidiary incorporated in the PRC that engages in trading activities and arranges the export of our products;

•

Shanghai Wan Su, our wholly owned subsidiary incorporated in the PRC that engages in the manufacture of the full range of our products;

•

Huajing Company, a subsidiary in which we hold an 80% equity interest incorporated in the PRC that engages in the manufacture of the full range of our products;

•

Quzhou Kangpeng, our wholly owned subsidiary incorporated in the PRC that engages in the manufacture of the full range of our products;

•

Jiangsu Wei Er, our wholly owned subsidiary incorporated in the PRC that engages in the manufacture of specialty chemicals used in agrochemicals and pharmaceuticals;

•

Binhai Kangjie, our wholly owned subsidiary incorporated in the PRC that engages in the manufacture of the full range of our products; and

•

Kangpeng Nong Hua, our wholly owned subsidiary incorporated in the PRC that engages in the manufacture and sales of chemical compounds.

On June 24, 2009, our ADSs were listed on the New York Stock Exchange.

For information relating to our capital expenditure, see “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources—Capital Expenditures.”

Going Private Transaction

On November 11, 2010, our board of directors received a proposal letter from Dr. Jianhua Yang, our founder, chief executive officer and chairman of our board of directors, to acquire all of our outstanding shares in a going private transaction. On March 21, 2011, we entered into a definitive agreement and plan of merger with Halogen Limited, an entity jointly owned by Dr. Jianhua Yang and an affiliate of Primavera Capital Management Ltd., or Primavera, and Halogen Mergersub Limited, or Merger Sub, a Cayman Islands exempted company wholly owned by Halogen Limited.

Under the terms of the merger agreement, each of our ordinary shares (including shares represented by ADSs, each of which represents 60 ordinary shares) issued and outstanding immediately prior to the effective time of the merger will be cancelled in exchange for the right to receive US$0.135 (or US$8.10 per ADS) in cash without interest (less US$0.05 per ADS cancellation fees payable to the ADS depositary), except for the ordinary shares and ordinary shares represented by ADSs beneficially owned by Dr. Jianhua Yang, Mr. Yunlong Yuan and Mr. Weinian Qi which will be cancelled without receiving any consideration.

Our board of directors, acting upon the unanimous recommendation of the independent committee, which is composed solely of directors unrelated to any of Halogen Limited, Merger Sub, Primavera or any of our management members, approved the merger agreement and resolved to recommend that our shareholders vote to adopt the merger agreement. The independent committee negotiated the terms of the merger agreement with the assistance of its financial and legal advisors.

The merger contemplated by the merger agreement is subject to the adoption of the merger agreement by an affirmative vote of shareholders in accordance with Cayman Islands law and an affirmative vote of the majority of our disinterested shareholders that are present and voting in person or by proxy at a meeting of our shareholders, as well as certain other customary closing conditions. Dr. Jianhua Yang has agreed to vote to adopt the merger agreement. Standard Chartered Bank (Hong Kong) Limited, or SCB, Halogen Limited and Merger Sub have entered into a facility agreement pursuant to which SCB has agreed to provide financing for the transaction, subject to certain conditions. We will schedule a meeting of our shareholders for the purpose of voting on the adoption of the merger agreement. On May 3, 2011, we filed a going private transaction statement on Schedule 13E-3 which attaches as an exhibit a preliminary proxy statement that, subject to completion, will be used in connection with the extraordinary general meeting of our shareholders, which we currently expect to hold in the third quarter of 2011. If completed, the merger will, under Cayman Islands laws, result in us becoming a privately-held company and our ADSs would no longer be listed on the New York Stock Exchange. The Company, as the surviving company, will continue to do business under the name “Chemspec International Limited” following the merger and will be wholly owned by Halogen Limited.

Based on the number of ordinary shares expected to be outstanding on the share record date, approximately 460,325,150 ordinary shares owned by unaffiliated shareholders must be voted in favor of the proposal to adopt the merger agreement in order for the proposal to be approved, assuming all unaffiliated shareholders will be present and voting in person or by proxy at the extraordinary general meeting.

B. Business Overview

We are a leading China-based contract manufacturer of highly engineered specialty chemicals.

We manufacture specialty chemicals, which are typically highly engineered chemicals used as building blocks in the manufacture of more advanced chemicals or to enhance the performance of the end products manufactured by our end users in various industries including electronics, pharmaceuticals and agrochemicals. In manufacturing specialty chemicals for our customers, we also provide process design and process development services, which enable efficient and rapid production of specialty chemicals that are incorporated into our end users’ own products, thereby enhancing the value of our customers’ end products. We believe that our highly experienced management and research and development capabilities, our ability to rapidly respond to new customer processing specifications and requirements, and our long-term cooperative relationships with our major customers distinguish us from many contract manufacturers of chemicals and that the need to develop some or all of these attributes to be competitive effectively creates barriers to entry into the fields in which we operate. With our six major flexible and responsive manufacturing facilities, we are equipped to produce specialty chemicals in both small batches for development stage projects and in large-scale amounts for commercialized projects, according to our customers needs. We refer to projects with sales of less than one metric ton per year, which typically indicates that they are still in a development or experimental stage, as “pipeline projects.” We refer to projects with sales of one metric ton per year or more as “commercialized projects.” We sell our specialty chemicals directly to end users that incorporate them into their products and to trading companies that then sell our products to final end users. We also assist certain of our long-term customers to source specialty chemicals from other producers in China. Since our establishment in 1996, we have developed a reputation for collaborating with our customers to develop and introduce more sophisticated design processes to produce specialty chemicals that meet their specific requirements. We believe that our strong research and development capabilities, efficient management of the manufacturing process and proven track record give us a competitive advantage over our competitors.

We have a demonstrated record of providing tailored contract manufacturing solutions to end users in the major end markets that use specialty chemicals. In particular, we are a principal supplier of fluorinated specialty chemicals used in the manufacture of thin film transistor liquid crystal displays, or TFT-LCDs, and other electronics. We are also a supplier of fluorinated specialty chemicals to a number of international pharmaceutical companies for use in a number of patented, FDA-approved drugs and to agrochemical companies. We expect that sales of our fluorinated specialty chemicals used in pharmaceutical research, development and manufacturing will benefit from both the rapid pace of pharmaceutical innovation and the introduction of new medicines and

recent trends in the pharmaceutical industry towards outsourcing of production of specialty chemicals as well as certain product and research and development functions. We believe we are well positioned to take advantage of increasing market demand for outsourcing of the design and manufacture of more complex and highly engineered specialty chemicals, including both fluorinated and other types of specialty chemicals.

We increased total headcount from 1,585 employees at the end of 2009 to 1,794 at the end of 2010. We also diversified our customer base and built a solid foundation that will allow us to diversify our product mix from traditional chemical intermediates manufacturing into downstream Active Pharmaceutical Ingredients, or APIs, for the pharmaceutical industry and Active Ingredients, or AIs, for the agrochemical industry. We received technology grants from the PRC central and local governments for four out of our six major manufacturing subsidiaries. Grants totaled RMB7.5 million (US$1.1 million) in the year 2010, a strong recognition of our leading position in different technologies in many industrial fields in which we are actively involved. We also increased the number of approved patents from 11 at the end of 2009 to 15 at the end of 2010. We currently have 35 approved and pending approval patents.

Our Products

We manufacture specialty chemicals on a contract basis for our customers. The manufacture of these specialty chemicals includes chemical design, processing and manufacturing solutions tailored to our customers’ specifications. The products we provide to customers are tailored to their requirements but generally include developing an efficient manufacturing process for the requested specialty chemicals, providing small-volume, pilot-level production and then providing commercial level production of specialty chemicals. The specialty chemicals we manufacture generally contain fluorine and are developed and produced by us through proprietary processes tailored for each individual specialty chemical with the qualities and performance characteristics required by the customer. These specialty chemicals are then incorporated into products made by our customers and end users for various applications in different industries, such as electronics, pharmaceuticals and agrochemicals, depending on the end user’s own product specifications and applications.

The prices we charge for our products incorporate fees for our process development services, as we provide these services to customers who place orders for products or whom we expect will place orders for products based on our previous transactions with them.

End Uses of Our Products

The products we manufacture are categorized as specialty chemicals in our industry, rather than as commodity chemicals. Specialty chemicals are highly engineered and produced on a custom basis to customer or end-user specifications. Our products are used in various end markets, including electronics, pharmaceuticals and agrochemicals. The specialty chemicals we produce are generally used by our customers and end users as intermediates, because they serve as building blocks for the manufacture of downstream products to produce a desired function or enhance performance.

Electronics Intermediates

The specialty chemicals we produce for the electronics industry are fluorinated intermediates primarily used in the production of TFT-LCDs and, to a lesser extent, other electronics products, such as semiconductors.

Liquid Crystal Intermediates . Fluorine enables liquid crystal formulations to retain liquid crystallinity with significantly reduced viscosity, resulting in much quicker response times and improved quality of TFT-LCDs. Our products are used as intermediates in the production of materials used by manufacturers of TFT-LCDs, primarily for computer monitors and LCD televisions, or LCD TVs. Our TFT-LCD products have been historically used as intermediates to make liquid crystal materials. We continue to work with our end users of these products to develop more advanced generations of specialty chemicals in this area, such as more complex, higher value-added multi-fluorine liquid crystal intermediaries, to further improve response time and picture quality of TFT-LCDs as the TFT-LCD industry continues to grow and develop.

Other Electronics Materials . We also produce materials that are used in other electronics applications, such as monomers for the synthesis of polymers used in the semiconductor industry, coatings and adhesives used in electronics manufacturing and specialty chemicals which increase the photo-sensitivity of products.

Pharmaceutical Intermediates

These specialty chemicals are used as pharmaceutical intermediates in the production of a variety of drugs, such as anti-depressants, diabetes medications, antibiotics, and pain killers. In recent years, the use of fluorine substitution has aided the design and effectiveness of many new pharmaceutical drugs and has resulted in pharmacological agents with improved biological properties, including steroidal and non-steroidal, anti- inflammatory agents, anticancer and antiviral agents and central nervous system drugs for the management of mental illnesses such as depression and psychoses.

We design production processes for our pharmaceutical products based on chemical structures identified by our customers. In the pharmaceutical sector, we typically target customers involved in the development of new drugs that address large markets. By working with pharmaceutical customers on new projects that are generally in an early stage of development, we are favorably positioned to be one of the principal suppliers of specialty chemicals for those customers when the drug reaches commercialization.

We also manufacture advanced chemical intermediates that are of more general application in the pharmaceutical industry and are incorporated into a range of different pharmaceuticals by end users.

Agrochemicals

We also manufacture specialty chemicals used as intermediates by agrochemical manufacturers and fine chemical companies. Our products in this category are used by large agrochemical manufacturers to make herbicides, pesticides and fungicides.

Process Development

In manufacturing specialty chemicals, we work to optimize reaction processes in order to produce specialty chemicals more efficiently than through existing processes. By optimizing and selecting more effective methods of compound synthesis, we reduce the cost of production for our customers. This may be achieved by reducing the quantity of raw materials or number of steps used in reactions, improving the yield of the requested specialty chemicals and accelerating the time needed for production and the overall time-to-market of the product. Our manufacturing facilities are effectively configured to accommodate varying scales of production volume. Our kilo-lab is used to produce small quantities of specialty chemicals that are in the early stages of development and are used on a test basis, or for complex specialty chemicals that are required only in small quantities. Our pilot plant is used to assist our customers during the development stage of products which they may order in larger quantities at a later date. Customers then may move from ordering smaller scale test production, measured in grams, to scale-up quantities, measured in kilograms, to process optimization quantities, which are measured in hundreds of kilograms, to commercial process development quantities, which are measured in tons. Through this range of services, we are able to meet the range of customer demands from clinical trials through commercialization and mass production.

Manufacturing Operations

We currently own and operate six major production facilities in China located in Shanghai, Jiangsu province and Zhejiang province. Each of our facilities has the flexibility to produce any of our specialty chemicals. We are in the process of expanding our manufacturing capacity. See “—Headquarters and Facilities.”

We also have the capability to employ specialized reaction technologies including low temperature (-80°C) reactions, organo-metallic reactions, catalytic reactions, high-vacuum reactions, pressure reactions, and reactions that must be carried out under moisture-free and air-free conditions. Our manufacturing processes also involve the use of cryogenic processes, high reactive and corrosive processes and high pressure processes.

We outsource limited production of simpler raw materials and chemicals requiring lower levels of technical expertise, including commodity chemicals, to third-party manufacturers in China, which enables us to focus our limited production capacity on more complex products that can be sold for higher prices.

We also have the ability to internally produce raw materials, such as fluorinated nitrobenzenes, which are essential ingredients used in producing our specialty chemicals. This provides us with a competitive cost advantage and assists us in maintaining a steady source of supply for certain materials.

In December 2008, we entered into a joint venture agreement with Central Glass pursuant to which we have invested US$2.0 million (approximately RMB13.7 million) through Shanghai ChemSpec and Quzhou Kangpeng to become a noncontrolling investor in the joint venture, which is named Central Glass Chemspec Company Limited. The production facility of Central Glass Chemspec Company Limited is currently under construction and does not generate revenue or pay dividend to us.

Sales of Purchased Goods

We also assist customers to source from other producers in China specialty chemicals involving lower levels of technology that we do not normally manufacture ourselves. These sourcing projects, which we also refer to as sales of purchased goods, generally involve locating appropriate sources of the specialty chemicals requested by our customers, examining the chemicals for quality assurance and purchasing and repackaging the chemicals under our brand name for export to the customer. These sourcing projects fluctuate according to individual customer demand.

Our Customers

Our customers consist both of (i) trading companies that then sell our products to the actual end users and (ii) direct end users, which primarily include electronics, pharmaceutical and agrochemical companies. We had 106 customers in seven countries and Hong Kong in 2010. Our end users include many of the leading global companies in the pharmaceutical, agrochemical and electronics industries, including Central Glass Co., Ltd., Chisso Corporation, Eli Lilly and Company, Lonza Group Ltd. and Merck KGaA. Our end users also include several of the global top pharmaceutical companies and several of the global top agrochemical companies in the world, as measured by sales of those companies in 2010. The majority of our end users are based in Japan, the United States and Europe. Our production methods and facilities have been audited periodically by several major international pharmaceutical companies. To date, most of our customers have returned to us for additional and often larger volume and longer term projects. In accordance with industry practice, we sell substantially all of our products on a purchase-order basis and generally do not enter into long- term contracts.

The table below illustrates our growing customer base:


	As of December 31,
	2008			2009			2010
Top three customer concentration (% of sales)		65	%		61	%		65	%
Total number of customers		71			107			106

In 2010, our top three customers accounted for approximately 65% of our sales. See “Item 3. Key Information—D. Risk Factors—Risks Relating to Our Company and Our Industry—Our current dependence on a limited number of customers may cause significant fluctuations or declines in our revenues” and “—A payment failure by any of our large customers could significantly harm our cash flows and results of operations.”

Sales, Marketing and Distribution

As a contract manufacturer with long-term relationships with many of our customers, we focus on cultivating our existing relationships, enhancing communications with them and responding to their manufacturing needs.

We periodically visit our customers to receive feedback on product quality, discuss their requirements and expectations, and anticipate production requirements. We also rely upon referrals from existing customers to extend our customer base and participate in international product fairs and exhibitions in relevant industries to make new contacts and cultivate new customer relationships. We have close to fifteen employees involved in sales and marketing, many of whom have technical expertise and industry knowledge.

Pricing of many of our products is based upon negotiation with customers. The primary factors that affect pricing are the level of technological differentiation required, the complexity of the manufacturing process, the amount of time required for product development and ramp up to commercial production levels, the level of research and development required to bring a new product to market, the cost of raw materials and the level of competition in the market.

Suppliers

Our suppliers are primarily located in China, and the principal raw materials or essential ingredients used in the production of our products are generally readily available in China. Prices for our main raw materials and ingredients are generally driven by underlying petrochemical benchmark prices and energy costs.

The raw materials that we purchased from our top five suppliers accounted for 35%, 26% and 36% of our total cost of revenues in 2008, 2009 and 2010, respectively, representing 20%, 16% and 22%, respectively, of our sales in those years.

Our principal raw materials include fluorine, hydrofluoric acid, and petroleum-based solvents. We purchase these raw materials from multiple suppliers at prevailing market prices, and alternative sources are generally available to enable our business to continue in the event of any interruption from present sources. In general, we buy materials on an as-needed basis on the open market at the market price when customer orders are placed. We also undertake some internal production of raw materials using our own facilities. See “—Manufacturing Operations.”

Research and Development

We believe that in order to maintain and enhance our margins and remain competitive, we must continually invest in research and development, product and process improvements and specialized customer services. Through research and development, we seek to introduce more highly engineered, higher-end specialty chemicals and more efficient and cost-effective manufacturing processes. We emphasize a customer-driven approach in developing new and improved processes and providing superior customer service through our technical staff that are directly responsive and relevant to our customers’ needs. Furthermore, through regular direct contact with our key customers and end users of our products, our research and development personnel accumulate relevant expertise and can better anticipate our customers’ and their end users’ requirements in planning research and development projects.

Our research and development activities are based in our headquarters in Shanghai. As of March 31, 2011, our research and development team included 101 research scientists and technicians, 16 and 22 of whom have received Ph.D. and M.S. degrees, respectively, in chemistry, engineering and other related sciences. Our research and development facilities include a broad range of synthesis and testing equipment to help us develop new processes to produce the products which our customers desire. Our research and development efforts focus on improving the quality of our products, decreasing the manufacturing time and time-to-market required for products and lowering manufacturing costs. We completed the construction of a new and state-of-art research and development center in Shanghai in October 2009. The facility will be able to support up to 350 research scientists and will enhance our ability to develop new processes and assist customers in research and development.

Development of new production processes is integrated with quality assurance procedures. Quality assurance procedures include strict record keeping of all procedures and processes and monitoring procedures to ensure the consistent application of our manufacturing processes. We also maintain quality control manuals for internal distribution among our factory managers and employees to maintain consistent production standards. Periodic audits by several major international pharmaceutical companies also provide independent third-party monitoring and review of our facilities. We also continuously focus on improving plant yields, lowering fixed costs and using our existing manufacturing capacity more efficiently for expanding sales.

We spent RMB27.5 million, and RMB30.9 million and RMB65.7 million (US$10.0 million) on research and development in 2008, 2009 and 2010, respectively.

Intellectual Property

We protect our and our customers’ intellectual property primarily by maintaining strict control over the use of production processes. We also rely on confidentiality procedures and contractual provisions to protect our technology in cases where the technology is not patented or patentable. All of our employees are required to execute confidentiality and nondisclosure agreements with us when their employment begins. In addition, for each project, only the personnel associated with the project have access to the related intellectual property. Access to proprietary data is limited to authorized personnel to prevent unintended disclosure or otherwise using our intellectual property without proper authorization.

Due to the rapid pace of change in our products as a result of constant changes in the requirements of our customers or the companies that use our products, we pursue only a limited number of patents. As of the date of this annual report, we had 16 patents granted by, and 19 patent applications pending before, the State Intellectual Property Office of the PRC, or SIPO. The majority of these patents and patent applications relate to process patents.

Generally, we do not use the proprietary technology of others, in order to minimize the risk of patent infringement and to ensure that our products may be sold to any customer. In special cases, technology transfer from the companies that use our products does occur pursuant to confidentiality agreements in order to expedite product delivery for those companies. In these cases, those companies generally indemnify us for the use of their technologies.

Occupational Health and Safety

Our business operations involve significant risks and hazards that are inherent in such activities. These risks and hazards could result in damage to, or destruction of, properties or production facilities, personal injury, environmental damage, business interruption and possible legal liability.

We regard occupational health and safety as an important operational and social responsibility and we have implemented an internal system for environmental, health and safety. In compliance with law, we provide periodic health checks for all employees to reduce the risk of work-related illnesses. In recent years, we have undertaken many measures to improve our facilities’ safety and we maintain a safety management system that sets targets against which performance is measured. We have adopted detailed safety procedures based on production methods of each plant in compliance with national safety guidelines, including weekly safety inspections and training in safe work practices for our employees. In addition, our facilities have been audited and approved by several major international pharmaceutical companies for compliance with their own quality assurance standards and PRC environmental, health and safety standards.

We have not had any fatalities in our production facilities. Although we have experienced minor accidents, including machinery incidents, our production facilities have not experienced major accidents that we believe to have had, individually or in the aggregate, a material adverse effect on our business, financial condition or results

of operations. While we are committed to maintaining high safety standards at our production facilities, accidents may occur in the future. See “Item 3. Key Information—D. Risk factors—Risks Related to Our Company and Our Industry—Our operations are subject to various risks associated with our use, handling, storage and disposal of hazardous materials, many of which are toxic and flammable. If we are found liable for contamination, injury to employees or others, or other harms related to our use, handling, storage and disposal of hazardous materials, our business, financial condition and results of operations will be adversely affected.”

Environmental

Our operations involve the use, handling, processing, storage, transportation and disposal of hazardous materials and our production processes generate noise, waste water, gaseous and other industrial wastes. Accordingly, we are subject to extensive environmental, health and safety regulations at the national, provincial and local level in China, including those governing the discharge of pollutants into the air and water, the management and disposal of hazardous substances and wastes, the maintenance of safe conditions in the workplace and the production, handling, labeling and use of chemicals used or produced by us, as well as requirements relating to operating permits that are subject to renewal or modification. Ongoing compliance with such regulations is an important consideration for us and we are committed to conducting our operations in compliance with applicable regulations. However, we are exposed to the risk of claims for environmental remediation or restoration and violations of environmental, health and safety regulations or permit requirements may result in restrictions being imposed on operating activities, substantial fines, penalties, damages or other costs.

We have consistently endeavored to maintain and improve our environmental, health and safety systems to try to maintain among the highest standards of chemical manufacturers based in China and to respond rapidly and effectively to all regulatory developments requiring more stringent standards. For example, we maintain (i) water treatment facilities for recycling and to ensure disposal of liquid waste that complies with all applicable laws and regulations, (ii) equipment to minimize noise pollution in compliance with local government regulations and (iii) high environmental and recycling standards that increase the efficiency of our production. In addition, we generally dispose of gaseous emissions by collecting them as they are produced and dissolving them in our internal water system for disposal with liquid waste, and solid waste is disposed of through qualified third- party contractors. However, in the past, certain of our manufacturing facilities have experienced environmental incidents as follows:

•

Jiangsu Wei Er: In 2007, prior to our acquisition of Jiangsu Wei Er, one of its production lines was temporarily shut down by local environmental officials and the facility received a “yellow” annual rating, or third of five possible ratings, on a local environmental ratings review, indicating that it is compliant with national pollutant discharge standards but did not meet certain other environmental protection standards. Subsequently, Jiangsu Wei Er implemented additional environmental measures and improved its local environmental rating to a ‘blue” annual rating for 2007, or second of five possible ratings. Since acquiring Jiangsu Wei Er in early 2008, we have endeavored to apply our overall environmental, health and safety standards to this manufacturing facility and to maintain and improve the annual environmental rating of this facility in 2008. In early June 2008, Jiangsu Wei Er was listed as a “high security risk company” in Yancheng City due to the historically inappropriate design of its chemical storage area, which was maintained close to a high-voltage electric transmission line at the boundary of the local government chemical processing zone in which Jiangsu Wei Er is located, and which was deemed to present a potential fire accident and toxic material leak. In order to remedy this deficiency, we engaged the local chemical processing zone authority to relocate this high-voltage electric line away from our chemical storage area and submitted a risk-elimination report, and in July 2008 the local authorities removed Jiangsu Wei Er from the list of “high security risk companies”;

•

Shanghai Qi Yue: In January 2008, local customs officials in Shanghai discovered and confiscated a shipment of dangerous chemicals that had been inappropriately declared by our subsidiary Shanghai Qi Yue due to an error in staff documentation processing resulting in a fine of RMB30,000. We have subsequently taken measures to strengthen and standardize our internal procedures and protocols for completing customs documentation;

•

Huajing Company: In March 2007, the general manager of Huajing Company was fined RMB20,000 in connection with a nitric acid leak. We have since implemented more stringent hazardous materials control procedures in Huajing Company consistent with the procedures and protocols we set at our headquarters; and

•

Taixing Chemspec: In October 2006, Taixing Chemspec was temporarily shut down by local officials due to the use of an inappropriate material in the facility’s underground rain discharge pipelines and was ordered to rectify noncompliance with certain environmental protection rules. We refurbished the underground rain, sewage and manufacturing discharge pipeline systems of this facility to comply with national and local environmental protection rules in late 2006. The facility was reopened later that year. In early 2008, during a nationwide safety risk assessment campaign, local safety production supervision officers discovered a potential safety risk in Taixing ChemSpec related to the elevation of a fire water pipeline crossing our facility side gate was 0.5 meters lower than the national standard, which could have potentially blocked access to the fire safety route. As of July 2008, we completed reconstruction of that side gate to elevate the fire water pipeline above the level required by the national standard.

We believe we are currently in compliance with applicable environmental regulations in all material aspects and have all necessary environmental and safety permits to operate our business as it is presently conducted. We do not believe that any of the incidents described above have had, individually or in the aggregate, a material adverse effect on our business and we are not aware of any material breaches of any environmental laws or regulations applicable to us. We believe that our environmental protection systems and facilities comply with applicable PRC national, provincial and local environmental protection laws and regulations in all material respects. The PRC government is moving toward more rigorous enforcement of applicable environmental laws and regulations and the adoption of more stringent environmental standards. Such developments could affect our financial condition and results of operations. We expect to continue to invest in our environmental control systems as the environmental regulatory regime in China develops. See “Item 3. Key Information—D. Risk factors—Risks Related to Our Company and Our Industry—Our use, production and disposal of hazardous materials subject us to stringent environmental, health and safety regulations. Any actual or alleged violation of these regulations could result in significant regulatory actions, fines and other penalties, including suspending production or ceasing operations, substantial civil or criminal claims resulting in potentially significant monetary damages, adverse publicity, and other negative consequences to our business,” “—Our operations are subject to various risks associated with our use, handling, storage and disposal of hazardous materials, many of which are toxic and flammable. If we are found liable for contamination, injury to employees or others, or other harms related to our use, handling, storage and disposal of hazardous materials, our business, reputation, financial condition and results of operations will be adversely affected” and “—Our failure to obtain and maintain permits, licenses and registrations necessary to conduct our business could materially harm our business and prospects.”

Competition

We compete with a variety of companies, including large global chemical companies and small specialty chemicals companies, in the specialty chemicals market. We believe the principal factors that determine competition in our industry include process development and innovation capabilities, quality of product, speed of production and rapid time-to-market manufacturing, ability to produce a wide range of products according to users’ individual technical specifications while maintaining low costs and price. We primarily compete with other specialty chemicals manufacturers, such as Lonza Group Ltd., Evonik Degussa GmbH, Lanxess AG, Balchem Corporation, Rohm and Haas Company, and Sigma-Aldrich Corporation, as well as some Chinese manufacturers, such as WuXi PharmaTech Co., Ltd., Asymchem Laboratories Co., Ltd., Xi’an Ruilian Modern Electronic Chemicals Co., Ltd., Yantai Valiant Fine Chemicals Co., Ltd. and Zhejiang Yongtai Chemical Co., Ltd. Most foreign competitors are large chemical companies with manufacturing facilities located both in their own countries as well as in lower cost manufacturing sites, including China. China-based competitors are generally small chemical companies.

We believe we compete favorably on the basis of our rapid turnaround time, design and innovation capabilities, research and development teams, price and geography. We continue to differentiate ourselves from

our competitors by our speed of bringing new products to commercial production, our process design expertise, our efficient manufacturing processes and our focus on product quality and customer service. In addition, we believe we maintain cost and manufacturing flexibility advantages as a China-based manufacturer versus international manufacturers which are based in higher-cost jurisdictions. Because of these competitive advantages, we are able to maintain and expand our customer base with a steady and increasing revenue stream.

Employees

See “Item 6. Directors, Senior Management and Employees—D. Employees” for certain information relating to our employees.

Headquarters and Facilities

We built and moved into our headquarter office in October 2009. Our principal headquarters are located at No. 200, Wu Wei Road, Putuo District, Shanghai, PRC. The majority of our senior management team, administrative staff and research and development employees began to work in the new office buildings since October 2009. We currently own and operate six major manufacturing facilities in the eastern coastal region of China. The following table sets forth the area and manufacturing capacity of each facility as of December 31, 2010:


Facility	Site area (sq. ft.)		Reactor volume (liters)		Number of workshops		Location	Products produced
Taixing ChemSpec		358,811		220,000		7	Taixing, Jiangsu province	Full range of products
Shanghai Wan Su		700,474		277,000		13	Fengxian District, Shanghai	Full range of products
Huajing Company		244,865		186,000		6	Quzhou, Zhejiang province	Specialty chemicals used in electronics and pharmaceutical applications
Jiangsu Wei Er		7,169,797		823,500		13	Xiangshui, Jiangsu province	Specialty chemicals used in agrochemical
Binhai Kangjie		1,125,457		626,300		4	Binhai, Jiangsu province	Full range of products
Quzhou Kangpeng		595,626		169,000		4	Quzhou, Zhejiang province	Specialty chemicals used in electronics

As of December 31, 2010, we had aggregate reactor volume of 2.3 million liters.

Insurance

As of December 31, 2010, we carried approximately RMB891.7 million (US$135.1 million) of insurance coverage, which includes coverage for certain of our property, plant and equipment and inventory, and for employee injury and third-party liability for all of our operations. We also have a D&O insurance with US$10 million coverage. We do not have insurance coverage on our other assets, other types of litigations or product liability. We do not maintain business interruption insurance. We believe our coverage and insured limits are customary for similar companies in our industry in China. In addition, we carry medical, third-party liability and unemployment insurance for our employees in compliance with applicable regulations.

We will continue to review and assess our risk exposures and make necessary and appropriate adjustments to our insurance coverage in line with our needs and with industry practice with respect to insurance in China. If we were held liable for amounts and claims exceeding the limits of our insurance coverage or outside the scope of our insurance coverage or if we suffer significant claims giving rise to increased premiums and deductibles, our business, results of operations and our financial condition may be materially and adversely affected.

Capital Expenditures and Divestitures

See “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources—Capital Expenditures” for a discussion of our capital expenditures.

Legal Proceedings

We are not currently involved in any material litigation, arbitration or administrative proceedings. We may from time to time become a party to various litigation, arbitration or administrative proceedings arising in the ordinary course of our business.

Regulation

Environmental Regulations

Our production processes generate noise, wastewater, gaseous and other industrial wastes, and our operating activities involve hazardous materials. We are subject to a variety of governmental regulations related to environmental protection. The major PRC environmental regulations applicable to us include the Environmental Protection Law, the Environmental Impact Appraisal Law, the Law on the Prevention and Control of Water Pollution and Implementation Rules of the Law on the Prevention and Control of Water Pollution.

The Environmental Protection Law sets out the legal framework for environmental protection in the PRC. The Ministry of Environmental Protection, or the MEP, of the PRC is primarily responsible for the supervision and administration of environmental protection work nationwide and formulating national waste discharge limits and standards. Local environmental protection authorities at the county level and above are responsible for the environmental protection in their jurisdictions.

Companies that discharge contaminants must report and register with the MEP or the relevant local environment protection authorities. Companies discharging contaminants in excess of the discharge limits prescribed by the central or local authorities must pay discharge fees for the excess in accordance with applicable regulations, and are also responsible for the treatment of the excessive discharge. Government authorities can impose different penalties on individuals or companies in violation of the Environmental Protection Law, depending on the individual circumstances of each case and the extent of contamination. Such penalties include warnings, fines, impositions of deadlines for remedying the contamination, orders to stop production or use, orders to re-install contamination prevention and treatment facilities which have been removed without permission or left unused, administrative actions against relevant responsible persons or companies, or orders to close down those enterprises. Where the violation is serious, the persons or companies responsible for the violation may be required to pay damages to victims of the contamination. Where serious environmental contamination occurs in violation of the provisions of the Environmental Protection Law which results in serious loss of public and private property, persons or enterprises directly responsible for such contamination may be held criminally liable.

Regulation on Work Safety

Our operating activities involve hazardous materials. We are subject to a variety of governmental regulations related to work safety. The major PRC regulations related to work safety applicable to us include Production Safety Law, Regulation on Work Safety Licenses and Regulation on the Safety Administration of Hazardous Chemicals.

Work Safety Law

The Production Safety Law, or PSL, was promulgated for implementation as of November 1, 2002, and amended according to Decision of the Standing Committee of the National People’s Congress on Amending Some Laws which took effect on August 27, 2009. The PSL is applicable to the work safety for entities engaging in production and business operation activities within the PRC. Such entities must comply with the PSL and other relevant laws and regulations concerning work safety and strengthen the administration of work safety, establish and perfect the system of responsibility for work safety, ensure conditions for safe production, and ensure safety in production.

The PSL and other provisions of the relevant laws and regulations create a system for affixing responsibility for work safety accidents and holding liable those found to be responsible for work safety accidents. Entities engaged in the production, operation and storage of hazardous substances, (i) should be subject to the examination and approval as well as the supervision and administration of relevant administrative departments, according to the provisions of relevant laws and regulations, national standards or industrial standards; (ii) must have archived files for substantial hazardous sources, make regular checks, appraisals, supervisions and controls, make emergency plans, and inform employees and other relevant people of the emergency measures that should be taken under emergency circumstances; (iii) must report, according to the relevant provisions of the state, the substantial hazardous sources and the corresponding safety measures and emergency measures to the administrative department and other relevant departments of the local people’s government in charge of the supervision and administration of work safety for archiving purposes; and (iv) must have exits in the sites of production and the dormitories of the employees which meet the requirements for emergency dispersal of people, have eye-catching marks and be clear of obstructions. It shall be prohibited to close or obstruct the exits of the sites of production and business operation and the dormitories of the employees.

Regulation on Work Safety Licenses

The Regulation on Work Safety Licenses, or RWSL, was promulgated by the State Council on January 13, 2004 and came into force on the same date. According to the RWSL, an enterprise engaging in the production of hazardous chemicals, or the Enterprise, must apply for a work safety license before production.

To obtain a work safety license, the Enterprise must satisfy certain work safety conditions, which mainly include: (i) establishing and improving a system for work safety, and formulating a complete set of work safety rules; (ii) investing in safety satisfying applicable work safety requirements; (iii) establishing administrative entities for work safety and installing full-time work safety administrative personnel; (iv) the principal of the enterprise and the work safety administrative personnel who have passed the appraisal conducted by the competent authority; (v) ensuring that special personnel have passed the appraisal conducted by the competent authority, and have obtained qualification certificates for special operations; (vi) ensuring employees have gone through work safety education and training; (vii) ensuring payment for the employment injury insurance for the employees in accordance with the relevant laws, regulations, standards and rules; (viii) ensuring premises, work sites, safety facilities, equipment and technology meet the requirements of the relevant work safety laws, regulations, standards and rules; (viiii) providing employees with labor protection articles which are up to the national standards or standards of the industrial sector concerned; (x) having the appraising of work safety in accordance with the relevant laws, regulations, standards and rules; (xi) establishing emergency rescue plans for accidents; (xii) appointing entities or personnel specializing in emergency rescue, and providing necessary emergency rescue materials and equipment; and (xiii) satisfying other conditions from relevant laws, regulations, standards and rules.

The valid period for a work safety license is three years. If a work safety license needs to be extended upon its expiration, the Enterprise shall go through the extension procedures three months prior to such expiration with the administrative department from which the license is issued.

Regulation on Safety Administration of Hazardous Chemicals

The Regulation on Safety Administration of Hazardous Chemicals was promulgated by the State Council on January 26, 2002, and took effect on March 15, 2002. This regulation sets forth general requirements for the production and operation of certain chemicals that are considered dangerous and listed in the Hazardous Chemicals Catalog, which shall be formulated and adjusted from time to time by The State Administration of Work Safety of the PRC, or the SAWS, and other relevant state government authorities. The Regulation on Safety Administration of Hazardous Chemicals was further supplemented and elaborated by subsequent regulations and rules. Under PRC law, the production, storage, usage, operation, transportation of chemicals in the Hazardous Chemicals Catalog and the industrial use of such chemicals require specific regulatory approval, licenses and permits. In addition, in order to strengthen the supervision and regulation of the safe operation and production of

chemicals in the Hazardous Chemicals Catalog, on October 8, 2002, the Commerce and Trade Committee of the PRC issued the Measures for the Administration of Registration of Hazardous Chemicals, according to which the enterprises should, within six months of the publication of the Hazardous Chemicals Catalog, complete registration for the production and storage of hazardous chemicals. On the same date, the Commerce and Trade Committee of the PRC also issued Measures for the Administration of Operating Licenses for Hazardous Chemicals, according to which, Operation License is required for the operation and sale of hazardous chemicals. Both of the two administration rules took effect on November 15, 2002. Pursuant to these regulations, the producers of chemicals in the Hazardous Chemicals Catalog will need to meet certain production safety requirements and pass a safety inspection conducted by the relevant government authorities. In addition, such producers will need to obtain the relevant work safety license prior to production.

Under the Regulations on the Administration of Precursor Chemicals which was issued by the State Council on August 26, 2005 and took effect on November 1, 2005, enterprise that produce precursor chemicals of the third catalog are required to register with county-level branches of the SAWS within 30 days from when the enterprise set out its operation with precursor chemicals of the third catalog. Operation enterprises that apply for purchasing the precursor chemicals which can be used as major materials for drug production shall submit certain certificates, including the business license and the certification of legal use and demand, and shall obtain the purchase license upon the examination and approval of the supervisory and administrative department of food and drugs of the people’s government of the province, autonomous region or municipality directly under the Central Government, or the public security organ of the people’s government of the province, autonomous region or municipality directly under the Central Government where the applicant is located.

Regulation on Labor Protection

The Labor Contract Law of the PRC was promulgated on June 29, 2007 and became effective on January 1, 2008. This law governs the establishment of employment relationships between employers and employees, and the conclusion, performance, termination of, and the amendment to employment contracts. To establish an employment relationship, a written employment contract must be signed. In the event that no written employment contract was signed at the time of establishment of an employment relationship, a written employment contract must be signed within one month after the date on which the employer starts engaging the employee.

PRC Patent Law

The PRC first allowed patents for the protection of proprietary rights, as set forth in the PRC Patent Law, in 1985, which was amended at the 6 ^th Session of Standing Committee of the 11 ^th National People’s Congress of the People’s Republic of China on December 27, 2008 and took effect on October 1, 2009.

Patent Prosecution

The patent prosecution system in China is different from the system in the United States in a number of ways. China, like most countries other than the United States, follows the “first to file” principle. In other words, when more than one person files a patent application for the same invention, the patent will be granted to the person who first filed the application. The United States, in contrast, uses a principle of first to invent to determine the granting of patents. In addition, the PRC requires absolute novelty in order for an invention to be patentable. Pursuant to this requirement, generally, with limited exceptions, any prior written or oral publication in or outside the PRC, demonstration or use in the PRC before the patent application filing prevents an invention from being patented in the PRC. Conversely, inventors in the United States can generally file a patent application within one year after publication of the invention if the inventor can demonstrate that the invention was made prior to the publication. Patents issued in the PRC are not enforceable in Hong Kong, Taiwan or Macau, each of which has an independent patent system. The fact that a patent application is pending is no guarantee that a patent will be granted, and even if granted, the scope of a patent may not be as broad as that of the initial application.

Patent Enforcement

When a patent infringement dispute arises, the patent holder or an interested party who believes the patent is being infringed may either file a civil lawsuit or file an administrative complaint with a provincial or municipal office of the State Intellectual Property Office, or SIPO. A PRC court may grant the patent holder’s or the interested party’s request for a preliminary injunction before or during the legal proceeding. Damages for infringement are calculated as either the loss suffered by the patent holder or the interested party due to the infringement. If the loss cannot be ascertained, the damage shall be calculated as the benefit gained by the infringer from the infringement. Typically, a patent holder in the PRC has the burden of proving that the patent is being infringed.

Compulsory Licensing

Under the PRC Patent Law, where the patent holder fails to utilize a patent technology without reason after the expiration of three years from the grant date of the patent and four years from the date of the patent application being filed, or where the patent holder has been legally identified as having engaged in monopolistic behavior by utilizing the certain patent, an interested party which is qualified to utilize a patented technology, but fails to obtain the license from the patent holder on reasonable terms and in a reasonable period of time, is entitled to apply to the State Intellectual Property Office (SIPO) for a compulsory license. A compulsory license can also be granted where a national emergency or any extraordinary state of affairs occurs, where the public interest so requires, or where a registered invention is substantially superior to a prior invention in connection with technology that has a notable economic significance and the application of the later invention relies on the application of the prior invention.

International Patent Treaties

The PRC is also a signatory to all major intellectual property conventions, including the Paris Convention for the Protection of Industrial Property, Madrid Agreement on the International Registration of Marks and Madrid Protocol, Patent Cooperation Treaty, Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and the Agreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPs.

Although patent rights are national rights, there is a large amount of international co-operation under the Patent Cooperation Treaty, or the PCT, to which China is a signatory. Under the PCT, applicants in one country can seek patent protection for an invention simultaneously in a number of other member countries by filing a single international patent application.

Foreign Exchange Regulation

See “Item 10. Additional Information—D. Exchange Controls.”

Dividend Distribution Regulation

The principal laws and regulations governing dividends paid by our PRC operating subsidiaries include the Company Law of the PRC (1993), amended and effective as of January 1, 2006, Wholly Foreign Owned Enterprise Law (1986), as amended in 2000, Implementation Rules of Wholly Foreign Owned Enterprise Law (1990), as amended in 2001, Chinese-Foreign Joint Venture Law (1979), as amended in 2001, and Implementation Regulation of Chinese-Foreign Joint Venture Law (1983), as amended in 2001. Under these laws and regulations, each of our PRC subsidiaries, including WFOEs, joint venture enterprise and domestic companies in China may pay dividends only out of their accumulated profits, if any, determined in accordance with PRC accounting standards and regulations. In addition, each of our PRC subsidiaries, including WFOEs, joint venture enterprise and domestic companies, is required to set aside at least 10.0% of its after-tax profit based on PRC accounting standards each year to its general reserves or statutory capital reserve fund until the

accumulative amount of such reserve reaches 50.0% of its respective registered capital. These reserves are not distributable as cash dividends. Furthermore, each of our WFOEs and joint venture enterprise in China is also required to allocate a portion of its after-tax profits, as determined by its board of directors, to its staff welfare, employment injury insurance and bonus funds, which may not be distributed as cash dividends.

Tax

See “Item 10. Additional Information—E. Taxation.”

Provisions Regarding Mergers and Acquisitions of Domestic Enterprises by Foreign Investors

On August 8, 2006, six PRC regulatory agencies, including the Chinese Securities Regulatory Commission, or CSRC, promulgated a rule entitled “Provisions Regarding Mergers and Acquisitions of Domestic Enterprises by Foreign Investors,” or the new M&A rule, which was amended by Order No. 6 [2009] of the Ministry of Commerce on June 22, 2009, to more effectively regulate foreign investment in PRC domestic enterprises. The new M&A rule took effect on September 8, 2006. The new M&A rule also contains a provision requiring SPVs formed for overseas listing purposes and controlled by PRC individuals to obtain the approval of the CSRC prior to publicly listing their securities on an overseas stock exchange.

The application of this new M&A rule is currently unclear. However, our PRC counsel, Jin Mao PRC Lawyers, has advised us that based on their understanding of the current PRC laws, rules and regulations and the new M&A rule, the new M&A rule does not require that we obtain prior CSRC approval for the listing and trading of our ADSs on the NYSE, because our acquisition of the equity interest in our PRC subsidiaries is not subject to the new M&A rule due to the fact they were already foreign-invested enterprises before September 8, 2006, the effective date of the new M&A rule.

See “Item 3. Key Information—D. Risk factors—Risks Relating to Doing Business in China—The approval of the Chinese Securities Regulatory Commission, or the CSRC, might have been required in connection with our initial public offering, and, if required, we could be subject to sanction, fines and other penalties.”

Regulations Relating to Employee Share Options

Pursuant to the Implementation Rules of the Administration Measure for Individual Foreign Exchange, or the Individual Foreign Exchange Rule, and an implementation notice on the rule, issued in January and March 2007, respectively, by the SAFE, PRC citizens who are granted share options by an overseas publicly-listed company are required, through a PRC agent designated by such overseas publicly-listed company, to register with the SAFE and complete certain other procedures related to the share options. PRC agents may be the subsidiary of such overseas publicly-listed company, trade union of any such PRC subsidiary having legal person status, a trust and investment company or other financial institution qualified to engage in assets custodian business. Such individuals’ foreign exchange income received from the sale of shares or dividends distributed by the overseas publicly-listed company must first be remitted into a collective foreign exchange account opened and managed by the PRC agent before distribution to such individuals in a foreign currency or in RMB. We and our PRC citizen employees who have been granted share options, or PRC optionees, will be subject to these rules when our company becomes an overseas publicly-listed company. If we or our PRC optionees fail to comply with these regulations, we or our PRC optionees may be subject to fines and legal sanctions. However, as these rules have only been recently promulgated, it is currently unclear as to how these rules will be interpreted and implemented.

C. Organizational Structure

Set forth below is a diagram indicating our organization structure and place of organization of each of our subsidiaries as of the date of this annual report.

LOGO

(1)	The remaining equity interest in this entity is held by unrelated third parties.

D. Property, Plant and Equipment

Please refer to “—B. Business Overview” for a discussion of our property, plant and equipment.

ITEM 4A.

UNRESOLVED STAFF COMMENTS

Not applicable.

ITEM 5.

OPERATING AND FINANCIAL REVIEW AND PROSPECTS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements included elsewhere in this annual report on Form 20-F. This discussion may contain forward-looking statements based upon current expectations that involve risks and

uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Item 3. Key Information—D. Risk Factors” or in other parts of this annual report on Form 20-F.

Overview

We are a leading China-based contract manufacturer of highly engineered specialty chemicals. We have established a loyal base of customers and end users who purchase or use our products and have returned to us with requests for new products. The end users of our products purchase them either directly from us or through chemical trading companies. In 2008, 2009 and 2010, we sold products for 50, 59 and 68 commercialized projects and 65, 72 and 84 pipeline projects to a total of 71, 107 and 106 customers, respectively. Our end users include Central Glass Co., Ltd., Chisso Corporation, Eli Lilly and Company, Lonza Group Ltd. and Merck KGaA. Our end users also include several of the top global pharmaceutical companies and several of the top global agrochemical companies in the world, as measured by sales in 2010.

Our business, especially the chemicals used in the electronics end-market, recovered in 2010 from the global financial crisis. The total sales in 2010 passed the milestone of RMB1 billion. This is a testimony of our relentless effort in the year to expand our business development and strengthen the relationship with our customers, especially after the downturn of 2009. We will continue to take certain measures to ensure a stable growth of our business. These measures include:

•

continuing to work closely with our customers in order to provide them with customized services and maintain long-term customer relationships;

•

expanding our research and development facilities in order to provide higher value-added services to our customers and to develop more efficient production processes that reduce raw material costs and increase the amount of recycled materials; and

•

continuing to expand into diverse end markets, including growth areas such as the pharmaceutical and agrochemical industries.

To address manufacturing constraints, we have been constructing new manufacturing facilities in order to position ourselves to take on all projects requested by our customers. In 2010, we spent RMB244.1 million (US$37.0 million) in capital expenditures to expand our R&D and production facilities and reduce bottlenecks that have impeded growth, at times, in the past. Total reactor volume increased from 2.0 million liters at the end of 2009 to 2.3 million liters at the end of 2010. Additional reactors will be installed after the completion of the current phase of expansion in 2011. Currently, we own and operate six major production facilities in China. See “Item 4. Information on the Company—B. Business Overview—Headquarters and Facilities.” Our manufacturing facilities provide the flexibility to produce any of the specialty chemicals we manufacture in varying quantities, as the volume of our individual reactors range from 50 liters to 10,000 liters.

We increased total headcount from 1,585 employees at the end of 2009 to 1,794 at the end of 2010. We received technology grants from the PRC central and local governments and the grants totaled RMB7.5 million (US$1.1 million) in the year 2010—a strong recognition of our leading position in different technologies in many industrial fields in which we are actively involved. We also increased the number of approved patents from 11 by the end of 2009 to 16 by the end of March, 2011. We currently have 35 approved and pending approval patents.

In November 2009, we acquired a 100% equity interest in Kangpeng Nong Hua for cash consideration of RMB25 million (US$3.7 million). As our Chairman and CEO, Dr. Yang held more than 50% voting ownership interest of both the Company and Kangpeng Nong Hua at the date of the acquisition, it was considered a transaction between entities under common control. Therefore, our consolidated financial statements have been retroactively adjusted to reflect the combined entities for the periods during which the entities were under common control.

In 2010, we substantially completed our share repurchase plan announced on September 22, 2010. The total funds used in the share repurchase plan were RMB11.0 million (US$1.6 million).

We had sales of RMB942.5 million, RMB820.3 million and RMB1,082.0 million (US$163.9 million) and net income attributable to our shareholders of RMB312.4 million, RMB172.4 million and RMB225.5 million (US$34.2 million) in 2008, 2009 and 2010, respectively.

Sales

Our sales are derived from the sale of specialty chemicals, which include the sales from commercialized projects, pipeline projects and sales of purchased goods. In connection with our manufacture of specialty chemicals we sell to our customers, we perform certain process and design engineering activities. Our sales are based upon the price and volume of chemical compounds we sell. The price we charge for specialty chemicals for commercialized and pipeline depends highly on the level of complexity involved in manufacture of such products, while prices for products sold as purchased goods depend on market prices for the goods. We price our products based on several factors, including manufacturing costs, product life cycle, complexity of the chemical compounds and order size, and, to a lesser extent, our relationship with the customer and the distribution method required.

Factors Affecting Our Sales

We believe that the most significant factors that affect our results of operations are:

•

Global economic conditions;

•

Successful commercialization of products;

•

Expansion of the end markets for our products;

•

Dependence on a limited number of customers;

•

Geographic concentration of sales;

•

Product mix; and

•

Manufacturing capacity.

Global Economic Conditions

Global economic conditions affect our sales. The global financial crisis and economic recession in previous two years contributed to the failure of key businesses, declines in consumer wealth estimated in the trillions of U.S. dollars, substantial financial commitments incurred by governments, and a significant decline in economic activity. Faced with one of the most challenging years in our history, our sales were largely affected in 2009. Significant decreases in demand for consumer electronics, beginning in the second half of 2008 brought on by the global economic downturn resulted in decreases in demand for our specialty chemicals used in the manufacture of TFT-LCDs in 2009. In addition, significant decreases in demand for agrochemicals beginning in the second half of 2009 resulted in decreases in demand for our specialty chemicals used in the agrochemical market in the second half of 2009. Mild recovery in demand for such products began in the first half of 2010. The recovery of the global economic conditions greatly attributed to our strong sales in 2010. The 2010 financial results reflected a strong upswing in demand in our end markets, particularly in the electronics sector where our highly engineered specialty chemical products are used.

Successful Commercialization of Products

Our sales are primarily driven by (i) the number and size of projects we complete for customers and (ii) the average selling prices of our products. The number and size of projects we complete for customers are affected

by market demand for our products and their end products, and the average selling prices are affected by the lifecycles of our products and of the end products into which they are incorporated, among other factors. During the early stages of each product’s lifecycle, the volume sold is generally lower and the average selling price is generally higher, while as the product matures, the volume sold generally increases but the average selling price generally decreases. Our ability to add new successfully commercialized products and enhance mature products, such as specialty chemicals for new end products and new generations of existing end products, will affect our sales in future periods.

Many customers and end users choose us for our ability to provide tailored design and process engineering to enable more efficient and rapid production of chemical intermediates for products still in a development stage. Many of these projects and small quantity orders are experimental and developmental in nature and may not successfully reach commercialization. We expect our revenues will increase as more of these projects successfully reach the stage of large-scale commercial production.

In particular, many of our pipeline projects involve specialty chemicals used in the production of pharmaceutical end products that are in a developmental stage. As drug companies develop and test new drugs, they conduct extensive research and development activities. In recent years, fluorine substitution has aided the design and effectiveness of many new drugs and has resulted in pharmacological agents with improved properties. Pharmaceutical companies have asked us to supply them with customized fluorinated specialty chemicals for use in their research and clinical development activities. Certain drug candidates that are developed using specialty chemicals that we produce may prove effective and obtain governmental approval in the future. If those approvals are obtained, and if those pharmaceuticals end products are successfully commercialized, we may be able to supply these pharmaceuticals companies with increasing quantities of our products for use in their commercial production. Thus, our future growth will be affected by the level of expenditures by drug companies on research and development activities, the number of drugs containing our products that receive the requisite regulatory approvals and are sold commercially and the demand for those approved drugs in the market. Some of these pipeline projects may not successfully reach commercialization. However, as more of these pipeline projects become commercialized, we expect our total sales to increase in future periods because commercialized projects generate greater sales volume.

Expansion of the End Markets for Our Products

Our sales growth is driven in part by growth in the end markets where our chemical intermediates are ultimately incorporated, such as the electronics, pharmaceuticals and agrochemicals industries. Our customers consist of direct end users as well as trading companies that then sell our products to end users. Most of those end users are in the electronics, pharmaceuticals and agrochemicals industries. While some of our sales are to direct end users, a significant proportion of our sales are made to trading companies that act as middlemen in the industry and who ultimately sell our products to end users for multiple industry applications. Due to this sales model, there is a degree of uncertainty about the identity of the ultimate end users of some of our products and accordingly about the industries in which our products are used. Accordingly, the estimated percentages of our sales attributable to each end user market represent our best estimates based primarily on the compositions of the various products we sell as well as our understanding of our customers and end users. The remaining portion of our sales not attributed to any particular end market during each period represents sales of purchased goods we made to our customers.

The largest percentage of our sales has historically been derived from end users in the electronics industry. The majority of these sales have been driven by increases in demand for TFT-LCD units into which our products are incorporated. We estimate that approximately 46% to 53%, 45% to 52% and 62% to 69% of our sales in 2008, 2009 and 2010, respectively, were derived from specialty chemicals sold to or used by end users in the electronics industry. Increases in the average screen size of TFT-LCDs sold and a shift in the orders of our customers towards production of higher-value-added components for liquid crystal formulations for larger LCD televisions drove increases in our sales.

The demand in the TFT-LCD electronics industry started to strongly recover in the first quarter of 2010 and the momentum lasted into the third quarter of 2010. The sales gradually slowed down in the fourth quarter of 2010 due to the seasonally weaker demand in the end-market.

Historically, the second largest percentage of our sales has been derived from end users in the pharmaceutical industry. We estimate that approximately 21% to 28%, 29% to 36% and 20% to 27% of our sales in 2008, 2009 and 2010, respectively, were derived from specialty chemicals sold to or used by end users in the pharmaceutical industry.

Historically the smallest source of sales of our products has been derived from the agrochemicals industry. We estimate that approximately 10% to 17%, 10% to 17% and 14% to 21% of our sales in 2008, 2009 and 2010, respectively, were derived from specialty chemicals sold to or used by end users in the agrochemicals industry.

In addition, the growing trend towards outsourcing the production of these specialty chemicals to high quality manufacturers in China is particularly important to our sales growth. See “Item 3. Key Information—D. Risk Factors—Risks Related to Our Company and Our Industry—If the end markets for our specialty chemicals do not grow, or if our customers do not succeed in increasing their market shares in those markets, our business prospects and results of operations could be harmed.”

Dependence on a limited number of customers

We depend on a small group of customers for a substantial portion of our sales. In aggregate, our top three customers accounted for 65%, 61% and 65% of our total sales in 2008, 2009 and 2010, respectively. Our single largest customer accounted for 35%, 24% and 33% of our total sales in 2008, 2009 and 2010, respectively. We are increasing the level of our collaboration with major customers with whom we have long-standing relationships to produce increasingly more complex and higher value-added products, including specialty chemicals for electronics, pharmaceuticals and agrochemicals. In addition, our sales are currently concentrated among customers who use our products in a limited number of end users. In particular, many of our large customers historically have been companies or suppliers for companies that use our products in the manufacture of TFT-LCDs.

Historically, we have maintained a limited customer base due to our preference to work with customers with whom we have existing long-term relationships, and many of them have repeatedly come to us for the development and manufacture of new products. As a result of our operating at or near our full manufacturing capacity in the past, we avoid using our limited capacity to develop and manufacture lower value-added products and instead focus our resources on higher value-added products, and we typically give preference to existing customers when deciding which projects to pursue and which orders to accept. While we believe that our close working relationships with our limited customer base offers us some competitive advantages, such as positioning us to become a primary supplier of newly developed and complex specialty chemicals products with higher average selling prices, any fluctuations in demand from any one of our large customers may have a pronounced effect on our total sales.

Our largest customers historically order varying amounts of our products, making our results of operations difficult to predict and likely to fluctuate between periods. In addition, we may not be able to retain existing customers or add to our existing customer base. The level of customer concentration we experience varies with the industry into which the end product incorporating our product is sold. Although we rely on a few key customers for sales of our chemical intermediates used in electronics, we sell products that are used in pharmaceutical research, development and manufacturing, on the other hand, to a relatively large number of customers.

Our business is affected by competition in the market for the products that many of our major customers sell, and any decline in their businesses could reduce purchase orders from these customers. Our customers have

sought, from time to time, to prospectively renegotiate pricing terms with us or obtain more favorable terms upon renewal of the contracts. Any adverse revisions to the terms of our arrangements with our key customers could have a material adverse effect on our business and results of operations. We expect that our operating results will, for the foreseeable future, continue to depend on the sale of our specialty chemicals to a relatively small number of customers, particularly with respect to products used in the electronics industry. Further, we expect that our results will continue to fluctuate and be difficult to predict as a result of customer concentration, demand experienced by our customers and the level of demand in the end markets served by our customers.

On the other hand, our relentless efforts to expand our customer base in the pharmaceutical and agrochemical business fields has been gradually paying us off as we have successfully established good communications with several global agrochemical leaders and biopharmaceutical players, started initial quality validation processes with them and even started some sample productions for them, including our first contract manufacturing of an Active Pharmaceutical Ingredient, or API, under Current Good Manufacturing Practice, or c GMP, condition for a new phase I stage drug of a biopharmaceutical company in the first quarter of 2010, and projects including Investigational New Drug, or IND enabling studies. Our state-of-the-art GMP facility has been fully operating under the ICH Q7 guideline and has been audited by several clients.

Geographic Concentration of Sales

We sell our products to trading companies, as well as directly to end users. When we make sales to trading companies, it is not always possible to determine the final country where our products are used by the end user. However, our sales have historically been concentrated in a limited number of countries, most notably Japan and Germany, where a significant portion of the end users of our products are located. As a result of this geographic concentration, our financial performance could be affected by events such as changes in foreign currency exchange rates, trade protection measures, changes in regional or worldwide economic, political or natural conditions, particularly conditions, changes and regulatory measures in Japan and Germany. For additional information regarding our geographic concentration of sales, see Note 18 of our consolidated financial statements for the years ended December 31, 2008, 2009 and 2010 included elsewhere in this annual report.

Product Mix

The mix of our products also affects our sales. In 2006 and 2007, when we were already operating near our full manufacturing capacity, we were required to choose which projects to pursue and which orders to accept. Producing a greater percentage of highly-engineered and newly-developed products will generally result in higher sales because these products usually command higher average selling prices. In 2008, Jiangsu Wei Er also contributed to an adjustment in our product mix through its production and sales of large volumes of products with lower average selling prices. We expect to gradually migrate Jiangsu Wei Er’s product mix over time towards more highly engineered products with higher average selling prices to converge with our overall product mix. In 2009, the demand for specialty chemicals used in the production of TFT-LCDs and agrochemicals decreased in line with the global economic slowdown. In 2010, the demand in the TFT-LCD end-market recovered since the first quarter of 2010, which contributed to the growth of total sales. As a result, the evolution of our product mix has affected our sales and will affect our sales for the foreseeable future.

In addition, our ability to maintain or increase our sales in products used in important end markets such as electronics, pharmaceuticals and agrochemicals will depend to a significant degree upon our ability to continuously convert our product range to newer, more advanced intermediates and to the more complex components for specialty chemicals intermediates that we are able to sell at higher prices.

Our sales are also influenced by the other projects we take on from time to time for our long-term customers. In particular, we assist some of our long-term customers to source from other producers in China specialty chemicals involving lower levels of technology that we do not normally manufacture ourselves. These sourcing projects, which we also refer to as sales of purchased goods, generally involve locating appropriate

sources of the specialty chemicals requested by our customers, examining the chemicals for quality assurance, purchasing and repackaging the chemicals under our brand name for export to the customer. These sales of purchased goods fluctuate according to individual customer demand and generally have significantly lower gross margins than our commercialized and pipeline products. While we may experience periodic increases in these orders, based on trends and customer requests we expect these sales of purchased goods to decrease in the foreseeable future.

Manufacturing Capacity

Our manufacturing capacity also affects our sales. For example, in 2006 and 2007, when we were already operating near our full manufacturing capacity, we could not accept all requested projects and orders from our customers. In addition, the expansion of manufacturing capacity requires time to (i) construct the facilities, (ii) obtain the necessary permits and certifications for operations, and (iii) recruit and train the employees for the new manufacturing facilities. We have been addressing the manufacturing constraints through the construction of new facilities and the acquisition of Jiangsu Wei Er in February 2008. Following these capital investments, we have substantially reduced the manufacturing constraints due to the added capacities. The availability of spare manufacturing capacity will often determine which projects and orders we accept, and we expect an expansion in manufacturing capacity to expand our sales in the foreseeable future. See “Item 4. Information on the Company—B. Business Overview—Headquarters and Facilities.”

Cost of sales

Our total cost of sales amounted to RMB548.5 million, RMB495.6 million and RMB664.8 million (US$100.7 million) in 2008, 2009 and 2010, respectively. The following table sets forth our cost of sales by amount and as a percentage of total sales for the periods indicated:


	Year Ended December 31,
	2008						2009						2010
	RMB			% of Total Sales			RMB			% of Total Sales			RMB			US$			% of Total Sales
	(in thousands, except percentages)
Total Sales:		942,487			100.00	%		820,295			100.00	%		1,082,031			163.944			100.00	%
Cost of Sales		(548,543	)		58.20	%		(495,584	)		60.42	%		(664,791	)		(100,726	)		61.44	%

Gross profit		393,944			41.80	%		324,711			39.58	%		417,240			63,218			38.56	%

Our cost of sales consists primarily of raw material costs, including solvents, initial building blocks and catalysts. The primary raw materials used in our manufacturing process include various petrochemical-based initial building blocks, fluorine and hydrofluoric acid, benzene, potassium fluoride and palladium or activated carbon catalysts. We purchase raw materials in various states of production, and, in some instances, our raw material costs include outsourcing costs payable to third-party manufacturers. Our cost of sales also includes utility costs, direct labor costs, material consumption in overhead, depreciation and other overhead.

We expect our cost of sales, including our raw materials costs, to increase significantly in absolute terms as our manufacturing business expands and as prices for fluorine-based materials continue to exhibit an upward trend, and the labor cost in China continues to increase, offset in part by (i) improvements in our manufacturing processes that reduce the raw materials consumed in production, (ii) economies of scale derived from better bargaining power and (iii) volume discounts associated with larger purchases. We expect cost of sales as a percentage of sales to fluctuate in the near future as a result of a change in our product mix. While we expect raw material costs to increase in the future, we believe that the increase will be partially offset by our continued refinement of our manufacturing processes, which focus around using less raw materials and manufacturing more efficiently.

Our cost of sales as a percentage of sales may also fluctuate as we commence production at new or revamped facilities, acquire additional production facilities or start to produce large quantities of new products. New or acquired facilities may affect our product mix and significantly increase our material costs temporarily or over a longer period of time, both of which could result in fluctuations to our cost of sales as percentage of sales.

Our cost of sales also includes that portion of the value added tax, or VAT, we are required to pay after taking into account any refunds we receive. In general, VAT at a rate of 17.0% is assessed on our sales outside of the PRC, less any deductible VAT already paid or borne by the taxpayer. Pursuant to the Provisional Regulation of China on Value Added Tax and its implementing rules, all entities and individuals that are engaged in the sale of goods, the provision of processing, repairs and replacement services and the importation of goods in China are generally required to pay the VAT. When we export goods, we are entitled to a portion or all of the refund of VAT that we have already paid or borne. Imported raw materials that are used for manufacturing export products and are deposited in bonded warehouses are exempt from import VAT. Pursuant to recent changes in policy, on average, the refund rate we are entitled to receive is between 9% and 13%.

Gross profit and gross profit margin

Changes in our gross profit and margin from period to period are primarily driven by pricing conditions, product mix, volume of sales, raw material costs, labor cost, exchange rate variations and the stage in the life cycle of the projects. Our gross profit and margin can also be affected by temporary market trends. For instance, we enjoyed enhanced gross margins from 2005 to 2007 in large part because of exceptional demand for specialty chemicals used in the electronics industry, as that sector experienced strong global growth during those periods. Our gross margin gradually decreased from 2008 to 2010 because of the shift in product mix and the price adjustment of certain products. We expect we may also face some gross profit margin compression due to the following: (i) our average selling price has generally been decreasing due to renegotiations in pricing terms with our customers once a product reaches a certain scale of production, (ii) our raw material costs are expected to continue to increase as the global economy recovers, (iii) anticipated appreciation of the Renminbi relative to the U.S. dollar, which would have a negative impact on our gross margins as much of our sales are denominated in U.S. dollars while much of our costs are denominated in Renminbi, (iv) increasing labor costs, and (v) fluctuations in the volume of sales of purchased goods we make, as these sales are generally made on a cost-plus basis and, accordingly, generally have lower gross margins than our commercialized and pipeline products. Starting in February 2008, after we acquired Jiangsu Wei Er and substantially entered into the agrochemical business, the decreasing trend in the average selling price of our products was attributable to the volume of products with lower average selling price produced by Jiangsu Wei Er in the agrochemical market. We expect to offset the pressure on our gross profit margin to a certain extent by focusing our product range on higher-value-added specialty chemicals involving greater process design and process development expertise, which allows these products to command higher prices. In addition, we expect our continued research and development efforts to further improve our manufacturing process to use less raw materials and manufacture more efficiently, which will help us partially improve on our gross profit margin.

Operating expenses

Our operating expenses consist of selling expenses, general and administrative expenses, research and development expenses and other operating expenses. The following table sets forth our operating expenses, divided into their major categories by amount and as a percentage of total sales for the periods indicated:


	Year Ended December 31,
	2008				2009				2010
	RMB		% of Total Sales		RMB		% of Total Sales		RMB		US$		% of Total Sales
	(in thousands, except percentages)
Total Sales:		942,487		100.00%		820,295		100.00%		1,082,031		163,944		100.00%
Gross profit		393,944		41.80%		324,711		39.58%		417,240		63,218		38.56%
Operating expenses:
Selling expenses		(11,898)		(1.26)%		(11,245)		(1.37)%		(11,130)		(1,686)		(1.03)%
General and administrative expenses		(58,947)		(6.25)%		(69,871)		(8.52)%		(77,768)		(11,783)		(7.19)%
Research and development expenses		(27,483)		(2.92)%		(30,913)		(3.77)%		(65,679)		(9,951)		(6.07)%
Other operating expenses		(2,188)		(0.23)%		(7,145)		(0.87)%		(2,736)		(415)		(0.25)%

Total operating expenses		(100,516)		(10.66)%		(119,174)		(14.53)%		(157,313)		(23,835)		(14.54)%

Selling expenses

Selling expenses accounted for 1.3%, 1.4% and 1.0% of our total sales in 2008, 2009 and 2010, respectively. Our selling expenses consist primarily of freight, delivery and packing costs of our products to either the port of Shanghai or the customer’s designated destination, shipping insurance, local taxes and customs fees, and other miscellaneous items. We ship our products either by sea or by air depending on our customer’s requirements and certain of our contracts require us to pay freight and shipping costs. Freight and shipping costs accounted for 72.8%, 53.6% and 73.1% of our selling expenses in 2008, 2009 and 2010, respectively. The increase in shipping costs as a percentage of sales and in absolute terms in 2010 was largely the result of more products were delivered by flight and higher cost of transportation compared with 2009. We expect that our selling expenses will increase in absolute amount and remain relatively stable as a percentage of sales due to the fact that most of these selling expenses, such as shipping costs, are related to the volume of our sales.

General and administrative expenses

General and administrative expenses accounted for 6.3%, 8.5% and 7.2% of our total sales in 2008, 2009 and 2010, respectively. General and administrative expenses consist primarily of salary and benefits for our management and administrative personnel (including share-based compensation), office expenses, traveling and entertainment expenses, insurance premiums, depreciation on the headquarters, computers and other office equipment, consulting and auditing fees, and other administrative costs and expenses. Beginning in 2008, general and administrative expenses also include an allocation of our share-based compensation charges with regard to management and administrative staff. See “—Critical Accounting Policies—Share-Based Compensation Expenses.”

We expect our general and administrative expenses to increase in an absolute term as our business expands in 2011. In addition, as the Company is in the process of a going private transaction, professional service fees to the legal counsels and the financial advisor and other associated fees will be incurred in 2011. See “Item 4. Information on the Company—A. History and Development of the Company—Going Private Transaction”.

Research and development expenses

Research and development expenses accounted for 2.9%, 3.8% and 6.1% of our total sales in 2008, 2009 and 2010, respectively. Research and development expenses consist primarily of (i) the cost of raw materials and equipment used in conducting research, experimentation and product and process development, (ii) salaries and associated benefits paid to employees involved in conducting research and development activities (including share-based compensation), and (iii) depreciation associated with the facilities and equipment used in connection with our research and development activities.

We expect to devote more efforts to research and development in the future and expand into more advanced specialty chemicals that require sophisticated engineering and process development to produce. We have built a new research and development center in Shanghai and moved in the facility in the fourth quarter of 2009. Our research and development expenses included depreciation of this facility during 2010. We expect that our continued efforts to improve our research and development activities and processes will help us further reduce internal test failure rates and achieve greater efficiency in raw material usage during research and development processes. In addition, we anticipate that by continuing to focus on our core fluorinated specialty chemicals and technologies and by leveraging them to selectively expand into new business areas, we may control research and development expenses as a percentage of our total sales.

Other operating expenses

Other operating expenses accounted for 0.2%, 0.9% and 0.3% of our total sales for 2008, 2009 and 2010, respectively. Other operating expenses consist primarily of loss on disposal of property, plant and equipment and miscellaneous costs and expenses.

Other operating income

Other operating income accounted for 0.1%, 0.1% and 0.2% of our total sales for 2008, 2009 and 2010, respectively. Other operating income in 2008, 2009 and 2010 consisted primarily of rental income from the lease of plant and equipment.

Government grants

Government grants we receive from local government authorities are provided to reimburse our research and development-related expenditures. We submit applications to the government for grants in relation to research and development-related projects each year. The government may not approve the grants in the same year as the applications were submitted. In addition, the amount granted may vary depending on government policy and other considerations. Accordingly, we cannot predict the timing or the amount of government grants approved in relation to our applications, and as a result, the amount we receive from government grants may fluctuate from year to year.

Interest expense

Interest expense consists of interest expense associated with finance costs for loans. We had short-term bank borrowings of RMB65.0 million as of December 31, 2008, long-term bank borrowings of RMB10.0 million as of December 31, 2009 and short-term bank borrowings of RMB20.0 million (US$3.0 million) and long-term bank borrowings, current portion, of RMB5.0 million (US$0.8million) as of December 31, 2010. These borrowings are secured by credit facility, our properties and land use rights or by our consolidated subsidiaries. The secured short-term bank borrowings and long-term bank borrowings, current portion, as of December 31, 2008 and 2010 bore weighted average interest rates 7.984% and 5.274% per year, respectively. All short-term bank borrowings and long-term bank borrowings, current portion, mature at various dates within one year. The secured long-term bank borrowings as December 31, 2009 bore weighted average interest rate of 5.751%

Share-based compensation

On January 1, 2008, we adopted our 2008 share incentive plan, which was modified on May 7, 2010, to provide additional incentives to our employees. As of December 31, 2010, there were outstanding unconditional options to purchase 37,324,760 of our ordinary shares and no outstanding conditional options. The amount of compensation cost recognized for these share options was RMB15.5 million and RMB2.4 million for 2008, respectively, RMB15.4 million and RMB15,000 for 2009, and RMB1.5 million (US$0.2 million) and nil for 2010, respectively. We allocate share-based compensation expense to selling, general and administrative, and research and development expenses based on the shares each recipient received and the job responsibility of each recipient.

Taxation and Incentives

Cayman Islands

We are incorporated in the Cayman Islands. Under the current law of the Cayman Islands, we are not subject to income tax.

British Virgin Islands

Under the current laws of the British Virgin Islands, we are not subject to income tax. In addition, upon any payment of dividends by us, no British Virgin Islands withholding tax is imposed.

Hong Kong

We did not have any assessable profits subject to the Hong Kong Profits Tax during the years ended December 31, 2008, 2009 and 2010.

People’s Republic of China

On March 16, 2007, the PRC government enacted the new Enterprise Income Tax law (“new EIT law”). The new EIT law and its relevant regulations impose a withholding tax at 10%, unless reduced by a tax treaty, for dividend distributions out of earnings accumulated beginning on January 1, 2008. Undistributed earnings generated prior to January 1, 2008 are exempt from such withholding tax. Under the China-Hong Kong tax arrangement, a qualified Hong Kong tax resident which is the “beneficial owner” and holds 25% or more of the equity interest in a PRC-resident enterprise is entitled to a reduced withholding rate of 5%.

Our subsidiaries in China are also subject to business tax and related surcharges by various local tax authorities at a rate of 5.0% on revenues generated from providing services. In addition, our subsidiaries in China were generally subject to the standard enterprise income tax rate, which was 33% prior to December 31, 2007. Shanghai Qi Yue was subject to a preferential tax rate of 15% because it is registered and operating in the Pudong New Area in Shanghai. Shanghai ChemSpec, Taixing ChemSpec and Shanghai Wan Su were subject to a preferential tax rate of 27% as a result of their conversion into foreign-owned enterprises in 2006. Shanghai ChemSpec, Taixing ChemSpec and Shanghai Wan Su are entitled to an exemption from the enterprise income tax for the first two years and a 50% reduction in the enterprise income tax in the subsequent three years, starting from its first profit-making year from PRC income tax perspective.

The statutory income tax rate under the new EIT law is 25%. The new EIT law was effective as of January 1, 2008. The new EIT law and its relevant regulations provide a 5-year transition period from its effective date for those companies which were entitled to a preferential lower tax rate under the then effective tax laws and regulations, as well as grandfathering certain tax holidays. Shanghai Qi Yue was subject to income tax at 18%, 20% and 22% for 2008, 2009 and 2010, respectively, and will be subject to income tax at 24% and 25% for 2011 and 2012, respectively. Some of our subsidiaries are subject to lower enterprise income tax rates due to

preferential tax treatments and holidays granted by the local government authorities for wholly foreign-invested enterprises and enterprises that operate in special geographic locations in China that offer tax incentives. The following table illustrates the tax benefits for our principal operating subsidiaries:


Entity Name	Normal EIT Rate		Tax Holiday
Taixing ChemSpec		25%	Tax holiday – 2 years tax free (2007 and 2008); 3 years tax at a discount of 50% off of the tax rate (2009-2011)
Shanghai Wan Su		25%	Tax holiday – 2 years tax free (2007 and 2008); 3 years tax at a discount of 50% off of the tax rate (2009-2011)
Shanghai ChemSpec		25%	Retroactive tax holiday – 2 years tax free (2006 and 2007); 3 years tax at a discount of 50% off tax rate (2008-2010)(1)
Jiangsu Wei Er		25%	15% preferential tax rate (2009-2011)(2)
Other PRC subsidiaries		25%	N/A

(1)

In 2007, Shanghai ChemSpec filed an application for a tax holiday, which application was initially rejected by the tax bureau. In July 2008, the local tax bureau of Shanghai Putuo district notified Shanghai ChemSpec that it was entitled to the exemption retroactively for the period from August 1, 2006 to December 31, 2007 and a 50% reduction in the income tax in the subsequent three years. The tax refund was recorded as a reduction of income tax expense in the consolidated statement of income for 2008.

(2)	Jiangsu Wei Er was subject to income tax at 25% for 2008. It is qualified as an “Advanced and New Technology Enterprise” under the new EIT law in 2009 and is entitled to the preferential income tax rate of 15% from 2009 to 2011. Thereafter, it will be subject to income tax at 25%.

Critical Accounting Policies

We prepare our financial statements in conformity with U.S. GAAP, which requires us to make estimates and assumptions that affect our reporting of, among other things, assets and liabilities, contingent assets and liabilities and net revenues and expenses. We continually evaluate these estimates and assumptions based on the most recently available information, our own historical experiences and other factors that we believe to be relevant under the circumstances. Since our financial reporting process inherently relies on the use of estimates and assumptions, our actual results could differ from what we expect. This is especially true with some accounting policies that require higher degrees of judgment than others in their application. We consider the policies discussed below to be critical to an understanding of our audited consolidated financial statements because they involve the greatest reliance on our management’s judgment.

Depreciation and amortization

Our long-lived assets primarily include property, plant and equipment. We depreciate and amortize our long-lived assets using the straight-line method over the estimated useful lives of the assets, taking into account the assets’ estimated residual values. We estimate the useful lives and residual values at the time we acquire the assets based on our management’s knowledge on the useful lives of similar assets and replacement costs of similar assets having been used for the same useful lives respectively in the market, and taking into account anticipated technological or other changes. If technological changes are to occur more rapidly than anticipated, we may shorten the useful lives or lower the residual value assigned to these assets, which will result in the recognition of increased depreciation and amortization expense in future periods. There were no significant changes in estimates for the useful lives or salvage values of our long-lived assets for the years ended December 31, 2008, 2009 and 2010.

Impairment of long-lived assets

We group our long-lived assets for impairment testing at the lowest level for which there are identifiable cash flows that are largely independent of other asset groups. Our approach in evaluating whether an asset group has identifiable cash flows that are largely independent of the cash flows of other asset groups focuses on the degree to which the Company’s total cash flows (inflows and outflows) depend on the activities of one or more other asset groups of the Company.

We evaluate our long-lived assets for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. Among other considerations, we consider the following factors:

•

the asset group’s ability to continue to generate income from operations and positive cash flow in future periods;

•

loss of customers due to the deterioration of specialty chemical industry conditions;

•

negative operating cash flows of the asset group;

•

increased competition;

•

a significant decrease in market price of the asset group;

•

a significant adverse change in the extent or manner in which it is being used or in its physical condition;

•

an accumulation of costs significantly in excess of the amount originally expected for its acquisition or construction; and

•

a current expectation that it is more-likely-than-not that the asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

We assess recoverability of our asset groups by comparing the carrying amount of our asset groups to the estimated undiscounted future cash flows expected to be generated. In determining estimates of future cash flows, we make significant judgment in terms of projection of future cash flows and assumptions. If the carrying amount of the asset groups exceed the sum of its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset groups exceed their fair value. We determine the fair value of our asset groups through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.

For the years ended December 31, 2008, 2009 and 2010, there were no impairment charges recognized on our long-lived assets.”

Inventory

At the beginning of every year, the management determines the appropriate level of inventories to maintain on the basis of annual production and operating plans, financial budgets and market conditions.

Our inventories are stated at the lower of cost or market. Cost of work-in-progress and finished goods is comprised of direct materials, direct labor and related manufacturing overhead based on normal operating capacity. We routinely evaluate the realizability of our inventories in light of market conditions and record write-downs against the cost of inventories. The evaluation takes into consideration a number of factors including historical and forecasted consumption of our raw materials, our sales contract of finished goods on hand, marketability of our inventories, anticipated change in market selling price, risk of obsolescence of our inventories due to change in technology or change in physical properties over time and other factors.

Write-down of finished goods were RMB1.1 million, RMB14.7 million and RMB7.3 million (US$1.1 million) during the years ended December 31, 2008, 2009 and 2010, respectively, which are included in cost of

sales. Due to the extremely difficult market situation in 2009, we recorded a provision of RMB 14.7 million to write down our obsolete finished goods. These inventories were related to the pre-production of certain of our products that can be used in producing agrochemical products on purchase orders that were subsequently cancelled or indefinitely postponed by our customers because of the deterioration in market conditions. We do not consider our raw materials to be subject to inventory write-down as they are general chemical materials that could be utilized in producing a wide range of our products that can be sold above cost.

Our average inventory turnover period increased from 117 days in 2008 to 176 days in 2009 and to 211 days in 2010. The increase in 2009 was primarily due to the reduced sales in 2009 as a result of the global economic recession and the year-end inventory increase as a result of the change in product mix caused by strong orders for our products used in the electronics chemical industry. The further increase in 2010 was due to a rise in the production and sales of more complex products, primarily for the electronics end-market.

Allowance for Doubtful Receivables

We maintain allowances for doubtful receivables for estimated losses resulting from the failure of customers to make required payments. We review the accounts receivable on a periodic basis and make specific allowances when there is doubt as to the collectability of individual balances. In evaluating the collectability of individual receivable balances, we consider many factors, including the age of the balance, the customer’s past payment history and current credit-worthiness and current economic trends. We wrote off nil, nil and RMB0.5 million in customer receivables in 2008, 2009 and 2010, respectively, while recording a reversal of allowance of RMB0.2 million, and RMB 0.1 million in 2008 and 2010, respectively, and recorded bad debt expenses of RMB0.1 million in 2009.

If our assumptions regarding the financial condition of our customers and their ability and willingness to pay us are incorrect, our actual bad debt provisions may be higher than estimated, which could result in a charge against our income and a higher level of allowance for doubtful receivables in the future, either of which could have a material adverse effect on our financial condition and results of operations.

Share-based compensation

On January 1, 2008, we adopted our 2008 share incentive plan, or the plan, which was modified in May 2010, to provide additional incentives to our employees. The plan provides for the grant of options, restricted shares, and restricted share units. The plan authorizes grants to purchase up to 180,000,000 of our ordinary shares. Stock options granted become exercisable over four years. We expect to issue new shares to satisfy share option exercises. Under the plan, we granted 13,555,000 unconditional share option awards and 13,555,000 conditional share option awards on January 1, 2008 and 22,700,000 unconditional share option awards and 900,000 conditional share option awards on June 30, 2008 to several of our executives and employees.

The unconditional awards were granted at an exercise price of RMB0.55 per share, vest over four years of continuous service, with 25% of the options vesting on each of the first, second, third and fourth anniversaries of the grant date, and expire ten years from the grant date.

The conditional awards are granted at an exercise price equal to 88% of the fair value of our ordinary shares on the respective grant date, vest over four years (provided that service remains continuous during such period) with 25% of the options vesting on each of the first, second, third and fourth anniversaries of the grant date or, where our audited financial statements for the year immediately preceding each such anniversary are not available on such anniversary, on the date such audited financial statements are issued. The conditional awards expire ten years from the date of grant. The vesting of conditional options to purchase our ordinary shares is contingent upon (i) our achieving revenue growth of at least 20% in the most recent fiscal year for which audited financial statements are available prior to each vesting date and (ii) our achieving a compound annual growth rate in sales of at least 20% from (x) the fiscal year immediately preceding the date of awards for which audited

financial statements are available, through (y) the most recent fiscal year for which audited financial statements prepared pursuant to U.S. GAAP are available immediately prior to each vesting date.

On May 7, 2010, our board of directors approved the grant of an aggregate of 24,497,500 unconditional share options. On the same date, we granted 12,277,500 unconditional share options in exchange for the 12,277,500 conditional share options previously granted under the plan, or the Modification. In addition, on the same date, we granted 12,220,000 share options to executives and employees who did not participate in the plan.

The Modification was treated as an exchange of the original conditional share option awards for the unconditional share option awards at the date of the Modification. There was no significant difference between fair value of the new unconditional share option awards and that of the original conditional option awards immediately before the Modification.

As further described in Note 17 to our audited financial statements included elsewhere in this annual report, we recognize share-based compensation as a compensation expense in our consolidated statements of income based on the fair value of equity awards on the date of the grant, with the compensation expense recognized over the period in which the recipient is required to provide service in exchange for the equity award.

The determination of fair value of equity awards such as options requires making complex and subjective judgments about the projected financial and operating results of the subject company. It also requires making certain assumptions relating to cost of capital, general market and macroeconomic conditions, industry trends, share price volatility of comparable companies, expected lives of options and discount rates. These assumptions are inherently uncertain. Changes in these assumptions could significantly affect the amount of employee share-based compensation expense we recognize in our consolidated financial statements. For the purpose of determining the estimated fair value of share options we have already granted, we believe that the expected volatility and the estimated share price of our ordinary shares are the most critical assumptions. Prior and subsequent to our IPO, since we did not have a trading history at the time the options were issued, and due to lack of sufficient historical trading record, the expected volatility was based on the historical volatilities of comparable publicly traded companies engaged in a similar industry. The estimated fair value of our ordinary shares on the date of grant prior IPO was determined based on valuation on our ordinary shares also performed by Jones Lang LaSalle Sallmanns Limited, or Sallmanns, an independent appraiser. Sallmanns determined the fair value of the ordinary shares using the income approach by applying appropriate discount rate to future free cash flows that are based on financial projections developed by the Company. The fair value of the shares underlying the options we have granted subsequent to our IPO has been based on the closing price of our ADSs listed on the New York Stock Exchange for the trading day prior to the grant date.

The fair value of each option granted was appraised on the date of grant using the lattice option-pricing model incorporating assumptions with regard to risk-free interest rate, dividend yield, expected term and expected volatility.

A summary of share option activity under unconditional share options awards during 2008, 2009 and 2010 is as follows:

Number of
options

Weighted
average
exercise price

Weighted
Average
remaining
contractual
term

Aggregate
intrinsic value

Outstanding as of December 31, 2008

35,622,500

RMB0.55

Outstanding as of December 31, 2009

35,497,500

RMB0.55

Outstanding as of December 31, 2010

37,324,760

RMB0.55

8.57 years

RMB10,100,000

Fully vested as of December 31, 2010

11,302,260

RMB0.55

8.14 years

RMB3,457,000

Exercisable as of December 31, 2010

11,302,260

RMB0.55

8.14 years

RMB3,457,000

The weighted-average grant-date fair value of unconditional share option awards granted during each of the year ended December 31, 2008 and 2010 was RMB 1.24 and RMB 0.52 (US$0.08) per share. During the years ended December 31, 2008 and 2009, no options were exercised and during the year ended December 31, 2010, 11,670,240 shares were exercised. As of December 31, 2010, there was a total unrecognized compensation cost of RMB6.7 million (US$1.0 million) related to non-vested share options under unconditional share options awards. This cost is expected to be recognized over the next 3.5 years.

A summary of share option activity under conditional share option awards during 2008, 2009 and 2010 is as follows:


	Number of options		Weighted average exercise price		Weighted average remaining contractual term		Aggregate intrinsic value
Outstanding as of December 31, 2008		13,652,500		RMB1.50
Outstanding as of December 31, 2009		13,527,500		RMB0.67
Outstanding as of December 31, 2010		—		—		—		—
Fully vested as of December 31, 2010		—		—		—		—
Exercisable as of December 31, 2010		—		—		—		—

The weighted-average fair value of conditional share options awards as of December 31, 2009 granted during 2008 was RMB0.73 per share option. During the years ended December 31, 2008, 2009 and 2010, no options were exercised. As of December 31, 2010, there was no unrecognized compensation cost. The conditional share option awards were cancelled on May 7, 2010.

Based on grants outstanding at December 31, 2010, and assuming no change in the estimated forfeiture rates, our total share-based compensation expenses for future periods in respect of the equity awards that we have granted to date is expected to be as follows:


	2011		2012		2013 and Beyond
	(in thousands of RMB)
Estimated impact for unconditional share options awards		4,355		1,498		896
Estimated impact for conditional share options awards		—		—		—

Total		4,355		1,498		896

Estimating the value of our share-based compensation expense for future periods requires the input of highly subjective assumptions, including estimated forfeitures and the price volatility of the underlying shares. We estimate our forfeitures rates based on past employee retention rates and our expectations of future retention rates. We will prospectively revise our forfeiture rates based on actual history. Our share compensation charges may change based on changes to our actual forfeitures. Our actual share-based compensation expenses may be materially different from our current expectations. In addition to the subjective assumptions and estimates discussed above, see “Item 5. Operating and Financial Review and Prospects. G. Safe Harbor” for information regarding the various risks and uncertainties inherent in estimates of this type.

If the going private transaction described in “Item 4. Information on the Company – A. History and Development of the Company – Going Private Transaction” is completed, Merger Sub will merge with and into the Company, with the Company continuing as the surviving company in the merger. At the effective time of the merger, the surviving company will make to each holder of outstanding vested options to purchase shares under our 2008 share incentive plan an unconditional and irrevocable offer which, if accepted by such holder, will result in such vested options being cancelled and converted into the right to receive, as soon as reasonably practicable after the effective time, a cash payment equal to the number of shares underlying such option immediately prior to the effective time multiplied by the amount by which US$0.1350 exceeds the exercise price per share of such vested option, without interest and less any applicable withholding taxes.

At the effective time of the merger, the surviving company will make to each holder of outstanding unvested options to purchase shares under the share incentive plan an unconditional and irrevocable offer which, if accepted by such holder, will result in such unvested options being cancelled and converted into the right to receive, as soon as reasonably practicable after the effective time, a restricted cash award in the amount equal to the number of shares underlying such option multiplied by the amount by which US$0.1350 exceeds the exercise price per share of such unvested option. Such restricted cash awards will be subject to the same vesting conditions applicable to the unvested options without giving effect to the merger and any such restricted cash awards will not be transferrable. On the date that the unvested options would have become vested without giving effect to the merger, such corresponding portion of the restricted cash awards will be delivered to the holder of such restricted cash award, without interest and less any applicable withholding taxes.

A. Operating Results

The following table sets forth our consolidated operating income information as a percentage of our total sales for the periods described:


	Year Ended December 31,
	2008			2009			2010
	(percentage of total sales)
Sales		100.0			100.0			100.0
Cost of sales		(58.2	)		(60.4	)		(61.4	)

Operating expenses:
Selling expenses		(1.3	)		(1.4	)		(1.0	)
General and administrative expenses		(6.3	)		(8.5	)		(7.2	)
Research and development expenses		(2.9	)		(3.8	)		(6.1	)
Other operating expenses		(0.2	)		(0.9	)		(0.3	)
Other operating income		0.1			0.1			0.2
Government grants		0.0			0.1			0.5

Income from operations		31.2			25.2			24.6
Other income (expenses):
Interest income		0.2			0.3			0.2
Interest expense		(0.3	)		(0.3	)		0.0
Foreign currency exchange loss, net		(1.0	)		(0.2	)		(0.3	)
Equity in loss of an affiliate		—			(0.0	)		(0.0	)
Other income		0.0			0.1			0.0

Earnings before income taxes		30.1			25.1			24.5
Income tax benefit (expense)		3.4			(3.5	)		(3.6	)

Net income		33.5			21.6			20.9
Net income attributable to noncontrolling interests		(0.5	)		(0.6	)		(0.1	)

Net income attributable to the Company		33.0			21.0			20.8

Year Ended December 31, 2010 compared to year ended December 31, 2009

Sales. Our sales increased by 31.9% from RMB820.3 million in 2009 to RMB1,082.0 million (US$163.9 million) in 2010, which reflected (i) an increase in sales generated from commercialized projects from RMB697.4 million in 2009 to RMB979.0 million (US$148.3 million) in 2010; (ii) a decrease in sales generated from pipeline projects from RMB96.4 million in 2009 to RMB86.4 million (US$13.0 million) in 2010; and (iii) a decrease in sales of purchased goods from RMB26.5 million in 2009 to RMB16.7 million (US$2.5 million) in 2010. Our increase in sales during the year was largely due to the upswing in the demand from our end markets, primarily as a recovery of the global financial crisis.

Cost of sales. Our cost of sales increased by 34.1% from RMB495.6 million in 2009 to RMB664.8 million (US$100.7 million) in 2010 due primarily to increased sales.

Gross profit. As a result of the foregoing, our gross profit increased 28.5% from RMB324.7 million in 2009 to RMB417.2 million (US$63.2 million) in 2010, while our overall gross profit margin decreased from 39.6% to 38.6%, respectively. The decrease in overall gross margin was primarily a result of (i) the shift in product mix, and (ii) reduced price in certain products.

Operating expenses. Our operating expenses increased 32.0% from RMB119.2 million in 2009 to RMB157.3 million (US$23.8 million) in 2010. This increase was primarily due to higher depreciation expenses associated with our new headquarters and research and development buildings, and consulting expenses associated with Sarbanes–Oxley (SOX) compliance and audit fees.

•

Selling . Selling expenses decreased 1.0% from RMB11.2 million in 2009 to RMB11.1 million (US$1.7 million) in 2010.

•

General and Administrative. G eneral and administrative expenses increased 11.3% from RMB69.9 million in 2009 to RMB77.8 million (US$11.8 million) in 2010 primarily due to an increase in depreciation expenses associated with the new office building completed in 2009 and fees relating to the SOX compliance consulting work.

•

Research and Development. Research and development expenses increased by 112.5% from RMB30.9 million in 2009 to RMB65.7 million (US$10.0 million) in 2010. We attribute the increase in our research and development expenses to the increase of material consumption expenses from RMB4.6 million in 2009 to RMB24.5 million in 2010 that were related to an increase of the active R&D projects to meet the anticipated demand from our customers and the increase in personnel cost from RMB20.2 million in 2009 to RMB28.7 million in 2010.

•

Other Operating Expenses. Other operating expenses decreased from RMB7.1 million in 2009 to RMB2.7 million (US$0.4 million) in 2010 due primarily to the decrease in disposal of the fixed assets in 2010.

Other operating income. We had other operating income of RMB1.6 million (US$0.2 million) in 2010 resulting from income from leases of plant and equipment.

Government grants. The government grants recognized as income increased from RMB1.0 million in 2009 to RMB5.2 million (US$0.8 million) in 2010.

Income from operations. As a result of the foregoing, we generated income from operations of RMB266.7 million (US$40.4 million) in 2010, representing an increase of 28.6% as compared to RMB207.5 million of income from operations in 2009.

Interest income. Our interest income decreased from RMB2.3 million 2009 to RMB2.0 million (US$0.3 million) in 2010 because our average cash on deposit in interest-bearing saving accounts decreased in 2010.

Interest expense. Our interest expense decreased from RMB2.1 million in 2009 to RMB80, 000 (US$12,000) in 2010, because the average borrowing balance decreased in 2010.

Foreign currency exchange loss, net. Our net foreign currency exchange loss increased from RMB2.0 million in 2009 to RMB3.2 million (US$0.5 million) in 2010 because the RMB appreciated against the U.S. dollar, as a large percentage of our sales were denominated in U.S. dollars during this period.

Other income. We had other income of RMB519,000 and RMB400,000 (US$61,000) in 2009 and 2010, respectively.

Earnings before income taxes . Earnings before income taxes increase by 28.8% from RMB206.0 million in 2009 to RMB265.2 million (US$40.2 million) in 2010.

Income tax expense. Our income tax expense was RMB39.0 million (US$5.9 million) for 2010, as compared with RMB28.8 million for 2009. The PRC statutory tax rate for 2010 and 2009 was 25%. The effective tax rate of 14.7% in 2010 was mainly due to the effect of a tax holiday amounting to RMB35.5 million which reduced our effective tax rate by 13.4%, partially offset by the effect of tax rate differential expenses on PRC operations amounting to RMB4 million which increased our effective tax rate by 1.5%.The effective tax rate of 14.0% in 2009 was mainly due to the effect of a tax holiday amounting to RMB26.0 million which reduced our effective tax rate by 12.6%.

Net income. As a result of the foregoing, we had net income of RMB226.2 million (US$34.3 million) in 2010, compared to net income of RMB177.2 million in 2009, an increase of 27.7%.

Net income attributable to noncontrolling interests. Net income attributable to noncontrolling interests amounted to RMB4.7 million and RMB685,000 (US$104,000) in 2009 and 2010, respectively, attributable to (i) 20% ownership interest in Huajing Company, which was held by Mr. Xuhua Ren; (ii) the 48.3% ownership interest in Kangpeng Nong Hua through November 2009, which was held by Mr. Zhiyan Shen, Ms. Yunfen Fan, Dr. Yunhong Tang and Kang Qi Investment Company, or Kang Qi, respectively; (iii) the 20% ownership interest in Jiangsu Wei Er through November 2009, which was held by Mr. Zhiyan Shen and Ms. Yunfen Fan; and (iv) the 8% ownership interest in Binhai Kangjie through March 2011, which was held by Mr. Yunxiang Wang.

Net income attributable to the Company. As a result of the foregoing, we had net income attributable to the Company of RMB225.5 million (US$34.2 million) in 2010, compared to RMB172.4 million 2009, an increase of 30.8%.

Year ended December 31, 2009 compared to year ended December 31, 2008

Sales. Our sales decreased by 13.0% from RMB942.5 million in 2008 to RMB820.3 million in 2009, which reflected (i) a decrease in sales generated from commercialized projects from RMB801.5 million in 2008 to RMB697.4 million in 2009; (ii) an increase in sales generated from pipeline projects from RMB59.2 million in 2008 to RMB96.4 million in 2009; and (iii) a decrease in sales of purchased goods from RMB81.8 million in 2008 to RMB26.5 million in 2009. Our decrease in sales during the year was due largely to weak demand in our end markets, primarily as a result of the global financial crisis.

Cost of sales. Our cost of sales decreased by 9.7% from RMB548.5 million in 2008 to RMB495.6 million in 2009 due primarily to reduced sales in electronic chemicals in 2009, particularly in the first quarter, and reduced sales in agrochemicals in the third and fourth quarters of 2009 caused by the extremely difficult market situation in 2009, partially offset by a provision of RMB 14.7 million to write down the value of some of our obsolete inventories at the end of 2009.

Gross profit. As a result of the foregoing, our gross profit decreased 17.6% from RMB393.9 million in 2008 to RMB324.7 million in 2009, while our overall gross profit margin decreased from 41.8% to 39.6%, respectively. The decrease in overall gross margin was primarily a result of (i) reduced sales in electronic chemicals in 2009 and (ii) reduced sales and gross margin for our agrochemical products due to severe competition caused by the global economic slowdown.

Operating expenses. Our operating expenses increased 18.6% from RMB100.5 million in 2008 to RMB119.2 million in 2009. This increase was primarily due to higher personnel salaries for experienced senior level employees, higher depreciation expenses associated with the construction of our new headquarters and research and development buildings, and other consulting and audit fees associated with being a publicly-listed company.

•

Selling . Selling expenses decreased 5.5% from RMB11.9 million in 2008 to RMB11.2 million in 2009 due primarily to a decrease in sales of products for which we bear shipping costs.

•

General and Administrative . General and administrative expenses increased 18.5% from RMB58.9 million in 2008 to RMB69.9 million in 2009 primarily due to an increase in the size of our administrative staff to support the growth of our operations, an increase in depreciation expenses associated with the new office building completed in 2009, and fees relating to the SOX compliance consulting work. In addition, in 2009, we recognized a share-based compensation expense of RMB11.8 million related to general and administrative expenses in connection with grants made under our 2008 share incentive plan.

•

Research and Development. Research and development expenses increased by 12.5% from RMB27.5 million in 2008 to RMB30.9 million in 2009. We attribute the increase in our research and development expenses to an increase in personnel expenses of RMB4.8 million, as a result of the expansion of our research and development staff, offset in part by a decrease in the raw materials used in our research and development activities from RMB7.3 million in 2008 to RMB4.6 million in 2009. We were able to reduce the amount of raw materials used in research and development activities because of reduced internal test failure rates when conducting experiments.

•

Other Operating Expenses. Other operating expenses increased from RMB2.2 million in 2008 to RMB7.1 million in 2009 due primarily to disposal of fixed assets in 2009.

Other operating income. We had other operating income of RMB1.0 million in 2009 resulting from income from leases of plant and equipment.

Government grants. The government grants recognized as income increased from RMB50,000 in 2008 to RMB1.0 million in 2009.

Income from operations. As a result of the foregoing, we generated income from operations of RMB207.5 million in 2009, representing a decrease of 29.6% as compared to RMB294.5 million of income from operations in 2008.

Interest income. Our interest income increased from RMB2.1 million in 2008 to RMB2.3 million in 2009 because our total cash on deposit in interest-bearing saving accounts and the relevant interest rates increased between these periods.

Interest expense. Our interest expense decreased from RMB2.7 million in 2008 to RMB2.1 million in 2009, due to (i) a decrease in bank borrowings outstanding from RMB65.0 million as of December 31, 2008 to RMB10.0 million as of December 31, 2009 and (ii) a decrease in the weighted average interest rate of our bank borrowings in 2009.

Foreign currency exchange loss, net. Our net foreign currency exchange loss decreased significantly from RMB9.5 million in 2008 to RMB2.0 million in 2009 because starting from mid 2008 our sales were no longer denominated in Euro and we were not subject to the exchange risk of the Euro against the U.S. dollar.

Other income. We had other income of RMB82,000 and RMB519,000 (US$76,000) in 2008 and 2009, respectively.

Earnings before income taxes . Earnings before income taxes decreased by 27.6% from RMB284.4 million in 2008 to RMB206.0 million in 2009.

Income tax benefit (expense). Our income tax expense was RMB28.8 million for 2009, as compared with an income tax benefit of RMB32.2 million for 2008. The PRC statutory tax rate for 2009 and 2008 was 25%. Our income tax expense in 2009 was reduced by effect of a tax holiday amounting to RMB26.0 million which reduced our effective tax rate by 12.6%. In addition, PRC dividend withholding tax was only accrued for certain undistributed earnings of our PRC subsidiaries as we plan to indefinitely reinvest a portion of the undistributed earnings in the PRC. These attributed to an overall effective tax rate of 14.0% in 2009. The effective tax benefit rate of 11.3% in 2008 was mainly due to (i) a reinvestment tax refund of RMB16.3 million; (ii) an income tax refund of RMB42.5 million; and (iii) effect of a tax holiday amounting to RMB61.9 million which reduced our effective tax rate by 5.7%, 14.9% and 21.8%, respectively. In addition, the new PRC corporate income tax law imposed dividend withholding tax on earnings generated since January 1, 2008, which increased our 2008 income tax expense by RMB13.9 million and the related tax effect was 4.9%.

Net income. As a result of the foregoing, we had net income of RMB177.2 million in 2009, compared to net income of RMB316.7 million in 2008, a decrease of 44.0%.

Net income attributable to noncontrolling interests. Net income attributable to noncontrolling interests amounted to RMB4.3 million and RMB4.7 million in 2008 and 2009, respectively, attributable to (i) the 40% ownership interest in Huajing Company before April 2008 and the 20% ownership interest after then, which was held by Mr. Xuhua Ren; (ii) the 48.3% ownership interest in Kangpeng Nong Hua from October 2008 through November 2009, which was held by Mr. Zhiyan Shen, Ms. Yunfen Fan, Dr. Yunhong Tang and Kang Qi, respectively; (iii) the 20% ownership interest in Jiangsu Wei Er from February 2008 through November 2009, which was held by Mr. Zhiyan Shen and Ms. Yunfen Fan; and (iv) the 8% ownership interest in Binhai Kangjie, which was held by Mr. Yunxiang Wang.

Net income attributable to the Company. As a result of the foregoing, we had net income attributable to the Company of RMB172.4 million in 2009, compared to RMB312.4 million in 2008, a decrease of 44.8%.

B. Liquidity and Capital Resources

Liquidity and Capital Resources

Our primary sources of liquidity have historically been cash generated from our operations. Historically, we were able to finance a significant portion of our operations and capital investments from our cash flows from operations. As of December 31, 2010, we had approximately RMB98.7 million (US$15.0 million) in cash. Our cash generally consists of cash on hand and demand deposits. We require cash to fund our ongoing business needs, particularly salary and benefits and material costs and expenses. Other cash needs include primarily the working capital for our daily operations and manufacturing activities, the purchase of equipment for our manufacturing facilities and expenditures related to the expansion of our manufacturing and research and development facilities. As of December 31, 2010, we had approximately RMB25 million (US$3.8 million) in short-term bank borrowings and long-term bank borrowing, current portion, with a weighted average interest rate of 5.27% per annum. The amount of unused credit facilities available associated with bank borrowings as of December 31, 2010 amounted to RMB75.0 million (US$11.4 million). Our short-term bank borrowings and long-term bank borrowings, current portion, are due in 2011. These facilities contain no specific renewal terms or any requirement for the maintenance of financial covenants. We have traditionally negotiated the renewal of facilities shortly before they mature although, no assurance can be made that we will be able to continue successfully re-negotiate the renewal of these facilities in the future. As of December 31, 2010, we had no long-term bank borrowings.

Cash decreased from RMB351.1 million as of December 31, 2009 to RMB98.7 million (US$15.0 million) as of December 31, 2010. The net cash outflow was primarily due to cash paid for capital expenditures of approximately RMB241.2 million (US$36.5 million) in 2010.

We conduct all of our business through our consolidated subsidiaries incorporated in China. We rely on dividends paid by consolidated subsidiaries for the cash needs of Chemspec International Limited, including the funds necessary to pay any dividends and other cash distributions to our shareholders, to service any debt we may incur and to pay our operating expenses. The payment of dividends by entities established in China is subject to limitations. Any limitations on the ability of our PRC subsidiaries to transfer funds to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends and otherwise fund and conduct our business. See “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—We rely on dividends paid by our subsidiaries for our cash needs, and any limitation on the ability of our subsidiaries to make payments to us could have a material adverse effect on our ability to conduct our business.”

We expect to continue to generate positive operating cash flow in 2011. During 2010, we generated net cash from operating activities which supported part of the investing and financing activities. For the year 2011, the Company expects to incur no more than RMB200 million in capital expenditures pursuant to the going private transaction merger agreement that was filed with SEC on March 21, 2011. See “Item 4. Information on the Company—A. History and Development of the Company—Going Private Transaction”. Based on current credit conditions in China and preliminary discussions with our local banks, we do not believe we will encounter any problems in increasing our borrowings if the need arises.

The following table sets forth a summary of our cash flows for the periods indicated:


	Year Ended December 31,
	2008			2009			2010
	(in thousands)
Cash		RMB 180,6022			RMB351,097			RMB 98,719		USD 14,957
Net cash provided by operating activities		289,746			209,252			96,162		14.570
Net cash used in investing activities		(112,175	)		(257,893	)		(254,677	)	(38,587	)
Net cash provided by (used in) financing activities		(54,190	)		219,082			92,563		(14,025	)

Operating Activities

Net cash provided by operating activities decreased from RMB209.3 million for the year ended December 31, 2009 to RMB96.2 million (US$14.6 million) in 2010. This decrease was the result of an increase in cash payment for building-up of inventory at the year-end due to strong orders for our products used in production of electronics chemicals, as our products in this field are technically highly complex and involve a long in-house production cycle.

Net cash provided by operating activities decreased from RMB289.7 million for the year ended December 31, 2008 to RMB209.3 million for the year ended December 31, 2009. This decrease was the result of (i) an increase in cash payment for build-up of inventory at the year-end due to strong orders for our products used in production of electronics chemicals to be delivered in the first quarter of 2010, as our products in this field are technically highly complex and involve a long in-house production cycle; (ii) a decrease in cash collected from our customers due to the reduced sales, especially in the fourth quarter of 2009; and (iii) an increase in cash payment for operating expenses due to the expansion of our business.

Investing Activities

Net cash used in investing activities amounted to RMB112.2 million, RMB257.9 million and RMB254.7 million (US$38.6 million) in 2008, 2009 and 2010, respectively. Net cash used in investing activities largely

reflects capital expenditures made in connection with the expansion and upgrade of our research and development and manufacturing facilities, and purchase of land use rights. These capital expenditure cash outflows were RMB127.8 million in 2008, RMB227.7 million in 2009 and RMB241.2 million (US$36.5 million) in 2010. In addition, we made payments of RMB17.5 million, RMB4.0 million and RMB4.5 million (US$0.7 million) for land use rights in 2008, 2009 and 2010, respectively, in connection with securing the land for construction of our new facilities. We expect to incur no more than RMB200 million in capital expenditures in 2011 pursuant to the going private transaction merger agreement that was filed with SEC on March 21, 2011. See “Item 4. Information on the Company—A. History and Development of the Company—Going Private Transaction”.

Financing Activities

Net cash used in financing activities amounted to RMB54.2 million and RMB92.6 million (US$14.0 million) in 2008 and 2010 respectively, and net cash provided by financing activities amounted to RMB219.1 million in 2009. Cash used in financing activities primarily consists of dividends paid to shareholders, repayment of bank loans, acquisition of additional equity interest in subsidiary, repurchase of ordinary shares from the open market and repayment of borrowings from related parties,. Cash provided from financing activities primarily consists of proceeds from bank loans, proceeds from borrowings from related parties, and proceeds of approximately RMB389.0 million (US$57.0 million) from our initial public offering in June 2009. We did not declare any dividends in 2008. One of our subsidiaries made a cash distribution of RMB 2.5 million to our noncontrolling interest holders in June 2009. On March 7, 2010, we declared the 2009 dividend of US$0.003 per ordinary share (US$0.18 per ADS) to shareholders of record as of March 31, 2010 with payment date of April 21, 2010. We do not expect to declare or pay any further dividends prior to the proposed merger which would result in us becoming a privately-held company, and under the terms of the going private transaction merger agreement, are prohibited from doing so without Halogen Limited’s prior written approval. See “Item 4. Information on the Company—A. History and Development of the Company—Going Private Transaction”.

Capital Expenditures

Our capital expenditures are incurred primarily in connection with (i) purchases of property, plant and equipment and construction of our head office, research and development center and production facilities, (ii) investment in equipment, technology and operating systems, and (iii) capitalized interest. Our capital expenditures were RMB163.1 million, RMB342.7 million and RMB244.1 million (US$37.0 million) in 2008, 2009 and 2010, respectively. Our primary planned capital expenditures for 2011 are for expansion of our manufacturing capacity in China, maintenance of our existing facilities, and enhancement of our research and development capabilities in China. See “Item 4. Information on the Company—B. Business Overview—Headquarters and Facilities.” We expect to incur no more than RMB200 million in capital expenditures in 2011 pursuant to the going private transaction merger agreement that was filed with SEC on March 21, 2011. See “Item 4. Information on the Company—A. History and Development of the Company—Going Private Transaction”.

Inventories and Receivables

Inventories and receivables are two principal components of our working capital, particularly during periods when sales increase. Accordingly, control of inventories and receivables are key aspects of our operations.

We sell to our principal customers on an open account basis, allowing credit terms of between 30 and 120 days, with most payments made within 90 days. The average collection days for our accounts receivable was 35 days in 2008, 56 days in 2009 and 37 days in 2010. The increase of the average collection days in 2009 was mainly due to the difficult global economic condition which caused the payment patterns of some of our customers to change. With the recovery of global business environment in 2010, the payment pattern came back to the 2008 level. Bad debt expense accounted for less than 1% of our sales in each of 2008, 2009 and 2010.

C. Research and Development, Patents and Licenses, Etc.

See “Item 4. Information on the Company—B. Business Overview—Research and Development” and “Item 4. Information on the Company—B. Business Overview—Intellectual Property.”

D. Trend Information

See “—Overview” for a discussion of the most significant recent trends that have had, and in the future may have, a material impact on our results of operations, financial condition and capital expenditures. In addition, see discussions included in this Item for a discussion of known trends, uncertainties, demands, commitments or events that we believe are reasonably likely to have a material effect on our net operating revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause reported financial information not necessarily to be indicative of future operating results or financial condition.

E. Off-Balance Sheet Arrangements

We do not have any outstanding off-balance sheet guarantees or interest rate swap transactions. We do not engage in trading activities involving non-exchange traded contracts. In our ongoing business, we do not enter into transactions involving, or otherwise form relationships with, unconsolidated entities or financial partnerships that are established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

F. Tabular Disclosure of Contractual Obligations

The following table sets forth our contractual obligations, including interest on borrowings, as of December 31, 2010:


	Payment Due by Period
	Total		Less than 1 year		1-3 years		3-5 years		More than 5 Years
	(RMB in millions)
Capital commitments		42.0		42.0		—		—		—
Operating lease commitments		0.4		0.3		0.1		—		—
Short-term bank borrowings		20.0		20.0		—		—		—
Long-term bank borrowings, current portion		5.0		5.0		—		—		—

Total		67.4		67.3		0.1		—		—

As of December 31, 2010, we had capital commitments of RMB42.0 million (US$6.4 million). We attribute the increase in capital commitments to the construction of new facilities and expansion of our existing facilities.

G. Safe Harbor

This annual report contains forward-looking statements that relate to future events, including our future operating results and conditions, our prospects and our future financial performance and condition, all of which are largely based on our current expectations and projections. The forward-looking statements are contained principally in the sections entitled “Item 3. Key Information—D. Risk Factors,” “Item 4. Information on the

Company” and “Item 5. Operating and Financial Review and Prospects.” These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as “may,” “will,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” “is/are likely to” or other and similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include, among other things, statements relating to:

•

the significant risks, challenges and uncertainties in the specialty chemicals industry and for our business generally, including our beliefs regarding the cost advantages and scalability provided by our chemical processes;

•

outsourcing and other trends in the specialty chemicals industry in China;

•

our ability to offset anticipated increases in raw material and other costs that could compress or decrease our gross margins;

•

our current expansion strategy, including our ability to expand production capacity and outputs;

•

market demand, including demand for our products and services by our customers and demand for the products that incorporate our products, including electronics, pharmaceutical products and agrochemicals;

•

the global economic downturn and its effect on our business and operations;

•

our beliefs regarding our strengths and strategies;

•

our ability to maintain strong relationships with suppliers or customers;

•

our beliefs as to the regulatory environment in China and in other jurisdictions in which we sell our products;

•

our ability to comply with all relevant environmental, health and safety laws and regulations;

•

our beliefs regarding the competitiveness of our products or pipeline products;

•

market acceptance of our products and pipeline products and our ability to attract new customers;

•

our ability to effectively protect our intellectual property and trade secrets and not infringe on the intellectual property and trade secrets of others;

•

our planned use of proceeds;

•

our ability to obtain permits and licenses to carry on our business; and

•

our future prospects, business development, results of operations and financial condition.

The forward-looking statements made in this annual report relate only to events or information as of the date on which the statements are made in this annual report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this annual report completely and with the understanding that our actual future results may be materially different from what we expect.

ITEM 6.

DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

A. Directors and Senior Management

The following table sets forth information regarding our directors and executive officers as of the date of this annual report on Form 20-F.


Name	Age		Position/ Title
Jianhua Yang(1)		57	Chairman of the Board of Directors; Chief Executive Officer
Zixin Wang(2)		33	Director, Vice President
Qian Zhao(3)		43	Director
Hai Mi(4)		44	Director
Kevin Wu(5)		55	Director
Zuowei Xie(6)		47	Director
Jinhua (Jim) Chen		49	Vice President
Yuelie Lu		53	Vice President
Yunlong Yuan		37	Vice President

(1)	Jianhua Yang is also chairman of our compensation committee.

(2)	Zixin Wang is also a member of our compensation committee.

(3)	Qian Zhao is an independent director.

(4)	Hai Mi is an independent director, chairman of our audit committee and a member of our corporate governance and nominating committee.

(5)	Kevin Wu is an independent director, a member of our audit committee and a member of our corporate governance and nominating committee.

(6)	Zuowei Xie is an independent director, a member of our audit committee, the chairman of our corporate governance and nominating committee and a member of compensation committee.

Dr. Jianhua Yang , our founder, has served as the chairman of the board of directors and the chief executive officer of Chemspec since its inception in 2006. Dr. Yang has been chairman and chief executive officer of Shanghai ChemSpec since he founded it in 1996. Dr. Yang has more than 20 years of experience in fluorinated specialty chemicals. Dr. Yang graduated from the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences with a Ph.D. in science in 1988. In 1991, Dr. Yang was awarded with the National Natural Science Award (First Class) by the Chinese Academy of Sciences and in 1993, was awarded with the National Natural Science Award (Second Class) by the State Commission on Science and Technology of China.

Mr. Zixin Wang has served as a vice president of Chemspec, responsible for finance, administration and human resources, since 2007. From 2006 to 2007, he was the financial controller of Shanghai Chemspec. Prior to joining us, Mr. Wang served as a project manager of Shanghai Boning Finance Advisory Limited, where he was responsible for advising on offshore initial public offerings of Chinese companies and investment activities in China of foreign companies. Mr. Wang received a master’s degree in accounting in 2004 and a bachelor’s degree in international accounting in 2001, both from Shanghai Jiaotong University.

Mr. Qian Zhao is a founding partner of CXC China Sustainable Growth Fund, a private equity fund that makes investments in China-based companies. Mr. Zhao is a lawyer by training and is admitted to practice law in both China and New York. Mr. Zhao co-founded Haiwen & Partners in 1992, a corporate finance law firm in China and previously worked as an attorney at Sullivan & Cromwell and Skadden, Arps, Slate, Meagher & Flom LLP. Mr. Zhao is currently a director and member of the audit committee of Trina Solar Limited and SouFun Holdings Limited, both of which are NYSE-listed companies, and CXC Capital, Inc., which is the management company of CXC China Sustainable Growth Fund. Mr. Zhao received a J.D. degree from the New York University School of Law in 1998 and an LL.B degree from University of International Business & Economics, Beijing, in 1990.

Dr. Hai Mi has a range of experience in his professional career in the pharmaceutical and related industries. From 2005 to 2009, Dr. Mi was a senior director of strategic planning and vice president of corporate communications at WuXi PharmaTech in Shanghai. From 2003 to 2004, Dr. Mi served as an independent consultant to Pfizer Inc. in New York, and from 1999 to 2001, he worked as a research scientist at Pfizer in Ann Arbor, Michigan. His other experience included serving as a general manager, financial advisor and business development consultant for biotech companies. Dr. Mi obtained a Ph.D. in organic chemistry from New York University in 1999, an MBA with a concentration in finance and strategic management from The University of Chicago Booth School of Business in 2003 and a B.S. in material science from Fudan University in Shanghai in 1989.

Dr. Kevin Wu currently serves as the commercial director of the emulsion division of Celanese Company, or Celanese, in the Asia Pacific region. Dr. Wu helped establish the emulsion division of Celanese in the region. Prior to joining Celanese in 2007, Dr. Wu spent 14 years at Rohm and Haas, where he served in various capacities at multiple locations around Asia and North America, including the general manager of the adhesives and sealants division in the Asia Pacific region; the general manager of the microelectronics division in Greater China (Mainland China, Taiwan and Hong Kong); and the general manager of Rohm and Haas Electronic Materials Company in Shanghai, China. Dr. Wu served on the board of directors at Rohm and Haas China Holding Company Ltd. from 2002 to 2007 and at Toyo Morton Company in Japan, which was a joint venture between Rohm and Haas and Toyo Ink, from 2002 to 2005. He was also a member of the graduate advisors committee for materials science at Rutgers University in 1999 and served as the chairman of the ceramic process branch of the U.S. Ceramic Society in 1995. Dr. Wu obtained a Ph.D. in chemistry from Columbia University in New York in 1991, an MBA. in marketing from Temple University in Philadelphia in 1999 and a B.S. from Peking University in Beijing, China in 1982. Dr. Wu also holds several U.S. and international patents.

Dr. Zuowei Xie is the associate dean of the faculty of science and the chair professor in the department of chemistry at The Chinese University of Hong Kong, where he started his career in 1995. During this period, he received the Croucher Award from the Croucher Foundation (Hong Kong) in 2003, and the State Natural Science Award from the State Commission on Science and Technology of China in 1997 and 2008. Dr. Xie obtained a Ph.D. in 1990 through a collaborative program between Shanghai Institute of Organic Chemistry, Shanghai, China and Technische Universität Berlin, Berlin, Germany. He obtained a B.S. degree in 1983 from Hangzhou University, Hangzhou, Zhejiang Province, China.

Dr. Jinhua (Jim) Chen became vice president of Chemspec in June 2008 and is responsible for marketing. He joined Chemspec in June 2008. Prior to being the vice president of marketing, he was a director (and then a vice president) of research and development at Chemspec. Prior to joining us, Mr. Chen served as an associate research investigator in the global pharmaceutical research and development division at Abbott Laboratories in Chicago, Illinois, USA, where he participated in the research and launch of the drugs Ritonavir and Lopinavir. Mr. Chen was also an American Chemical Society Industrial Innovation Award winner. He holds a Ph.D. in organometallic chemistry from the University of New Brunswick in Canada and a B.S. in organic chemistry from Xiamen University in the People’s Republic of China.

Dr. Yuelie Lu became vice president of Chemspec in June 2009 and is responsible for marketing. Mr. Lu has extensive experience in pharmaceutical chemical process research and development, project management, and CMC management. Prior to joining us, he served as an associate director of chemical development at Lexicon Pharmaceuticals in New Jersey, USA and a principle scientist at Amgen Inc. in California, USA. Mr. Lu holds a Ph.D. from Purdue University and a B.S. and M.S. from the University of Science & Technology of China.

Mr. Yunlong Yuan has been vice president of Chemspec since July 2008 and is responsible for overseeing technology transfer, quality assurance and repurchasing. From 1998 to 2007, he was a director of research and development for Shanghai ChemSpec and was responsible for the research and development activities of Shanghai ChemSpec jointly with Dr. Tang. Mr. Yuan has more than 10 years of experience in fluorinated specialty chemicals. Prior to joining our company, he served as a technician with Nanjing Chemical Industrial (Group) Co., Ltd. Mr. Yuan graduated from the chemistry department of East China University of Science and Technology majoring in industrial catalysis in 1996.

The address of our directors and executive officers is c/o Chemspec International Limited, No. 200, Wu Wei Road, Shanghai 200331, People’s Republic of China.

B. Compensation

Cash Compensation

In 2010, the aggregate cash compensation to our executive officers, including all the directors, was RMB5.4 million (US$0.8 million). For options granted to officers and directors, see “—2008 Share Incentive Plan.”

2008 Share Incentive Plan

We have adopted our 2008 share incentive plan, as modified in 2010, to attract and retain the best available personnel, provide additional incentives to our employees, directors and consultants, and promote the success of our business. The 2008 share incentive plan provides for the grant of options, restricted shares, and restricted share units, collectively referred to as “awards.” Our board of directors has authorized the issuance of up to 180,000,000 ordinary shares upon exercise of awards granted under our 2008 share incentive plan.

Plan Administration . Our compensation committee, or prior to such committee’s formation, our board or directors, will administer the 2008 share incentive plan. The committee or the full board of directors, as appropriate, will determine the participants to receive awards, the type and number of awards to be granted, and the terms and conditions of each award grant.

Award Agreements . Awards granted under our 2008 share incentive plan are evidenced by an award agreement that sets forth the terms, conditions and limitations for each grant, which may include the term of the award, the provisions applicable in the event that the grantee’s employment or service terminates, and our authority to unilaterally or bilaterally amend, modify, suspend cancel or rescind the award.

Transfer Restrictions . The right of a grantee in an award granted under our 2008 share incentive plan may not be transferred in any manner by the grantee other than by will or the laws of succession and, with limited exceptions, may be exercised during the lifetime of the grantee only by the grantee.

Option Exercise . The term of options granted under the 2008 share incentive plan may not exceed ten years from the date of grant. The consideration to be paid for our ordinary shares upon exercise of an option or purchase of shares underlying the option may include cash, check or other cash-equivalent, ordinary shares, consideration received by us in a cashless exercise, or any combination of the foregoing methods of payment.

Acceleration upon a Change of Control . If a change of control of our company occurs, (i) the compensation committee may determine that any outstanding unexercisable, unvested or lapsable awards shall automatically be deemed exercisable, vested and not subject to lapse immediately prior to the event triggering the change of control and (ii) the compensation committee may cancel such awards for fair value, provide for the issuance of substitute awards or provide that for a period of at least 15 days prior to the event triggering the change of control, such options shall be exercisable and that upon the occurrence of the change of control, such options shall terminate and be of no further force and effect.

Termination and Amendment . Unless terminated earlier, our 2008 share incentive plan will expire after ten years. Our board of directors has the authority to amend or terminate our 2008 share incentive plan subject to shareholder approval to the extent necessary to comply with applicable laws. Shareholders’ approval is required for any amendment to the 2008 share incentive plan that (i) increases the number of ordinary shares available under the 2008 share incentive plan or changes the maximum number of shares for which awards may be granted to any participant or, (ii) diminish any of the rights of the participant under any award previously granted to such participant under the plan without such participant’s consent.

Our board of directors has granted options to participants in our 2008 share incentive plan. As of December 31, 2010, the following grants of options to our directors, officers and employees were outstanding:

•

grants of options to purchase 35,622,500 and 24,497,500 of our ordinary shares in 2008 and 2010, respectively, at an exercise price of RMB0.55 per share with a vesting schedule of four years.

129,290,000 ordinary shares are available for future issuance upon the exercise of future grants under our 2008 share incentive plan. The following table summarizes, as of December 31, 2010, the options granted to our directors and executive officers and other individuals as a group, without giving effect to options that were exercised or terminated:


Name	Number of ordinary shares to be issued upon exercise of options	Exercise price per ordinary share	Date of grant	Date of expiration
		(in RMB)
Zixin Wang	*	0.55	January 1, 2008	December 31, 2017
Jinhua (Jim) Chen	*	0.55	June 30, 2008	June 29, 2018

*	Upon exercise of all options granted, would beneficially own less than 1% of our outstanding ordinary shares.

C. Board Practices

Committees of the Board of Directors

Audit Committee

Our audit committee consists of Dr. Hai Mi, Dr. Kevin Wu and Dr. Zuowei Xie. Each of them satisfies the “independence” requirements of Section 303A of the NYSE Listed Company Manual, or Section 303A, and Rule 10A-3 promulgated under the United States Securities Exchange Act of 1934, as amended, or the Exchange Act. Dr. Mi is the chairman of our audit committee and meets the definition of an audit committee “financial expert” as set forth under Item 401(h) of Regulation S-K. The audit committee is responsible for, among other things:

•

selecting our independent registered public accounting firm and pre-approving all auditing and non-auditing services permitted to be performed by our independent registered public accounting firm;

•

reviewing with our independent registered public accounting firm any audit problems or difficulties and management’s response;

•

reviewing and approving all proposed related-party transactions, as defined in Item 404 of Regulation S-K under the Securities Act;

•

discussing the annual audited financial statements with management and our independent registered public accounting firm;

•

reviewing major issues as to the adequacy of our internal controls and any special audit steps adopted in light of significant control deficiencies;

•

annually reviewing and reassessing the adequacy of our audit committee charter;

•

such other matters that are specifically delegated to our audit committee by our board of directors from time to time; and

•

meeting separately and periodically with management and our internal auditor and independent registered public accounting firm.

Compensation Committee

Our compensation committee consists of Dr. Jianhua Yang, Mr. Zixin Wang and Dr. Zuowei Xie. Dr. Zuowei Xie is an “independent director” within the definition set forth in Section 303A of the NYSE Listed

Company Manual. Dr. Jianhua Yang is the chairman of our compensation committee. As two of the directors on our compensation committee are not independent, we are relying on home country practice pursuant to the NYSE Listed Company Manual Section 303A.00 in lieu of the requirements of Section 303A.05 relating to our compensation committee. Our compensation committee assists the board in reviewing and approving the compensation structure of our directors and executive officers, including all forms of compensation to be provided to our directors and executive officers. Members of the compensation committee are not prohibited from direct involvement in determining their own compensation. The compensation committee is responsible for, among other things:

•

approving and overseeing the compensation package for our executive officers;

•

reviewing and making recommendations to the board with respect to the compensation of our directors; and

•

reviewing periodically and making recommendations to the board regarding any long-term incentive compensation or equity plans, programs or similar arrangements, annual bonuses, employee pension and welfare benefit plans.

Corporate Governance and Nominating Committee

Our corporate governance and nominating committee consists of Dr. Zuowei Xie, Dr. Kevin Wu and Dr. Hai Mi. All of them are “independent directors” within the definition set forth in Section 303A. Dr. Zuowei Xie is the chairman of our corporate governance and nominating committee. The corporate governance and nominating committee assist the board of directors in identifying individuals qualified to become our directors and in determining the composition of the board and its committees. The corporate governance and nominating committee is responsible for, among other things:

•

identifying and recommending to the board nominees for election or re-election to the board, or for appointment to fill any vacancy;

•

reviewing annually with the board the current composition of the board in light of the characteristics of independence, age, skills, experience and availability of service to us;

•

advising the board periodically with respect to significant developments in the law and practice of corporate governance as well as our compliance with applicable laws and regulations, and making recommendations to the board on all matters of corporate governance and on any corrective action to be taken; and

•

monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.

Duties of Directors

Under Cayman Islands law, our directors have a fiduciary duty to act honestly, in good faith and with a view to our best interests. Our directors also have a duty to exercise the skill they actually possess and such care and diligence that a reasonably prudent person would exercise in comparable circumstances. In fulfilling their duty of care to us, our directors must ensure compliance with our memorandum and articles of association, as amended and restated from time to time.

The functions and powers of our board of directors include, among others:

•

convening shareholders’ annual general meetings and reporting its work to shareholders at such meetings;

•

declaring dividends and distributions;

•

appointing officers and determining the term of office of officers;

•

exercising the borrowing powers of our company and mortgaging the property of our company; and

•

approving the transfer of shares of our company, including the registering of such shares in our share register.

Terms of Directors and Executive Officers

Our executive officers are elected by and serve at the discretion of the board of directors. Our directors are not subject to a term of office and hold office until such time as they resign or are removed from office without cause by special resolution or the unanimous written resolution of all shareholders or with cause by ordinary resolution or the unanimous written resolutions of all shareholders. A director will be removed from office automatically if, among other things, the director (i) becomes bankrupt or makes any similar arrangement or compromise with his creditors; or (ii) dies or is found by our company to be or becomes of unsound mind. We have not entered into any service agreements with our directors that provide for any type of compensation upon termination.

Employment Agreements

We have entered into employment agreements with all of our executive officers. Under these agreements, each of our executive officers is employed for a specified time period. We may terminate his or her employment for cause at any time, with prior written notice, for certain acts of the employee, including but not limited to a conviction to a felony, or willful gross misconduct by the employee in connection with his employment, and in each case if such acts have resulted in material and demonstrable financial harm to us. An executive officer may, with prior written notice, terminate his or her employment at any time for any material breach of the employment agreement by us that is not remedied promptly after receiving the remedy request from the employee. Furthermore, either party may terminate the employment agreement at any time without cause upon advance written notice to the other party. Upon termination, the employee is generally entitled to a severance pay equal to a certain specified number of months of his or her then base salary, depending on the length of his or her employment with us.

Each executive officer has agreed to hold, both during and subsequent to the terms of his or her agreement, in confidence and not to use, except in pursuance of his or her duties in connection with the employment, any of our confidential information, technological secrets, commercial secrets and know-how. Each of our executive officers has entered into a confidentiality agreement with us. Our executive officers have also agreed to disclose to us all inventions, designs and techniques that have resulted from work performed by them, and to assign us all right, title and interest of such inventions, designs and techniques.

D. Employees

We had 1,171, 1,585 and 1794 employees as of December 31, 2008, 2009 and 2010, respectively. The following table sets forth the number of our employees for each of our areas of operations and as a percentage of our total workforce as of December 31, 2010:


	As of December 31, 2010
	Employees		Percentage of Total
Research & Development		103		5.7	%
Management and Administration		348		19.4	%
Production		1,328		74.1	%
Sales and Marketing		15		0.8	%

Total		1,794		100.0	%

Certain of our employees at our headquarters and our Shanghai Wan Su facility are unionized, but we do not have collective bargaining agreements with these employees. We believe that we have good working relationships with our employees and the unions that represent them, and we have operated without a labor work stoppage since we commenced operations.

E. Share Ownership

The following table sets forth information with respect to the beneficial ownership of our ordinary shares, as of March 31, 2011, by each of our directors and executive officers, each of our directors and executive officers as a group, and each person known to us to own beneficially more than 5.0% of our ordinary shares.


	Shares Beneficially Owned(1)(2)
	Number		%
Directors and Executive Officers:
Jianhua Yang(3)		1,206,990,441		55.8
Yunlong Yuan (4)		21,330,000		1.0
Qian Zhao		—		—
Hai Mi		—		—
Kevin Wu		—		—
Zuowei Xie		—		—
Jinhua (Jim) Chen(5)		*		*
Zixin Wang(6)		*		*
Yuelie Lu		—		—
All directors and executive officers as a group		1,228,320,441		56.8

Principal Shareholders:
Wise Lion Limited/Jianhua Yang		1,206,990,441		55.8
David Yunhung Tang(7)		213,300,000		9.9
J.P. Morgan Trust Company of Delaware, as Trustee of the Tang Family 2006 Irrevocable Trust(8)		89,100,000		4.1
Solar Stone Limited(9)		35,550,000		1.6
Prosper Advance Management Limited (10)		21,330,000		1.0
Summer Lake Development Limited(11)		14,220,000		0.7

*	Upon exercise of all options granted, would beneficially own less than 1.0% of our outstanding ordinary shares.

(1)	Beneficial ownership is determined in accordance with Rule 13d-3 of the General Rules and Regulations under the Exchange Act, and includes voting or investment power with respect to the securities and outstanding share options exercisable within 60 days of this annual report.

(2)

The number of ordinary shares outstanding in calculating the percentages for each listed person includes the ordinary shares underlying options held by such person. The percentage of beneficial ownership of each listed person is based on 2,163,190,740 ordinary shares outstanding as of December 31, 2010, and includes the ordinary shares underlying share options exercisable by such person within 60 days of this annual report.

(3)

Includes 1,202,724,441 ordinary shares and 71,100 ADSs representing 7,266,000 ordinary shares held by Wise Lion Limited, a limited liability company organized under the laws of the British Virgin Islands. Dr. Jianhua Yang is the sole director of Wise Lion Limited, which is owned by Sanbrook Holdings Limited, a Bahamian company. Sanbrook Holdings is in turn wholly owned by Credit Suisse Trust Limited as trustee of the JH Yang Family Trust, which is a revocable trust constituted under the laws of Singapore with Dr. Jianhua Yang as settlor and Dr. Jianhua Yang’s family members as beneficiaries. The business address of Dr. Jianhua Yang is c/o Chemspec International Limited, No. 200, Wu Wei Road, Shanghai 200331, People’s Republic of China. Dr. Jianhua Yang is the sole director of Wise Lion Limited, and our founder, chairman and chief executive officer.

(4)

Includes 21,330,000 ordinary shares held by Prosper Advance Management Limited, a limited liability company organized under the laws of the British Virgin Islands, of which Mr. Yunlong Yuan is the sole shareholder and director. Mr. Yunlong Yuan is our vice president responsible for overseeing our technology transfer, quality assurance and purchasing. The business address of Mr. Yunlong Yuan is c/o Chemspec International Limited, No. 200, Wu Wei Road, Shanghai 200331, People’s Republic of China.

(5)	Includes options to purchase our ordinary shares. The business address of Mr. Chen is c/o Chemspec International Limited, No. 200, Wu Wei Road, Shanghai 200331, People’s Republic of China.

(6)	Includes options to purchase our ordinary shares. The business address of Mr. Wang is c/o Chemspec International Limited, No. 200, Wu Wei Road, Shanghai 200331, People’s Republic of China.

(7)

Includes 213,300,000 ordinary shares held by Dr. David Yunhung Tang. Dr. Tang was formerly a director, interim chief financial officer and executive vice president of marketing and sales of the Company. The business address of Dr. Tang is 2386 Black River Falls Drive, Henderson, NV 89044, United States of America.

(8)

J.P. Morgan Trust Company of Delaware holds 89,100,000 shares as trustee of the Tang Family 2006 Irrevocable Trust u/a dated August 23, 2006. Ms. Lan-Fen Hu Tang, the wife of Dr. Tang, controls the voting and investment power over the shares held by J.P. Morgan Trust Company of Delaware. The beneficiaries under the irrevocable trust only include certain members of Dr. Tang’s family and do not include Dr. Tang or his wife. The address of J.P. Morgan Trust Company of Delaware is 500 Stanton Christiana Road, Newark, DE 19713, United States of America.

(9)

Solar Stone Limited, or Solar Stone, is 60% and 40% owned by Wujun Yang and Yueping Zha, respectively. Mr. Yang was our vice president responsible for overseeing the construction of facilities and purchase of raw materials. Mr. Yang retired in December 2010. Ms. Zha is a non-executive employee of the Company. The address of Solar Stone is Sea Meadow House, Blackburne Highway, Road Town, Tortola, British Virgin Islands. Pursuant to Rule 13d-3 promulgated under the Exchange Act, each of Wujun Yang and Yueping Zha may be deemed to beneficially own all of the shares held by Solar Stone. Wujun Yang and Yueping Zha may also be deemed to be a group for the shares as defined in Rule 13d-5(b) under the Exchange Act, and each member of such group may be deemed to beneficially own the shares beneficially owned by other members constituting such group.

(10)

Prosper Advance Management Limited is a British Virgin Islands company that is wholly owned by Mr. Yunlong Yuan. The address of Prosper Advance Management Limited is c/o NovaSage Incorporations (BVI) Limited, Quastisky Building, PO Box 4389, Road Town, Tortola, British Virgin Islands. Mr. Yunlong Yuan is our vice president responsible for overseeing our technology transfer, quality assurance and purchasing.

(11)

Summer Lake Development Limited is a British Virgin Islands company that is wholly owned by Mr. Weinian Qi. The address of Summer Lake Development Limited is c/o NovaSage Incorporations (BVI) Limited, Quastisky Building, PO Box 4389, Road Town, Tortola, British Virgin Islands. Mr. Weinian Qi is a management member of the Company.

None of our shareholders has different voting rights from other shareholders. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our Company other than the going private transaction as disclosed in “Item 4. Information on the Company—A. History and Development of the Company—Going Private Transaction”.

Employee Stock Subscription Program

See “—B. Compensation—2008 Share Incentive Plan.”

ITEM 7.

MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

A. Major Shareholders

See “Item 6. Directors, Senior Management and Employees—Share Ownership.”

B. Related Party Transactions

We adopted an audit committee charter, which requires that the audit committee review all related party transactions on an ongoing basis and all such transactions be approved by the committee. Set forth below is a description of all of our related party transactions for the years ended December 31, 2008, 2009 and 2010.

Transactions with Jiangsu Kangpeng Nong Hua Company Limited

Before a restructuring in September and October 2008, Kangpeng Nong Hua was 44.1% owned directly by Dr. David Yunhung Tang and 23.5% owned indirectly by Dr. Yang. Dr. Tang and Dr. Yang are our executive directors and principal shareholders. Following the restructuring in 2008, Kangpeng Nong Hua was 51.7% owned indirectly by Dr. Yang, 25.0% owned by Dr. Tang, 3.3% owned indirectly by four of our senior managers, with the remaining 20% owned by unrelated third parties. In November 2009, we acquired 100% of the equity interest of Jiangsu Kangpeng Nong Hua for RMB25 million in cash.

In 2008, we purchased goods, consisting of chemicals produced by Kangpeng Nong Hua, from Kangpeng Nong Hua totaling RMB26.2 million, respectively. We then resell these goods to customers in the pharmaceutical and agrochemical industries with a 1% to 7% mark-up. In 2008, we also made sales of goods produced by our newly acquired subsidiary Jiangsu Wei Er to Kangpeng Nong Hua in the amount of RMB32.0 million consisting of raw materials for its manufacturing of goods to be sold in the open market and to us. We believe these transactions were conducted in the ordinary course of business on terms comparable to those with unrelated third parties.

We made non-interest bearing advances to Kangpeng Nong Hua in the amount of RMB28.4 million in 2008. We made these advances to support Kangpeng Nong Hua’s operating activities and repaid these advances in full in 2008.

We made trade advances to Kangpeng Nong Hua in the amount of RMB23.6 million in 2007. These trade advances to Kangpeng Nong Hua were prepayments for the purchase of goods. The full amount of the prepayments has been utilized in the purchase of raw materials in 2008.

We also received a non-interest bearing advance from Kangpeng Nong Hua in the amount of RMB14.4 million in 2008. We repaid this advance in full as of June 30, 2008.

Leasing Transactions with Shanghai Ambiopharm

Shanghai Ambiopharm Inc., or Ambiopharm, engages in the manufacture of advanced pharmaceutical intermediates. Dr. Jianghua Yang indirectly owns 70.5% of Ambiopharm.

We lease plant and equipment to Ambiopharm, which uses these equipment and facilities for production of chemicals. The leases are for terms of two years with total annual rents per year of RMB0.9 million. In 2009 and 2010, we recorded lease income from Ambiopharm in the amount of RMB0.9 million and RMB0.9 million (US$0.1 million), respectively.

We lease certain equipment from Ambiopharm for use in our chemical production operations. The initial lease term was two years, commencing in July 2008, and was renewed for an additional two-year period in June 2010, with total annual rents per year of RMB100,000. In 2008, 2009 and 2010, we incurred lease expenses in the amount of RMB42,000, RMB100,000 and RMB100,000 (US$15,000), respectively.

Transactions with Central Glass Company Limited

Central Glass Chemspec Co., Ltd, or Central Glass Chemspec, is our affiliate. Central Glass Company Limited, or Central Glass, is the controlling shareholder of Central Glass Chemspec. In 2009 and 2010, we made sales of goods to Central Glass in the amount of RMB4.0 million and RMB3.7 million (US$0.6 million), respectively.

Non-Interest Bearing Borrowings from Related Parties

In 2006, we borrowed US$9.7 million from Wise Lion Limited as part of our reorganization to finance our acquisition of the operating subsidiaries. Wise Lion Limited is one of our shareholders, and Wise Lion Limited is beneficially owned by our director, Dr. Jianhua Yang, and his wife Ms. Yuezhen Cha. We repaid US$1.7 million and US$2.5 million to Wise Lion Limited in 2006 and 2007, respectively. The borrowing was repaid in full in September 2009.

We borrowed RMB50,000 in 2007 from Dr. Jianhua Yang, his wife Ms. Yuezhen Cha and his son Mr. Chongbo Yang, or the Yang Family. As of December 31, 2009 and 2010, the balance of our amount due to the Yang Family was RMB59,000 (US$9,000).

In 2008 and 2009, we borrowed RMB6.0 million and RMB6.0 million (US$0.9 million) from Kang Qi which is a subsidiary owned by the Yang Family. The borrowings were repaid in full in February 2008 and in April 2009, respectively.

Non-Interest Advances to Related Parties

In 2008, we advanced RMB2.5 million to the noncontrolling shareholder of Kangpeng Nong Hua, Mr. Zhiyan Shen. This amount was repaid in full in January 2009.

Non-Interest Bearing Borrowings by Jiangsu Wei Er from Related Parties

In February 2008, we paid a cash consideration of RMB4.0 million (US$0.6 million) to acquire an 80% ownership stake in Jiangsu Wei Er, which had been one of our long-term suppliers and produces a number of specialty chemicals used in increasingly popular agrochemical products currently on the market. In November 2009, we acquired the remaining noncontrolling shares of Jiangsu Wei Er for RMB41.0 million (US$6.0 million) in cash. In 2008, Jiangsu Wei Er borrowed RMB49.3 million and RMB5 million from Kangpeng Nong Hua and Kang Qi, respectively. These borrowings were repaid in full as of December 31, 2008.

Non-Interest Bearing Borrowings by Kangpeng Nong Hua from Related Parties

Prior to October 8, 2008, Kangpeng Nong Hua borrowed RMB14.3 million, RMB0.7 million, RMB0.2 million and RMB3,000, which were non-interest bearing, from Kang Qi, the Yang Family, Mr. Zhiyan Shen and Ms. Yunfen Fan, respectively. The advances from the Yang Family, Mr. Zhiyan Shen and Ms. Yunfen Fan were repaid in full as of December 31, 2009. We repaid RMB2,958,000 in 2008 after the acquisition, RMB2,769,000 and RMB4,000,000 in 2009 and 2010, respectively.

C. Interests of Experts and Counsel

Not applicable.

ITEM 8.

FINANCIAL INFORMATION

A. Consolidated Statements and Other Financial Information

We have appended consolidated financial statements filed as part of this annual report.

Legal and Administrative Proceedings

We are currently not a party to any other material legal or administrative proceedings, and we are not aware of threatened material legal or administrative proceedings against us. We may from time to time become a party to various legal or administrative proceedings arising in the ordinary course of our business.

Dividend Policy

Our board of directors has complete discretion on whether to pay dividends on our shares. Even if our board of directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that the board of directors may deem relevant.

We did not declare any dividends in 2008. One of our subsidiaries made a cash distribution of RMB 2.5 million to our noncontrolling shareholders in June 2009. On March 7, 2010, we declared a 2009 dividend of US$0.003 per ordinary share (US$0.18 per ADS) to shareholders of record as of March 31, 2010 with payment date of April 21, 2010. In the future, at the determination of our board of directors, we may from time to time pay a cash dividend to our shareholders equal to an aggregate of no less than 10% of our net income determined in accordance with U.S. GAAP for each such year. The payment of any such dividend will depend upon our profitability and will be subject to the discretion of our management and the approval of our board of directors. Aside from the payment of such dividends, we currently intend to retain the remainder of our available funds and any future earnings to operate and expand our business.

Notwithstanding the above paragraph, we do not expect to declare or pay any further dividends prior to the proposed merger which would result in us becoming a privately-held company, and under the terms of the going private transaction merger agreement, are prohibited from doing so without Halogen Limited’s prior written approval. See “Item 4. Information on the Company—A. History and Development of the Company—Going Private Transaction”.

In addition, our ability to pay dividends depends substantially on the payment of dividends to us by our operating subsidiaries in China. Each of the operating subsidiaries may pay dividends only out of its accumulated distributable profits, if any, determined in accordance with its articles of association, and the accounting standards and regulations in China. Each of our PRC subsidiaries, including wholly foreign-owned enterprises, or WFOEs, and joint venture enterprises is also required to set aside at least 10% of its after-tax profit based on PRC accounting standards each year to its general reserves or statutory capital reserve fund until the aggregate amount of such reserves reaches 50% of its respective registered capital. Our statutory reserves are not distributable as loans, advances or cash dividends. In addition, if any of our PRC subsidiaries incurs debt on its own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us. Any limitation on the payment of dividends by our subsidiaries could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our businesses, pay dividends and otherwise fund and conduct our businesses. See “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—We rely on dividends paid by our subsidiaries for our cash needs, and any limitation on the ability of our subsidiaries to make payments to us could have a material adverse effect on our ability to conduct our business”.

In addition, under a new PRC tax law that became effective in January 2008, dividends paid from our PRC subsidiaries to us through our Hong Kong subsidiary will be subject to a withholding tax at a rate of 5%. The withholding tax on dividends may be exempted or reduced by the State Council of the PRC. Furthermore, the

ultimate tax rate will be determined by treaty between the PRC and the tax residence of the holder of the PRC subsidiary. See “Item 5. Operating and Financial Review and Prospects—Taxation and Incentives—People’s Republic of China,” and “Item 10. Additional Information. E. Taxation—People’s Republic of China Taxation.” We are actively monitoring the withholding tax and are evaluating appropriate organizational changes to minimize the corresponding tax impact.

If we pay any dividends, the depositary will distribute such payments to our ADS holders to the same extent as holders of the corresponding numbers of our ordinary shares, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. Cash dividends on our ordinary shares, if any, will be paid in U.S. dollars.

B. Significant Changes

Except as disclosed elsewhere in this annual report, we have not experienced any significant changes since the date of our audited consolidated financial statements included elsewhere in this annual report.

ITEM 9.

THE OFFER AND LISTING

A. Offer and Listing Details

Our ADSs, each representing 60 of our ordinary shares, have been listed on the New York Stock Exchange since June 24, 2009 under the symbol “CPC.” The table below shows, for the periods indicated, the high and low closing prices on the New York Stock Exchange for our ADSs. The closing price for our ADSs on the New York Stock Exchange on June 17, 2011 was US$7.12 per ADS.


	Closing Price Per ADS (in US$)
	High		Low
Annual:
2009		9.65		5.33
2010		9.04		5.93
2011 (through June 17)		7.68		7.05
Quarterly:
2009
Second quarter		9.07		8.00
Third quarter		9.65		6.74
Fourth quarter		8.13		5.33
2010
First quarter		8.05		6.50
Second quarter		9.04		6.90
Third quarter		8.00		5.93
Fourth quarter		7.91		5.95
2011
First quarter		7.68		7.05
Monthly:
2010
December		7.70		7.08
2011
January		7.68		7.30
February		7.55		7.29
March		7.53		7.05
April		7.50		7.24
May		7.50		7.22
June (through June 17)		7.43		7.06

As of March 31, 2011, a total of 2,163,190,740 common shares were outstanding. As of March 31, 2011, a total of 545,746, 140 common shares, representing 9,095,769 ADSs were registered in the name of a nominee of Citibank, N.A., the depositary for the ADSs. In addition, as of March 31, 2011, approximately 27.5% of our total outstanding shares are held by 23 record shareholders in the United States. We have no further information as to common shares or ADSs held, or beneficially owned, by U.S. persons.

B. Plan of Distribution

Not applicable.

C. Markets

Our ADSs, each representing 60 of our ordinary shares, have been listed on the New York Stock Exchange since June 24, 2009 under the symbol “CPC.”

D. Selling Stockholders

Not applicable.

E. Dilution

Not applicable.

F. Expenses of the Issue

Not applicable.

ITEM 10.

ADDITIONAL INFORMATION

A. Share Capital

Not applicable.

B. Memorandum and Articles of Incorporation

We incorporate by reference into this annual report the description of our amended and restated memorandum of association contained in our registration statement on Form F-1 (File No. 333-159471), as amended, initially filed with the SEC on May 26, 2009.

C. Material Contracts

We have not entered into any material contracts other than in the ordinary course of business and other than those described elsewhere in this annual report.

D. Exchange Controls

Pursuant to the Foreign Exchange Administration Rules promulgated on January 29, 1996 and amended on January 14, 1997 and August 5, 2008, and various regulations issued by the SAFE and other relevant PRC government authorities, RMB is freely convertible only with respect to current account items, such as trade- related receipts and payments, interest and dividends. Capital account items, such as direct equity investments, loans and repatriations of investments, require the prior approval of the SAFE or its local branches for conversion of RMB into foreign currency, such as U.S. dollars, and remittance of the foreign currency outside the PRC.

Payments for transactions that take place within the PRC must be made in RMB. Unless otherwise approved, PRC companies must repatriate foreign exchange payments received from abroad. Foreign-invested enterprises may retain foreign exchange in accounts with designated foreign exchange banks subject to a cap set by the SAFE or its local counterpart. Unless otherwise approved, domestic enterprises must convert all of their foreign exchange receipts into RMB.

Pursuant to the SAFE’s Notice on Relevant Issues Concerning Foreign Exchange Administration for PRC Residents to Engage in Financing and Inbound Investment via Overseas Special Purpose Vehicles, or the SAFE Circular No. 75, issued on October 21, 2005, (i) a PRC resident must register with the local SAFE branch before establishing or controlling an overseas special purpose vehicle, or SPV, for the purpose of obtaining overseas equity financing using the assets of or equity interests in a domestic enterprise; (ii) when a PRC resident contributes the assets of or its equity interests in a domestic enterprise into an SPV, or engages in overseas financing after contributing assets or equity interests into an SPV, such PRC resident must register his or her interest in the SPV and any subsequent change thereto with the local SAFE branch; and (iii) when the SPV undergoes a material event, such as a change in share capital, merger and acquisition, share transfer or exchange, spin-off or long-term equity and debt investment, the PRC resident must, within 30 days from the occurrence of such event, register such change with the local SAFE branch. On May 29, 2007, the SAFE issued relevant guidance to its local branches for the implementation of the SAFE Circular No. 75. This guidance standardizes more specific and stringent supervision on the registration requirement relating to the SAFE Circular No. 75 and further requests PRC residents holding any equity interests or options in SPVs, directly or indirectly, controlling or nominal, to register with the SAFE.

Our beneficial owners who are or may be considered PRC residents have registered with the local SAFE branch as required under the SAFE Circular No. 75, and the required amendment to such registrations have been completed. See “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—Recent PRC regulations relating to the establishment of offshore special purpose companies by PRC residents may subject our PRC resident shareholders to personal liability, limit our ability to inject capital into our PRC subsidiaries, limit our PRC subsidiaries’ ability to distribute profits to us, or otherwise adversely affect us.”

E. Taxation

Cayman Islands Taxation

The Cayman Islands currently levy no taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature of inheritance tax or estate duty. No Cayman Islands stamp duty will be payable unless an instrument is executed in, brought to, or produced before a court of the Cayman Islands. The Cayman Islands are not parties to any double-tax treaties which are applicable to payments made to or by our Company. There are no exchange control regulations or currency restrictions in the Cayman Islands.

People’s Republic of China Taxation

The newly enacted PRC Enterprise Income Tax Law, or the EIT Law, and the implementation regulations for the EIT Law issued by the PRC State Council, became effective as of January 1, 2008. The EIT Law provides that enterprises established outside of China whose “de facto management bodies” are located in China are considered “resident enterprises” and are generally subject to the uniform 25% enterprise income tax rate as to their worldwide income. On December 6, 2007, the State Council adopted the Regulation on the Implementation of PRC Enterprise Income Tax Law, effective as of January 1, 2008, which defines the “de facto management body” as an establishment that has substantial management and control over the business, personnel, accounts and properties of an enterprise. Currently no interpretation or application of the new EIT Law and its implementing rules is available for non-Chinese enterprise or group enterprise controlled entity. Therefore, although substantially all of our operational management is currently based in the PRC, it is unclear whether PRC tax authorities would require (or permit) us to be treated as a PRC resident enterprise.

Under the EIT Law and implementation regulations issued by the State Council, PRC income tax at the rate of 10% is applicable to dividends payable to investors that are “non-resident enterprises” (and that do not have an establishment or place of business in the PRC, or that have such establishment or place of business but the relevant income is not effectively connected with the establishment or place of business) to the extent such dividends have their sources within the PRC. Similarly, any gain realized on the transfer of ADSs or shares by such investors is also subject to 10% PRC income tax if such gain is regarded as income derived from sources within the PRC. However, under a new PRC tax law that became effective in January 2008 and the Arrangement between the PRC and the Hong Kong Special Administrative Region on the Avoidance of Double Taxation and Prevention of Fiscal Evasion , or the China-Hong Kong tax arrangement, which became effective on January 1, 2007, dividends from our PRC subsidiaries paid to us through our Hong Kong subsidiary are subject to a withholding tax at a rate of 5%. If we are considered a PRC “resident enterprise,” it is unclear whether dividends we pay with respect to our ordinary shares or ADSs, or the gain you may realize from the transfer of our ordinary shares or ADSs, would be treated as income derived from sources within the PRC and would be subject to PRC tax. It is also unclear whether, if we are considered a PRC “resident enterprise,” holders of our ordinary shares or ADSs might be able to claim the benefit of income tax treaties entered into between China and other countries.

United States Federal Income Taxation

The following summary describes the material United States federal income tax consequences of the ownership of our ordinary shares or ADSs as of the date hereof. The discussion is applicable to United States Holders (as defined below) who hold our ordinary shares or ADSs as capital assets. As used herein, the term “United States Holder” means a holder of an ordinary share or ADS that is for United States federal income tax purposes:

•

an individual citizen or resident of the United States;

•

a corporation (or other entity treated as a corporation for United States federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia;

•

an estate the income of which is subject to United States federal income taxation regardless of its source; or

•

a trust if it (1) is subject to the primary supervision of a court within the United States and one or more United States persons have the authority to control all substantial decisions of the trust or (2) has a valid election in effect under applicable United States Treasury regulations to be treated as a United States person.

This summary does not represent a detailed description of the United States federal income tax consequences applicable to you if you are subject to special treatment under the United States federal income tax laws, including if you are:

•

a dealer in securities or currencies;

•

a financial institution;

•

a regulated investment company;

•

a real estate investment trust;

•

an insurance company;

•

a tax-exempt organization;

•

a person holding our ordinary shares or ADSs as part of a hedging, integrated or conversion transaction, a constructive sale or a straddle;

•

a trader in securities that has elected the mark-to-market method of accounting for your securities;

•

a person liable for alternative minimum tax;

•

a person who owns or is deemed to own 10% or more of our voting stock;

•

a partnership or other pass-through entity for United States federal income tax purposes (or hold your ordinary shares or ADSs through a partnership or other pass-through entity); or

•

a person whose “functional currency” is not the United States dollar.

The discussion below is based upon the provisions of the Internal Revenue Code of 1986, as amended, or the Code, and regulations, rulings and judicial decisions thereunder as of the date hereof, and such authorities may be replaced, revoked or modified so as to result in United States federal income tax consequences different from those discussed below. In addition, this summary is based, in part, upon representations made to us by the depositary and assumes that the deposit agreement, and all other related agreements, will be performed in accordance with their terms.

If a partnership holds ordinary shares or ADSs, the tax treatment of a partner will generally depend upon the status of the partner and the activities of the partnership. If you are a partner of a partnership holding our ordinary shares or ADSs, you should consult your tax advisors.

This summary does not contain a detailed description of all the United States federal income tax consequences to you in light of your particular circumstances nor does it address any United States federal tax laws other than United States federal income tax laws. If you are considering the purchase, ownership or disposition of our ordinary shares or ADSs, you should consult your own tax advisors concerning the United States federal tax consequences to you in light of your particular situation as well as any consequences arising under the laws of any other taxing jurisdiction .

The U.S. Treasury has expressed concerns that intermediaries in the chain of ownership between the holder of an ADS and the issuer of the security underlying the ADS may be taking actions that are inconsistent with the claiming of foreign tax credits for United States Holders of ADSs. Such actions would also be inconsistent with the claiming of the reduced rate of tax, described below, applicable to dividends received by certain non-corporate holders. Accordingly, the analysis of the creditability of PRC taxes, if any, and the availability of the reduced tax rate for dividends received by certain non-corporate holders, each described below, could be affected by actions taken by intermediaries in the chain of ownership between the holder of an ADS and our company.

ADSs

If you hold ADSs, for United States federal income tax purposes, you generally will be treated as the owner of the underlying ordinary shares that are represented by such ADSs. Accordingly, deposits or withdrawals of ordinary shares for ADSs will not be subject to United States federal income tax.

Taxation of Dividends

Subject to the discussion under “—Passive Foreign Investment Company” below, the gross amount of distributions on the ordinary shares or ADSs (including amounts withheld to reflect PRC withholding taxes) will be taxable as dividends, to the extent paid out of our current or accumulated earnings and profits, as determined under United States federal income tax principles. Such income will be includable in your gross income as ordinary income on the day actually or constructively received by you, in the case of ordinary shares, or by the depositary, in the case of ADSs. Such dividends will not be eligible for the dividends-received deduction allowed to corporations under the Code.

The amount of any dividend paid in Renminbi will equal the United States dollar value of the Renminbi received calculated by reference to the exchange rate in effect on the date the dividend is received by you,

regardless of whether the Renminbi are converted into United States dollars. If the Renminbi received as a dividend are converted into United States dollars on the date they are received, you generally will not be required to recognize foreign currency gain or loss in respect of the dividend income. If the Renminbi received as a dividend are not converted into United States dollars on the date of receipt, you will have a basis in the Renminbi equal to their United States dollar value on the date of receipt. Any gain or loss realized on a subsequent conversion or other disposition of the Renminbi will be treated as United States source ordinary income or loss.

With respect to non-corporate United States Holders, certain dividends received in taxable years beginning before January 1, 2013 from a qualified foreign corporation may be subject to reduced rates of taxation. A foreign corporation is treated as a qualified foreign corporation with respect to dividends received from that corporation on shares (or ADSs backed by such shares) that are readily tradable on an established securities market in the United States. United States Treasury Department guidance indicates that our ADSs, which are listed on the NYSE, but not our ordinary shares, will be readily tradable on an established securities market in the United States. There can be no assurance that our ADSs will be considered readily tradable on an established securities market in later years. A qualified foreign corporation also includes a foreign corporation that is eligible for the benefits of certain income tax treaties with the United States. In the event that we are deemed to be a PRC “resident enterprise” under PRC tax law (see discussion under “Taxation—People’s Republic of China Taxation”), we may be eligible for the benefits of the income tax treaty between the United States and the PRC and, if we are eligible for such benefits, dividends we pay on our ordinary shares, regardless of whether such ordinary shares are represented by ADSs, would be subject to the reduced rates of taxation.

Non-corporate holders that do not meet a minimum holding period requirement during which they are not protected from the risk of loss or that elect to treat the dividend income as “investment income” pursuant to Section 163(d)(4) of the Code will not be eligible for the reduced rates of taxation regardless of our status as a qualified foreign corporation. In addition, the rate reduction will not apply to dividends if the recipient of a dividend is obligated to make related payments with respect to positions in substantially similar or related property. This disallowance applies even if the minimum holding period has been met. You should consult your own tax advisors regarding the application of these rules given your particular circumstances.

In the event that we are deemed to be a PRC “resident enterprise” under PRC tax law, you may be subject to PRC withholding taxes on dividends paid to you with respect to the ordinary shares or ADSs (see discussion under “Taxation—People’s Republic of China Taxation”). In that case, however, you may be able to obtain a reduced rate of PRC withholding taxes under the treaty between the United States and the PRC if certain requirements are met. In addition, subject to certain conditions and limitations, PRC withholding taxes on dividends may be treated as foreign taxes eligible for credit against your United States federal income tax liability. For purposes of calculating the foreign tax credit, dividends paid on the ordinary shares or ADSs will be treated as foreign-source income and will generally constitute passive category income. Furthermore, in certain circumstances, if you have held the ordinary shares or ADSs for less than a specified minimum period during which you are not protected from risk of loss, or are obligated to make payments related to the dividends, you will not be allowed a foreign tax credit for any PRC withholding taxes imposed on dividends paid on the ordinary shares or ADSs. The rules governing the foreign tax credit are complex. You are urged to consult your tax advisors regarding the availability of the foreign tax credit under your particular circumstances.

Subject to the discussion under “—Passive Foreign Investment Company” below, to the extent that the amount of any distribution exceeds our current and accumulated earnings and profits for a taxable year, as determined under United States federal income tax principles, the distribution will first be treated as a tax-free return of capital to the extent of your adjusted basis in the ordinary shares or ADSs, as applicable, and the balance in excess of adjusted basis will be taxed as capital gain recognized on a sale or exchange. However, we do not expect to keep earnings and profits in accordance with United States federal income tax principles. Therefore, you should expect that a distribution will generally be treated as a dividend (as discussed above).

Passive Foreign Investment Company

Based on the past composition of our income and valuation of our assets, including goodwill, we believe that we were not a PFIC for United States federal income tax purposes for our taxable year ending December 31, 2010, and we do not expect to become one in the future, although there can be no assurance in this regard.

In general, we will be a PFIC for any taxable year in which:

•

at least 75% of our gross income is passive income; or

•

at least 50% of the value of our assets (based on an average of the quarterly values) is attributable to assets that produce or are held for the production of passive income.

For this purpose, passive income generally includes dividends, interest, royalties and rents (other than royalties and rents derived in the active conduct of a trade or business and not derived from a related person). If we own at least 25% (by value) of the stock of another corporation, we will be treated, for purposes of the PFIC tests, as owning our proportionate share of the other corporation’s assets and receiving our proportionate share of the other corporation’s income.

The determination of whether we are a PFIC is made annually. Accordingly, it is possible that we may become a PFIC in the current or any future taxable year due to changes in our income or asset composition. Because we have valued our goodwill based on the market value of our ordinary shares and ADSs, a decrease in the price of our ordinary shares or ADSs may result in our becoming a PFIC. If we are a PFIC for any taxable year during which you hold our ordinary shares or ADSs, you will be subject to special tax rules discussed below.

If we are a PFIC for any taxable year during which you hold our ordinary shares or ADSs, you will be subject to special tax rules with respect to any “excess distribution” received and any gain realized from a sale or other disposition, including a pledge, of ordinary shares or ADSs. Distributions received in a taxable year that are greater than 125% of the average annual distributions received during the shorter of the three preceding taxable years or your holding period for the ordinary shares or ADSs will be treated as excess distributions. Under these special tax rules:

•

the excess distribution or gain will be allocated ratably over your holding period for the ordinary shares or ADSs;

•

the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which we were a PFIC, will be treated as ordinary income; and

•

the amount allocated to each other year will be subject to tax at the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.

In addition, non-corporate United States Holders will not be eligible for reduced rates of taxation on any dividends received from us in taxable years beginning prior to January 1, 2013, if we are a PFIC in the taxable year in which such dividends are paid or in the preceding taxable year. You will be required to file Internal Revenue Service Form 8621 if you hold our ordinary shares or ADSs in any year in which we are classified as a PFIC.

If we are a PFIC for any taxable year during which you hold our ordinary shares or ADSs and any of our non-United States subsidiaries is also a PFIC, a United States Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC for purposes of the application of these rules. You are urged to consult your tax advisors about the application of the PFIC rules to any of our subsidiaries.

In certain circumstances, in lieu of being subject to the excess distribution rules discussed above, you may make an election to include gain on the stock of a PFIC as ordinary income under a mark-to-market method, provided that such stock is regularly traded on a qualified exchange. Under current law, the mark-to-market election may be available to holders of ADSs because the ADSs are listed on the NYSE, which constitutes a qualified exchange, although there can be no assurance that the ADSs will be “regularly traded” for purposes of the mark-to-market election. It should be noted that only the ADSs, and not the ordinary shares, are listed on the NYSE. Consequently, if you are a holder of ordinary shares that are not represented by ADSs, you generally will not be eligible to make a mark-to-market election if we are or were to become a PFIC.

If you make an effective mark-to-market election, instead of applying the PFIC rules above you would include in each year as ordinary income the excess of the fair market value of your ADSs at the end of the year over your adjusted tax basis in the ADSs. You would be entitled to deduct as an ordinary loss each year the excess of your adjusted tax basis in the ADSs over their fair market value at the end of the year, but only to the extent of the net amount previously included in income as a result of the mark-to-market election. If you make an effective mark-to-market election, any gain you recognize upon the sale or other disposition of ADSs would be treated as ordinary income and any loss would be treated as ordinary loss, but only to the extent of the net amount previously included in income as a result of the mark-to-market election. Your adjusted tax basis in the ADSs would be increased by the amount of any income inclusion and decreased by the amount of any deductions under the mark-to-market rules. If you make a mark-to-market election it will be effective for the taxable year for which the election is made and all subsequent taxable years unless the ADSs are no longer regularly traded on a qualified exchange or the Internal Revenue Service consents to the revocation of the election. You are urged to consult your tax advisors about the availability of the mark-to-market election, and whether making the election would be advisable in your particular circumstances.

If we are or were to become a PFIC, the rules described above could be avoided if you elected to treat us as a “qualified electing fund” under Section 1295 of the Code. However, this option would not be available to you because we do not intend to comply with the requirements necessary to permit you to make this election.

You are urged to consult your tax advisors concerning the United States federal income tax consequences of holding ordinary shares or ADSs if we are considered a PFIC in any taxable year.

Taxation of Capital Gains

For United States federal income tax purposes and subject to the discussion under “—Passive Foreign Investment Company” above, you will recognize taxable gain or loss on any sale, exchange or other taxable disposition of ordinary shares or ADSs in an amount equal to the difference between the amount realized for the ordinary shares or ADSs and your tax basis in the ordinary shares or ADSs. Such gain or loss will generally be capital gain or loss. Capital gains of non-corporate United States Holders derived with respect to capital assets held for more than one year are eligible for reduced rates of taxation. The deductibility of capital losses is subject to limitations. Any gain or loss recognized by you will generally be treated as United States-source gain or loss. However, in the event that we are deemed to be a PRC “resident enterprise” under PRC tax law, we may be eligible for the benefits of the income tax treaty between the United States and the PRC. Under that treaty, if any PRC tax was to be imposed on any gain from the disposition of the ordinary shares or ADSs, a United States Holder that is eligible for treaty benefits may elect to treat the gain as PRC-source income. You are urged to consult your tax advisors regarding the tax consequences if a foreign tax is imposed on gain on a disposition of our ordinary shares or ADSs, including the availability of the foreign tax credit under your particular circumstances.

Information Reporting and Backup Withholding

In general, information reporting will apply to dividends in respect of our ordinary shares or ADSs and to the proceeds from the sale, exchange or redemption of our ordinary shares or ADSs that are paid to you within

the United States (and in certain cases, outside the United States), unless you are an exempt recipient such as a corporation. A backup withholding tax may apply to such payments if you fail to provide a correct taxpayer identification number or certification of other exempt status or fail to report in full dividend and interest income or otherwise fail to comply with the backup withholding rules. Backup withholding is not an additional tax. Rather, any amounts withheld as backup withholding may be credited against your United States federal income tax liability, if any, and you may obtain a refund of any excess withheld under the backup withholding rules by filing the appropriate claim for refund with, and provided the required information is properly furnished to, the Internal Revenue Service.

PROSPECTIVE PURCHASERS OF OUR ADSS OR ORDINARY SHARES SHOULD CONSULT WITH THEIR OWN TAX ADVISORS REGARDING THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY ADDITIONAL TAX CONSEQUENCES RESULTING FROM PURCHASING, HOLDING OR DISPOSING OF OUR ADSS OR ORDINARY SHARES, INCLUDING THE APPLICABILITY AND EFFECT OF THE TAX LAWS OF ANY STATE, LOCAL OR NON-U.S. JURISDICTION, INCLUDING ESTATE, GIFT, AND INHERITANCE LAWS.

F. Dividends and Paying Agents

Not applicable.

G. Statement by Experts

Not applicable.

H. Documents on Display

We have filed this annual report on Form 20-F, including exhibits, with the SEC. As allowed by the SEC, in Item 19 of this annual report, we incorporate by reference certain information we filed with the SEC. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this annual report.

You may read and copy this annual report, including the exhibits incorporated by reference in this annual report, at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 and at the SEC’s regional offices in New York, New York and Chicago, Illinois. You can also request copies of this annual report, including the exhibits incorporated by reference in this annual report, upon payment of a duplicating fee, by writing information on the operation of the SEC’s Public Reference Room.

The SEC also maintains a website at www.sec.gov that contains reports, proxy statements and other information regarding registrants that file electronically with the SEC. Our annual report and some of the other information submitted by us to the SEC may be accessed through this web site.

I. Subsidiary Information

Not applicable.

ITEM 11.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market risk is the risk of loss related to adverse changes in market prices, including interest rates and foreign exchange rates, of financial instruments. In the normal course of business, we are routinely subject to a variety of risks, including changes in foreign currency exchange rates and interest rates and inflation.

Foreign Exchange Risk

A majority of our sales are denominated in U.S. dollars, with the remainder denominated in Renminbi, Euro and Japanese Yen. Our costs and capital expenditures are largely denominated in Renminbi. The value of the Renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in the PRC’s political and economic conditions. The conversion of Renminbi into foreign currencies, including the U.S. dollar, is based on rates set by the People’s Bank of China. The conversion of Renminbi into foreign currencies, including U.S. dollars, is based on rates set by the People’s Bank of China. The PRC government allowed the Renminbi to appreciate by more than 20% against the U.S. dollar between July 2005 and July 2008. Between July 2008 and June 2010, this appreciation halted and the exchange rate between the Renminbi and the U.S. dollar remained within a narrow band. Since June 2010, the PRC government has allowed the Renminbi to appreciate slowly against the U.S. dollar again. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the Renminbi and the U.S. dollar in the future. Fluctuations in currency exchange rates could have a significant effect on our financial condition and results of operations due to the extent of our transactions denominated in foreign currencies as well as any mismatch among various foreign currency-denominated assets and liabilities. Fluctuations in exchange rates pertaining to our foreign currency transactions, particularly between the U.S. dollar and Renminbi, affect our gross and net profit margins.

The functional currency of our PRC subsidiaries is the Renminbi. Transactions denominated in other currencies are re-measured into Renminbi and any resulting foreign currency exchange gains and losses are recognized in our consolidated statements of income. Our exposure to foreign currency exchange risk primarily relates to our accounts receivable and cash that are denominated in currencies other than the Renminbi. As of December 31, 2010, we held an equivalent of RMB137.9 million (US$20.9 million) in accounts receivable, of which RMB68.2 million (US$10.3 million) was denominated in U.S. dollars. As of December 31, 2008, December 31, 2009 and December 31, 2010, we also held an equivalent of RMB180.6 million, RMB351.1 million and RMB98.7 million (US$15.0 million), respectively, in cash, of which RMB19.3 million, RMB223.4 million and RMB38.5 million (US$5.8 million), respectively, was denominated in U.S. dollars. Generally, the appreciation of the Renminbi against the U.S. dollar will result in foreign exchange losses for monetary assets denominated in U.S. dollars and foreign currency exchange gains for monetary liabilities denominated in U.S. dollars, and vice versa. We incurred net foreign currency exchange losses of approximately RMB9.5 million, RMB2.0 million and RMB 3.2 million (US$0.5 million) during 2008, 2009 and 2010, respectively, which are reported in our consolidated statements of income. These net foreign currency exchange losses recognized under our statement of income were partially offset by net foreign currency translation adjustments of RMB2.4 million, RMB54,000 and RMB1.6 million (US$0.2 million) in 2008, 2009 and 2010, respectively.

We and our subsidiaries located outside the PRC use the U.S. dollar as our functional currency. Our assets and liabilities and those of our subsidiaries located outside the PRC are translated into our reporting currency, the Renminbi, using the exchange rate on the balance sheet date. Our revenues and expenses and those of our subsidiaries located outside the PRC are translated into our reporting currency at average rates prevailing during the year. Our gains and losses resulting from the translation of the financial statements and those of our subsidiaries located outside the PRC are reported as a separate component of accumulated other comprehensive income within equity in our consolidated financial statements. As of December 31, 2008, our net liabilities denominated in currencies other than RMB of our subsidiaries located outside of the PRC was RMB23.3 million. As of December 31, 2009 and December 31, 2010, our net assets denominated in currencies other than RMB of our subsidiaries located outside of the PRC was RMB109.0 million and RMB25.3 million (US$3.8 million). We

recognized foreign currency translation gains of approximately RMB2.4 million, RMB54,000 and RMB1.6 million (US$0.2 million) in 2008, 2009 and 2010, respectively. We have reported a net foreign currency translation gain despite the Renminbi appreciation against the U.S. dollar because the majority of our total assets and those of our subsidiaries located outside of the PRC comprise of investments in the PRC subsidiaries, which is eliminated on consolidation. The remaining assets and liabilities are mostly denominated in Renminbi, except for amounts due to a related party transaction totaling RMB38 million as of December 31, 2008 and nil as of December 31, 2009, which are denominated in U.S. dollars.

We are exposed to the exchange risk of the Renminbi against the U.S. dollar as majority of our sales are denominated in the U.S. dollar while majority of our purchases are denominated in the Renminbi. We currently do not plan to enter into any hedging arrangements to reduce the effect of our foreign currency exchange risk exposure. Even if we decide to enter into any such hedging activities in the future, we cannot assure you that we would be able to effectively manage our foreign currency exchange risk exposure.

Interest Rate Risk

Our exposure to interest rate risk relates to interest expense incurred by our borrowings and interest income on our interest-bearing cash and pledged deposit balances. As of December 31, 2010, we had RMB 25 million (US$3.8 million) of short-term bank borrowings and long-term bank borrowings, current portion, and RMB155.5 million (US$23.6 million) of interest-bearing cash and pledged deposit balances, respectively.

We have not used any derivative financial instruments or engaged in any interest rate hedging activities to manage our interest rate risk exposure. Our future interest expense on our long-term borrowings may increase or decrease due to changes in market interest rates. Our bank borrowings had a weighted average interest rate of 5.27% per annum during 2010 and mature in 2011. Our future interest income on our interest-bearing cash balances may increase or decrease due to changes in market interest conditions.

Our interest expense and interest income has historically been immaterial to our consolidated financial statements. Consequently, we believe we currently do not have any significant interest rate risk exposure.

Inflation

Inflation in China has not materially impacted our results of operations in recent years. According to the National Bureau of Statistics in China, consumer price inflation in China was 5.9%, -0.7% and 3.3% in 2008, 2009 and 2010, respectively. Although we have not been materially affected by inflation in the past, we cannot assure you that we will not be affected by higher rates of inflation in China in the future which could affect our costs and our advantages as a China-based manufacturer.

ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

A. Debt Securities

Not applicable

B. Warrants and Rights

Not applicable

C. Other Securities

Not applicable

D. American Depositary Shares

Depositary Fees

Under the terms of the deposit agreement for our ADSs, an ADS holder may have to pay the following service fees to the depositary:


Service		Fees

Issuance of ADSs		Up to US$0.05 per ADS issued
Cancellation of ADSs		Up to US$0.05 per ADS cancelled
Distribution of cash dividends or other cash distributions		Up to US$0.02 per ADS held
Distribution of ADSs pursuant to stock dividends, free stock distributions or exercises of rights.		Up to US$0.05 per ADS held
Distribution of securities other than ADSs or rights to purchase additional ADSs		Up to US$0.05 per ADS held

Depositary Charges

In addition, an ADS holder shall be responsible for the following charges:

•

taxes (including applicable interest and penalties) and other governmental charges;

•

such registration fees as may from time to time be in effect for the registration of common shares or other deposited securities on the share register and applicable to transfers of common shares or other deposited securities to or from the name of the custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively;

•

such cable, telex and facsimile transmission and delivery expenses as are expressly provided in the deposit agreement to be at the expense of ADS holders and beneficial owners of ADSs;

•

the expenses and charges incurred by the depositary in the conversion of foreign currency; and

•

the fees and expenses incurred by the depositary, the custodian or any nominee in connection with the servicing or delivery of deposited securities.

Depositary fees payable upon the issuance and cancellation of ADSs are typically paid to the depositary by the brokers (on behalf of their clients) receiving the newly-issued ADSs from the depositary and by the brokers (on behalf of their clients) delivering the ADSs to the depositary for cancellation. The brokers in turn charge these transaction fees to their clients.

Depositary fees payable in connection with distributions of cash or securities to ADS holders and the depositary services fee are charged by the depositary to the holders of record of ADSs as of the applicable ADS record date. The depositary fees payable for cash distributions are generally deducted from the cash being distributed. In the case of distributions other than cash (i.e., stock dividends, rights offerings), the depositary charges the applicable fee to the ADS record date holders concurrent with the distribution. In the case of ADSs registered in the name of the investor (whether certificated or un-certificated in direct registration), the depositary sends invoices to the applicable record date ADS holders. In the case of ADSs held in brokerage and custodian accounts via the central clearing and settlement system, The Depository Trust Company, or DTC, the depositary generally collects its fees through the systems provided by DTC (whose nominee is the registered holder of the ADSs held in DTC) from the brokers and custodians holding ADSs in their DTC accounts. The brokers and custodians who hold their clients’ ADSs in DTC accounts in turn charge their clients’ accounts the amount of the fees paid to the depositary.

In the event of refusal to pay the depositary fees, the depositary may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder.

The fees and charges ADS holders may be required to pay may vary over time and may be changed by us and by the depositary. ADS holders will receive prior notice of such changes.

Payments by Depositary

In 2010, we received reimbursement funds of US$148,000 from Citibank, N.A., the Depositary Bank, for our ADR program.

PART II

ITEM 13.

DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

None.

ITEM 14.

MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

See “Item 10. Additional Information” for a description of the rights of securities holders, which remain unchanged.

ITEM 15.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

As of the end of the period covered by this annual report, an evaluation has been carried out under the supervision and with the participation of our management, including our chief executive officer and our principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on that evaluation, our chief executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended. Our management evaluated the effectiveness of our internal control over financial reporting based on criteria established in the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management has concluded that our internal control over financial reporting was effective as of December 31, 2010.

Internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and/or Board; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Our internal control over financial reporting is designed to provide reasonable, but not absolute, assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness of our internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

Our independent registered public accounting firm, KPMG, has audited the effectiveness of our internal control over financial reporting as of December 31, 2010, as stated in its report dated June 20, 2011 filed herewith.

Attestation Report of the Registered Public Accounting Firm

Report of Independent Registered Public Accounting Firm

The Board of Directors and Shareholders of

Chemspec International Limited:

We have audited Chemspec International Limited’s internal control over financial reporting as of December 31, 2010, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Chemspec International Limited’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, Chemspec International Limited maintained, in all material respects, effective internal control over financial reporting as of December 31, 2010, based on criteria established in Internal Control—Integrated Framework issued by COSO.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Chemspec International Limited and subsidiaries as of December 31, 2009 and 2010, and the related consolidated statements of income, equity and comprehensive income , and cash flows for each of the years in the three-year period ended December 31, 2010, and our report dated June 20, 2011 expressed an unqualified opinion on those consolidated financial statements.

/s/ KPMG

Hong Kong, China

June 20, 2011

Changes in Internal Controls

Except as discussed below, there were no changes in internal control for the year ended December 31, 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

In connection with the audit of our consolidated financial statements as of and for the year ended December 31, 2009, our independent registered public accounting firm identified and communicated to us a significant deficiency in our internal control over financial reporting, as defined by Auditing Standard No. 5 of the Public Company Accounting Oversight Board. For details of such a significant deficiency, see Item 5 of our annual report on Form 20-F for 2009 filed with the Securities and Exchange Commission on June 17, 2010. To address this significant deficiency, as well as certain other control deficiencies, we took the following measures to rectify the deficiency in 2010:

•

implemented strict accounting and closing procedures during the process of working with the hired SOX compliance consulting firm, and

•

hired an external inspection firm to ensure that construction progress milestones are properly and timely reported then recorded in our accounting books, and properly and timely transferred to fixed assets once projects are completed.

ITEM 16A.

AUDIT COMMITTEE FINANCIAL EXPERT

Hai Mi is our audit committee financial expert and independent director. See “Item 6. Directors, Senior Management and Employees—C. Board Practices.”

ITEM 16B.

CODE OF ETHICS

We have adopted a code of ethics that applies to our directors, officers and employees, including our Chief Executive Officer and Principal Financial Officer. We have filed this code of business conduct and ethics as an exhibit to our registration statement on Form F-1. No changes have been made to the code of business conduct and ethics since its adoption. A copy of our code of business conduct and ethics is available to any shareholder upon request.

100

ITEM 16C.

PRINCIPAL ACCOUNTANT FEES AND SERVICES

The following table sets forth the aggregate fees by categories specified below in connection with certain professional services rendered by KPMG, our principal accountant for the years indicated. We did not pay any other fees to KPMG during the periods indicated below.


	For the year ended December 31,
	2008		2009		2010
	RMB		RMB		RMB		US$
	(in thousands)
Audit fees(1)		1,000		2,800		5,560		842
Audit-related fees(2)		4,094		2,055		—		—
Tax fees(3)		—		—		193		29

(1)	“Audit fees” means the aggregate fees billed for professional services rendered by our independent auditors for the audit of our annual financial statements and the review of our comparative interim financial statements.

(2)	“Audit related fees” represents aggregate fees billed for professional services rendered by our independent auditors for the assurance and related services, which mainly included the review of registration documents in connection with our initial public offering.

(3)	“Tax fees” include fees billed for tax compliance services

The policy of our audit committee is to pre-approve all audit and non-audit services provided by our independent registered public accounting firm, including audit services, audit-related services, tax services and all other services as described above. All services rendered by KPMG were pre-approved by our audit committee.

ITEM 16D.

EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

Not applicable.

ITEM 16E.

PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

On September 29, 2009, our board of directors authorized a share repurchase program, under which we may repurchase up to US$15 million worth of our issued and outstanding ADSs from the open market from time to time and before December 31, 2009. As of December 31, 2009, we have repurchased 12,060,000 our ordinary shares for a total purchase price of approximately US$1.2 million pursuant to this program. Set for below contains certain information regarding our share repurchase program.


Period	Total Number of ADSs Purchased		Average Price Paid per ADS (US$)		Total Number of ADSs Purchased Under the Program		Maximum Number of ADSs that May Yet be Purchased Under the Program
2009
November		117,000		5.94		117,000		(1)
December		84,000		5.79		201,000		(1)

(1)	The share repurchase program ended in March 2010 based on a resolution adopted at our board of directors’ meeting on March 7, 2010.

In September 2010, our board of directors authorized the repurchase of up to US$10 million worth of the Company’s issued and outstanding ADSs from the open market from time to time over a twelve-month period.

101

This repurchase program was implemented through a Rule 10b5-1 plan and the first purchases thereunder were made on September 22, 2010. This program was terminated on October 12, 2010. We have repurchased 16,579,500 of our ordinary shares for a total purchase price of approximately US$ 1.6 million (RMB11.0 million) in September and October 2010 pursuant to this program. Set for below contains certain information regarding our share repurchase program.


	Total Number of ADSs Repurchased		Average Price Paid per ADS
2010
September (from September 22, 2010)		141,600	$	6.0750
October (through October 11, 2010)		126,725	$	6.0243
Total		268,325	$	6.0511

ITEM 16F.

CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT

Not applicable.

ITEM 16G.

CORPORATE GOVERNANCE

We are a “foreign private issuer” (as such term is defined in Rule 3b-4 under the Exchange Act), and our ADSs, each representing 60 ordinary shares, are listed on the New York Stock Exchange, or NYSE. Under Section 303A of the NYSE Listed Company Manual, NYSE-listed companies that are foreign private issuers are permitted to follow home country practice in lieu of the corporate governance provisions specified by the NYSE with limited exceptions. The following summarizes some significant ways in which our corporate governance practices differ from those followed by domestic companies under the listing standards of the NYSE:

•

The NYSE standards for domestic companies require that non-management directors meet at regularly scheduled executive sessions without management. Except for meetings in August and November 2010 and independent committee meetings in connection with the going private transaction, our non-management directors have not met in executive sessions without management, and there is no requirement under the laws of the Cayman Islands that our non-management directors meet in executive sessions.

PART III

ITEM 17.

FINANCIAL STATEMENTS

The Registrant has elected to provide the consolidated financial statements and related information specified in Item 18 in lieu of Item 17.

102

ITEM 18.

FINANCIAL STATEMENTS

The following is a list of the audited consolidated financial statements and a report of the independent registered public accounting firm included in this annual report beginning on page F-1.


	Page
Report of Independent Registered Public Accounting Firm		F-1

Consolidated Balance Sheets as of December 31, 2009 and 2010		F-2

Consolidated Statements of Income for the years ended December 31, 2008, 2009 and 2010		F-3

Consolidated Statements of Equity and Comprehensive Income for the years ended December 31, 2008, 2009 and 2010		F-4

Consolidated Statements of Cash Flows for the years ended December 31, 2008, 2009 and 2010		F-5

Notes to the Consolidated Financial Statements for the years ended December 31, 2008, 2009 and 2010		F-7

ITEM 19.

EXHIBITS


Exhibit Number		Description of Exhibits

1.1		Amended and Restated Memorandum and Articles of Association of Chemspec International Limited (incorporated by reference to Exhibit 1.2 of the Company’s 2009 Form 20-F filed on June 17, 2010)

2.1		Specimen Certificate for Ordinary Shares of Chemspec International Limited (incorporated by reference to Exhibit 2.1 of the Company’s 2009 Form 20-F filed on June 17, 2010)

4.1		Registrant’s 2008 Share Incentive Plan Adopted as of January 1, 2008 (incorporated by reference to Exhibit 4.2 of the Company’s 2009 Form 20-F filed on June 17, 2010)

4.2		Form of Indemnification Agreement with the Registrant’s Directors (incorporated by reference to Exhibit 4.3 of the Company’s 2009 Form 20-F filed on June 17, 2010)

4.3		Form of Non-disclosure, Non-competition and Proprietary Information Agreement (incorporated by reference to Exhibit 4.4 of the Company’s 2009 Form 20-F filed on June 17, 2010)

4.4		Form of Employment Agreement (incorporated by reference to Exhibit 4.5 of the Company’s 2009 Form 20-F filed on June 17, 2010)

4.5		Agreement and Plan of Merger dated as of March 21, 2011, by and among the Company, Dr. Jianhua Yang, Halogen Limited and Merger Sub (incorporated by reference to Annex A to the preliminary proxy statement filed as exhibit (a)-1 to the Company’s Schedule 13E-3 filed on May 3, 2011)

8.1*		List of Subsidiaries

11.1		Code of Business Conduct and Ethics (incorporated by reference to Exhibit 11.1 of the Company’s 2009 Form 20-F filed on June 17, 2010)

12.1*		Certification of our Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

12.2*		Certification of our Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

13.1*		Certification of our Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

13.2*		Certification of the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

15.1*		Consent of Independent Registered Public Accounting Firm

*	Filed herewith

103

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.


CHEMSPEC INTERNATIONAL LIMITED

By:		/s/ Z IXIN W ANG
Name:		Zixin Wang
Title:		Vice President of Finance
		(Principal Financial Officer)

Date: June 20, 2011

104

Report of Independent Registered Public Accounting Firm

THE BOARD OF DIRECTORS AND SHAREHOLDERS OF

CHEMSPEC INTERNATIONAL LIMITED:

We have audited the accompanying consolidated balance sheets of Chemspec International Limited and subsidiaries as of December 31, 2009 and 2010, and the related consolidated statements of income, equity and comprehensive income, and cash flows for each of the years in the three-year period ended December 31, 2010. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Chemspec International Limited and subsidiaries as of December 31, 2009 and 2010, and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2010, in conformity with U.S. generally accepted accounting principles.

The accompanying consolidated financial statements as of December 31, 2010 and for the year then ended have been translated into United States dollars solely for the convenience of the reader. We have audited the translation and, in our opinion, such financial statements expressed in Renminbi have been translated into United States dollars on the basis set forth in Note 2(c) to the consolidated financial statements.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Chemspec International Limited’s internal control over financial reporting as of December 31, 2010, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated June 20, 2011 expressed an unqualified opinion on the effectiveness of the Chemspec International Limited’s internal control over financial reporting.

/s/ KPMG

KPMG

Hong Kong, China

June 20, 2011

F-1

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Amounts expressed in thousands, except share and per share data)


	Note		As of December 31
	Note		2009		2010		2010
			RMB		RMB		US$
ASSETS
*Current assets*
Cash				351,097		98,719		14,957
Pledged bank deposits				37,919		56,746		8,598
Accounts receivable, net		(3)		94,154		137,873		20,890
Bills receivable				1,327		1,200		182
Inventories		(4)		271,434		470,432		71,278
Prepayment and other receivables		(5)		38,738		73,449		11,128
Amounts due from related parties		(19)		64		—		—
Deferred income tax assets		(9)		3,424		6,369		965

Total current assets				798,157		844,788		127,998
Property, plant and equipment, net		(6)		699,181		871,398		132,030
Land use rights		(8)		56,064		59,201		8,970
Intangible assets				839		730		111
Goodwill				7,446		7,446		1,128
Equity investment in an affiliate		(7)		13,296		12,793		1,938
Deferred income tax assets		(9)		300		—		—

Total assets				1,575,283		1,796,356		272,175

LIABILITIES AND EQUITY
*Current liabilities*
Short-term bank borrowings		(10)		—		20,000		3,030
Long-term bank borrowings, current portion		(10)		—		5,000		758
Accounts payable				81,870		142,319		21,564
Bills payable		(11)		49,738		64,340		9,748
Accrued expenses and other payables		(12)		183,266		148,238		22,461
Amounts due to related parties		(19)		23,659		5,559		842
Deferred income				—		14,215		2,154
Income taxes payable				1,298		5,408		819

Total current liabilities				339,831		405,079		61,376
Long-term bank borrowings		(10)		10,000		—		—
Deferred income tax liabilities		(9)		18,056		21,517		3,260
Deferred income				15,136		3,280		497

Total liabilities				383,023		429,876		65,133

Equity
Ordinary shares:
Par value: HK$ 0.01 Authorized: 20,000,000,000 shares in 2009 and 2010 Issued and outstanding: 2,167,620,000 shares in 2009 and 2,163,190,740 shares in 2010				21,686		21,649		3,280
Additional paid-in capital				323,916		319,048		48,341
Statutory reserves				63,422		85,820		13,003
Accumulated other comprehensive income				6,803		5,197		787
Retained earnings				770,425		929,108		140,774

Equity attributable to Chemspec International Limited				1,186,252		1,360,822		206,185
Noncontrolling interests				6,008		5,658		857

Total equity				1,192,260		1,366,480		207,042

Commitment and contingencies		(15)
Total liabilities and equity				1,575,283		1,796,356		272,175

See accompanying notes to the consolidated financial statements.

F-2

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(Amounts expressed in thousands, except per share data)


			Year ended December 31
	Note		2008			2009			2010			2010
			RMB			RMB			RMB			US$
Sales		(18)		942,487			820,295			1,082,031			163,944
Cost of sales				(548,543	)		(495,584	)		(664,791	)		(100,726	)

Gross profit				393,944			324,711			417,240			63,218
Selling expenses				(11,898	)		(11,245	)		(11,130	)		(1,686	)
General and administrative expenses				(58,947	)		(69,871	)		(77,768	)		(11,783	)
Research and development expenses				(27,483	)		(30,913	)		(65,679	)		(9,951	)
Other operating expenses				(2,188	)		(7,145	)		(2,736	)		(415	)
Other operating income				1,012			953			1,624			246
Government grants				50			971			5,152			781

Income from operations				294,490			207,461			266,703			40,410
Other income (expenses):
Interest income				2,116			2,296			1,954			295
Interest expense				(2,746	)		(2,149	)		(80	)		(12	)
Foreign currency exchange loss, net				(9,514	)		(1,961	)		(3,249	)		(492	)
Equity in loss of an affiliate				—			(176	)		(503	)		(76	)
Other income				82			519			400			61

Earnings before income taxes				284,428			205,990			265,225			40,186
Income tax benefit (expense)		(9)		32,240			(28,838	)		(38,999	)		(5,909	)

Net income				316,668			177,152			226,226			34,277
Net income attributable to the noncontrolling interests				(4,307	)		(4,721	)		(685	)		(104	)

Net income attributable to Chemspec International Limited				312,361			172,431			225,541			34,173

Basic earnings per share		(16)		RMB0.17			RMB0.09			RMB0.10		US$	0.02

Diluted earnings per share		(16)		RMB0.17			RMB0.09			RMB0.10		US$	0.02

See accompanying notes to the consolidated financial statements.

F-3

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EQUITY

AND COMPREHENSIVE INCOME

(Amounts expressed in thousands, except share data)


	Ordinary shares						Additional paid-in capital			Statutory reserves		Accumulated other comprehensive income			Retained earnings			Equity Attributable to Chemspec International Limited			Noncontrolling interests			Total Equity
	Number			Amount			Additional paid-in capital			Statutory reserves		Accumulated other comprehensive income			Retained earnings			Equity Attributable to Chemspec International Limited			Noncontrolling interests			Total Equity
				RMB			RMB			RMB		RMB			RMB			RMB			RMB			RMB
Balance as of January 1, 2008		1,800,000,000			18,446			12,680			44,307		4,312			307,276			387,021			7,613			394,634
Net income		—			—			—			—		—			312,361			312,361			4,307			316,668
Foreign currency exchange translation adjustment, net of nil tax		—			—			—			—		2,437			—			2,437			—			2,437

Comprehensive income																			314,798			4,307			319,105
Appropriation to statutory reserves (Note 14)		—			—			—			1,530		—			(1,530	)		—			—			—
Share-based compensation (Note 17)		—			—			17,917			—		—			—			17,917			—			17,917
Acquisition of a subsidiary		—			—			—			—		—			—			—			267			267
Acquisition of noncontrolling interests		—			—			—			—		—			—			—			(3,989	)		(3,989	)
Adjustment for the acquisition of Kangpeng Nong Hua (Note 20(c))		—			—			8,616			—		—			1,781			10,397			6,882			17,279

Balance as of December 31, 2008		1,800,000,000			18,446			39,213			45,837		6,749			619,888			730,133			15,080			745,213
Net income		—			—			—			—		—			172,431			172,431			4,721			177,152
Foreign currency exchange translation adjustment, net of nil tax		—			—			—			—		54			—			54			—			54

Comprehensive income																			172,485			4,721			177,206
Appropriation to statutory reserves (Note 14)		—			—			—			17,585		—			(17,585	)		—			—			—
Share-based compensation (Note 17)		—			—			15,443			—		—			—			15,443			—			15,443
Issuance of ordinary shares upon initial public offering (“IPO”), net of issuance costs of RMB59,590,000 (Note 13)		379,680,000			3,346			326,086			—		—			—			329,432			—			329,432
Repurchase of ordinary shares (Note 13)		(12,060,000	)		(106	)		(8,028	)		—		—			—			(8,134	)		—			(8,134	)
Capital contributions to a subsidiary by noncontrolling interests		—			—			—			—		—			—			—			1,600			1,600
Dividend by a subsidiary to noncontrolling interests		—			—			—			—		—			—			—			(2,500	)		(2,500	)
Acquisition of noncontrolling interest in Jiangsu Wei Er (Note 20(b))		—			—			(33,047	)		—		—			—			(33,047	)		(7,953	)		(41,000	)
Acquisition of equity interest in Kangpeng Nong Hua from Dr. Jianhua Yang (Note 20(c))		—			—			(8,616	)		—		—			(4,309	)		(12,925	)		—			(12,925	)
Acquisition of noncontrolling interest in Kangpeng Nong Hua (Note 20(c))		—			—			(7,135	)		—		—			—			(7,135	)		(4,940	)		(12,075	)

Balance as of December 31, 2009		2,167,620,000			21,686			323,916			63,422		6,803			770,425			1,186,252			6,008			1,192,260
Net income		—			—			—			—		—			225,541			225,541			685			226,226
Foreign currency exchange translation adjustment, net of nil tax		—			—			—			—		(1,606	)		—			(1,606	)		—			(1,606	)

Comprehensive income																			223,935			685			224,620
Dividends declared and paid (Note 21)		—			—			—			—		—			(44,460	)		(44,460	)		—			(44,460	)
Appropriation to statutory reserves (Note 14)		—			—			—			22,398		—			(22,398	)		—			—			—
Share-based compensation (Note 17)		—			—			1,499			—		—			—			1,499			—			1,499
Issuance of ordinary shares upon exercise of share options (Note 13)		11,670,240			102			6,212			—		—			—			6,314			—			6,314
Repurchase of ordinary shares (Note 13)		(16,099,500	)		(139	)		(10,814	)		—		—			—			(10,953	)		—			(10,953	)
Acquisition of noncontrolling interest in Binhai Kangjie (Note 20(b))		—			—			(1,765	)		—		—			—			(1,765	)		(1,035	)		(2,800	)

Balance as of December 31, 2010		2,163,190,740			21,649			319,048			85,820		5,197			929,108			1,360,822			5,658			1,366,480

Balance as of December 31, 2010—in US$					3,280			48,341			13,003		787			140,774			206,185			857			207,042

See accompanying notes to the consolidated financial statements.

F-4

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts expressed in thousands)


	Year ended December 31
	2008			2009			2010			2010
	RMB			RMB			RMB			US$
Cash flows from operating activities
Net income		316,668			177,152			226,226			34,277
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of property, plant and equipment		24,700			37,204			70,760			10,721
Land use right expenses		998			1,132			1,315			199
Loss on disposal of property, plant and equipment		1,424			6,505			1,165			177
Amortization of intangible assets		27			108			109			17
Bad debt expense (reversal)		(241	)		64			(81	)		(12	)
Write-down of inventories		1,090			14,696			7,296			1,105
Equity in loss of an affiliate		—			176			503			76
Gain on transfer of land use right to an affiliate		—			(290	)		—			—
Unrealized foreign exchange loss, net		1,573			92			255			39
Share-based compensation		17,917			15,443			1,499			227
Deferred income tax (benefit) expense		16,024			(644	)		816			124
Changes in operating assets and liabilities, net of effect of acquisitions:
Pledged bank deposits related to purchase of inventories		(17,587	)		994			(17,235	)		(2,611	)
Inventories		(80,490	)		(67,867	)		(206,294	)		(31,256	)
Accounts receivable		(48,158	)		42,354			(44,199	)		(6,697	)
Bills receivable		—			(1,327	)		127			19
Prepayment and other receivables		13,658			(14,141	)		(34,575	)		(5,239	)
Accounts payable		12,691			488			60,449			9,159
Bills payable related to purchase of inventories		14,084			(5,158	)		22,810			3,456
Accrued expenses and other payables		11,531			(2,202	)		(8,749	)		(1,326	)
Deferred income		5,566			9,570			2,359			357
Income taxes payable		(1,729	)		(5,097	)		4,110			623

Net cash provided by operating activities		289,746			209,252			88,666			13,435

Cash flows from investing activities
Capital expenditures, including interest capitalized		(127,846	)		(227,749	)		(241,201	)		(36,546	)
Pledged bank deposits related to purchase of property, plant and equipment		—			(17,377	)		(1,592	)		(241	)
Proceeds from sale of property, plant and equipment		200			—			—			—
Proceeds from the sale of a subsidiary		3,420			—			—			—
Investment in an affiliate		—			(11,225	)		—			—
Non-interest bearing advances to related parties		(30,900	)		(64	)		—			—
Non-interest bearing advances repaid by related parties		48,480			2,500			64			10
Net cash assumed from acquisition of subsidiaries		11,988			—			—			—
Payments for land use rights		(17,517	)		(3,978	)		(4,452	)		(675	)

Net cash used in investing activities		(112,175	)		(257,893	)		(247,181	)		(37,452	)

See accompanying notes to the consolidated financial statements.

F-5

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS—(CONTINUED)

(Amounts expressed in thousands)


	Year ended December 31
	2008			2009			2010			2010
	RMB			RMB			RMB			US$
Cash flows from financing activities
Capital contributions to a subsidiary by noncontrolling interest holders		—			1,600			—			—
Dividend by a subsidiary to noncontrolling interest holders		—			(2,500	)		—			—
Dividends paid		—			—			(44,460	)		(6,735	)
Proceeds from issuance of ordinary shares upon IPO		—			389,022			—			—
Issuance costs of ordinary shares upon IPO		(9,843	)		(46,719	)		(3,028	)		(459	)
Proceeds from exercise of share options		—			—			6,178			936
Acquisition of additional equity interest in subsidiaries from noncontrolling interest holders		(8,000	)		(17,500	)		(38,375	)		(5,815	)
Acquisition of equity interest in Kangpeng Nong Hua from Dr. Jianhua Yang		—			—			(12,925	)		(1,958	)
Proceeds from short-term bank borrowings		70,000			15,000			20,000			3,030
Repayment of short-term bank borrowings		(50,000	)		(80,000	)		—			—
Proceeds from long-term bank borrowings		—			10,000			—			—
Repayment of long-term bank borrowings		—			—			(5,000	)		(758	)
Repurchase of ordinary shares		—			(8,134	)		(10,953	)		(1,660	)
Proceeds from non-interest bearing borrowings from related parties		20,400			6,000			—			—
Repayment of non-interest bearing borrowings from related parties		(76,747	)		(47,687	)		(4,000	)		(606	)

Net cash (used in) provided by financing activities		(54,190	)		219,082			(92,563	)		(14,025	)

Effect of foreign currency exchange rate changes on cash		292			54			(1,300	)		(197	)

Net increase (decrease) in cash		123,673			170,495			(252,378	)		(38,239	)
Cash at beginning of year		56,929			180,602			351,097			53,196

Cash at end of year		180,602			351,097			98,719			14,957

Supplemental disclosures of cash flow information:
Income taxes paid		12,725			34,579			36,050			5,462
Income tax refund		58,767			—			—			—
Interest paid, net of amounts capitalized		2,746			2,149			80			12

Noncash investing and financing activities:
Accrued IPO cost		—			3,028			—			—
Payable for purchase of property, plant and equipment		35,547			118,174			129,323			19,594
Payable for acquisition of noncontrolling interest in Jiangsu Wei Er		—			23,500			—			—
Payable for acquisition of Kangpeng Nong Hua		—			25,000			—			—
Bills payable for purchase of property, plant and equipment		771			28,105			19,897			3,015
Land use right contributed to an affiliate		—			1,957			—			—

See accompanying notes to the consolidated financial statements.

F-6

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Amounts expressed in thousands, except share and per share data)

(1) PRINCIPAL ACTIVITIES AND BASIS OF PRESENTATION

Principal activities

The consolidated financial statements consist of the financial statements of Chemspec International Limited (the “Company”) and its subsidiaries (collectively referred to as the “Group”).

The Group’s principal activities are the manufacturing and sale of chemical compounds through its subsidiaries in the People’s Republic of China (“PRC”).

The Company has direct and indirect interests in the following subsidiaries. The particulars of these subsidiaries are set out below:


Name of company		Place and date of incorporation	Percentage of equity interests as of December 31,						Principal activities
Name of company		Place and date of incorporation	2009			2010			Principal activities
Stanley Space Limited (“Stanley Space”)		British Virgin Islands February 3, 2006		100	%		100	%	Investment holding
Wisecon Limited (“Wisecon”)		Hong Kong April 20, 2006		100	%		100	%	Investment holding
Shanghai ChemSpec Corporation (“Shanghai ChemSpec”)		PRC November 14, 1996		100	%		100	%	Design and manufacture of chemical compounds
Taixing ChemSpec Specialty Chemicals Co., Ltd. (“Taixing ChemSpec”)		PRC November 8, 2000		100	%		100	%	Manufacturing and sale of chemical compounds
Shanghai Qi Yue Trading Co., Ltd. (“Shanghai Qi Yue”)		PRC July 23, 2002		100	%		100	%	Sale of chemical compounds
Shanghai Wan Su Chemicals Co., Ltd. (“Shanghai Wan Su”)		PRC April 22, 2005		100	%		100	%	Manufacturing and sale of chemical compounds
Zhejiang Huajing Flurochemical and Technology Co., Ltd. (“Huajing Company”)	(i)	PRC January 25, 2006		80	%		80	%	Manufacturing and sale of chemical compounds
Quzhou Kangpeng Chemicals Co., Ltd. (“Quzhou Kangpeng”)		PRC November 19, 2007		100	%		100	%	Manufacturing and sale of chemical compounds
Jiangsu Wei Er Chemicals Co., Ltd. (“Jiangsu Wei Er”)	(ii)	PRC March 6, 2003		100	%		100	%	Manufacturing and sale of chemical compounds
Binhai Kangjie Chemicals Co., Ltd. (“Binhai Kangjie”)	(iii)	PRC April 15, 2009		92	%		100	%	Manufacturing and sale of chemical compounds
Jiangsu Kangpeng Nong Hua Co., Limited (“Kangpeng Nong Hua”)	(iv)	PRC April 25, 2001		100	%		100	%	Manufacturing and sales of chemical compounds

F-7

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

Notes:

(i)	In 2008, the Group acquired an additional 20% equity interest in Huajing Company from the noncontrolling interest holder for cash consideration of RMB8,000. See Note 20(b).

(ii)

In February 2008, the Group completed its acquisition of an 80% equity interest in Jiangsu Wei Er from independent third parties. In November 2009, the Group acquired the remaining 20% equity interest in Jiangsu Wei Er from the noncontrolling interest holders for cash consideration of RMB 41,000. See Notes 20(a) and 20(b).

(iii)

Binhai Kangjie was established in 2009. The Group contributed RMB18,400 for a 92% equity interest in Binhai Kangjie and the noncontrolling interest holder contributed RMB1,600 for an 8% equity interest. In March 2010, the Group acquired an additional 8% equity interest in Binhai Kangjie from the noncontrolling interest holder for cash consideration of RMB2,800. See Note 20(b).

(iv)

The Group acquired 100% equity interest in Kangpeng Nong Hua in November 2009 for cash consideration of RMB25,000. As Dr. Jianhua Yang (“Dr. Yang”) held more than 50% voting ownership interest of both the Company and Kangpeng Nong Hua at the date of the acquisition, it is considered a transaction between entities under common control. The Company’s consolidated financial statements have been retrospectively adjusted to reflect the acquisition since October 8, 2008, which is the earliest date that both entities were under the common control of Dr. Yang. See Note 20(c).

Basis of presentation

The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). This basis of accounting differs in certain material respects from that used for the preparation of the books of account of the Company’s subsidiaries, which are prepared in accordance with the accounting principles and the relevant financial regulations established by the Ministry of Finance of the PRC (“PRC GAAP”), the accounting standards used in the PRC. The accompanying consolidated financial statements reflect necessary adjustments not recorded in the books of account of the Company’s subsidiaries to present them in conformity with U.S. GAAP.

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Principles of consolidation

The accompanying consolidated financial statements include the financial statements of the Company and its subsidiaries. Investments in companies of which the Group has significant influence, but not a controlling interest are accounted for using the equity method of accounting as discussed in footnote 2(n). All significant intercompany transactions and balances have been eliminated in consolidation.

(b) Use of estimates

The preparation of financial statements in accordance with U.S. GAAP requires management of the Group to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include collectibility of trade receivables, realization of inventories and deferred income tax assets, the determination of useful lives and residual values of property, plant and equipment, and the determination of fair values of share-based compensation awards and assets and liabilities acquired in purchase business combinations and the measurement of income tax uncertainties. These estimates are often based on judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable.

F-8

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(c) Foreign currency transactions and translation

The Group’s reporting currency is the RMB. The functional currency of the Company’s subsidiaries located in the PRC is the RMB as the PRC is the primary economic environment in which these entities operate. Transactions at these subsidiaries that are denominated in currencies other than the RMB are translated into RMB at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated into RMB using the applicable exchange rates at each balance sheet date. The resulting exchange differences are recorded in foreign currency exchange gain (loss), net in the consolidated statements of income.

The functional currency of the Company and its subsidiaries located outside of the PRC is the U.S. dollar. Assets and liabilities of the Company and subsidiaries located outside of the PRC are translated into RMB using the exchange rates at each balance sheet date. Revenue and expenses are translated into RMB at average rates prevailing during the reporting period. The gains and losses, net of tax, resulting from translation into RMB are reported as a separate component of accumulated other comprehensive income within equity.

For the convenience of the readers, the December 31, 2010 RMB amounts included in the accompanying consolidated financial statements have been translated into U.S. dollars at the rate of US$1.00=RMB6.6000, being the noon buying rate for U.S. dollars in the City of New York in effect on December 30, 2010 for cable transfers in RMB per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. No representation is made that the RMB amounts could have been, or could be, converted into U.S. dollars at that rate or at any other rate on December 30, 2010 or at any other date.

(d) Commitments and contingencies

In the normal course of business, the Group is subject to loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources. An accrual for a loss contingency is recorded when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

(e) Cash

Cash consists of cash on hand and cash at banks. As of December 31, 2010, the Group held cash RMB69,605 (US$10,546) in major financial institutions located in the PRC (2009: RMB239,073) and RMB 29,114 (US$4,411) in major financial institutions in Hong Kong (2009: RMB86,028). Management believes that these major financial institutions have acceptable credit rating.

(f) Pledged bank deposits

Pledged bank deposits represent amounts held by financial institutions in the PRC, which are not available for the Group’s use, as security for issuance of bills payable and letters of credit. Upon maturity of the bills payable, which is generally within 6 months, the cash becomes available for use by the Group. Pledged bank deposits related to purchase of inventories are reported within cash flows from operating activities and pledged bank deposits related to purchase of property, plant and equipment are reported within cash flows from investing activities in the consolidated statements of cash flows.

F-9

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(g) Accounts receivable

Accounts receivable primarily represent amounts due from customers, that are recorded at the invoiced amount and do not bear interest. Management reviews its accounts receivable on a periodic basis and records allowances when there is a doubt as to the collectibility of the balance. In evaluating the collectibility of an account receivable balance, management considers various factors, including, the age of the balance, customer specific facts and economic conditions. Accounts receivable balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Group does not have any off-balance-sheet credit exposure related to its customers.

(h) Inventories

Inventories are stated at the lower of cost or market. Cost is determined using the weighted average method. Cost of work-in-progress and finished goods is comprised of direct materials, direct labor and related manufacturing overhead based on normal operating capacity.

(i) Property, plant and equipment, net

Property, plant and equipment are stated at cost. Depreciation is calculated on a straight-line method over the estimated useful lives of the assets, taking into consideration the assets’ estimated salvage value. Leasehold improvements are amortized over the shorter of the lease term or estimated useful lives. When items are retired or otherwise disposed of, loss is charged for the difference between the net book value and proceeds received thereon. Ordinary maintenance and repairs are charged to expense as incurred. The estimated useful lives of the Group’s property, plant and equipment are as follows:


Buildings			20 years
Plant machinery			5-10 years
Office equipment			3-5 years
Motor vehicles			4-5 years
Leasehold improvements			5 years

Costs incurred during the construction and installation of the assets are initially capitalized as construction in progress and transferred to property, plant and equipment when the assets are ready for their intended use, at which time depreciation commences. The capitalized costs include an allocation of interest cost incurred.

(j) Land use rights

Land use rights represent the cost of land use rights in the PRC. Land use rights are recorded at cost and charged to expense on a straight-line basis over the term of the land use rights.

(k) Intangible assets

Intangible assets represent customer relationship, which are amortized on a straight-line basis over their estimated useful lives of 9 years.

Amortization expense for intangible assets was RMB27, RMB108 and RMB109 (US$17) for the years ended December 31, 2008, 2009 and 2010. Estimated amortization expense for each of the next five years is RMB108.

F-10

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(l) Goodwill

Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a purchase businesses combination. Goodwill is not amortized, but is instead evaluated for impairment at least annually. The goodwill impairment test is a two-step process. Under the first step, the estimated fair value of the reporting unit, which in this case is the Group as a whole, is compared with its carrying value (including goodwill). The Group used its market capitalization based on the quoted market price of its ordinary shares in determining the fair value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying value, an indication of goodwill impairment exists and management must then perform step two of the impairment test (measurement). Under step two, an impairment loss is recognized for any excess of the carrying amount of the reporting unit’s goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value of the reporting unit in a manner similar to a purchase price allocation and the residual fair value after this allocation is the implied fair value of the reporting unit goodwill.

The Company performs its annual impairment review of goodwill at December 31, or when a triggering event occurs between annual impairment tests. No impairment of goodwill was recognized for the years ended December 31, 2008, 2009 and 2010.

(m) Impairment of long-lived assets

Long-lived assets including property, plant and equipment, land use rights, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. Long lived assets are grouped for impairment testing at the lowest level for which there are identifiable cash flows that are largely independent of other asset groups. The approach in evaluating whether an asset group has identifiable cash flows that are largely independent of the cash flows of other asset groups focuses on the degree to which the Company’s total cash flows (inflows and outflows) depend on the activities of one or more other asset groups of the Company. Recoverability of the asset groups is measured by a comparison of the carrying amount of the asset groups to the estimated undiscounted future cash flows expected to be generated. If the carrying amount of the asset groups exceed the sum of its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset groups exceed their fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. No impairment of long-lived assets was recognized for the years ended December 31, 2008, 2009 and 2010.

(n) Equity investment in an affiliate

Equity investments where the Company does not have a controlling financial interest, but has the ability to exercise significant influence over the operating and financial policies of the investee, are accounted for using the equity method. Under the equity method of accounting, the Group’s share of the investee’s results of operations is reported as equity in income (loss) of an affiliate in the consolidated statements of income.

The Group recognizes an impairment loss when there is a decline in value below the carrying value of the equity investment that is considered to be other-than-temporary. The process of assessing and determining whether impairment on an investment is other-than-temporary requires a significant amount of judgment. To determine whether impairment is other-than-temporary, management considers whether it has the ability and intent to hold the investment until recovery and whether evidence indicating the carrying value of the investment is recoverable outweighs evidence to the contrary. Evidence considered in this assessment includes the reasons for the impairment, the severity and duration of the decline in value, any change in value subsequent to the period end, and forecasted performance of the investee. Based on management’s evaluation, there were no impairment charges on the equity investment for the years ended December 31, 2009 and 2010.

F-11

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(o) Bills payable

Bills payable represent bills issued by financial institutions to the Group’s suppliers that normally do not exceed six months. The bills payable are recognized when the banks accept the bills and the Group is liable to pay the banks. The bills payable are derecognized when the Group pays the banks and is relieved of its obligation for the liability.

(p) Revenue recognition

The Group sells specialty chemicals directly to end users that incorporate them into their products, and to trading or distribution companies that then sell the specialty chemicals to end users. Sales represent the invoiced value of products sold, net of value added taxes (“VAT”). The Group recognizes revenue from the sales of chemical compounds when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed and determinable, and collectibility is reasonably assured. For sales to end users outside the PRC, products are considered delivered when the goods have been loaded on the ship at the port of shipment. For sales to end users in the PRC, delivery occurs upon receipt of products by the customers. For sales to trading companies, delivery occurs upon receipt of products by the customers at the customers’ warehouse or designated destination.

In the PRC, VAT of 17% on invoice amount is collected, in respect of the sales of goods to customers in the PRC, on behalf of tax authorities. VAT collected from customers in the PRC, net of VAT paid, is recorded as a liability in the consolidated balance sheets until it is paid to the authorities. No VAT is collected in respect of the sales of goods to customers outside the PRC. For VAT paid, a certain percent is recorded as a receivable (see Note 5) in the consolidated balance sheets until it is recovered from the tax authorities. The non-refundable portion of VAT paid is recognized as a part of cost of sales when the corresponding sales are recognized.

(q) Government grants

Government grants are recognized in the consolidated balance sheets initially as deferred income when received and recognized as income when all the conditions for receipt have been met. Grants that reimburse the Group for expenses incurred are recognized as income on a systematic basis in the same periods in which the expenses are incurred. Grants that reimburse the Group for the cost of an asset are recognized as income on a straight-line basis over the useful life of the assets.

During the years ended December 31, 2008, 2009 and 2010, government grants of RMB5,616, RMB10,541 and RMB7,511 (US$1,138) were received from local government authorities for the Group to reimburse its research and development expenditures, and RMB50, RMB971 and RMB5,152 (US$781) have been recognized as income, respectively.

(r) Shipping and handling costs

Costs to ship products to customers are included in selling expenses in the consolidated statements of income. Cost to ship products to customers were RMB8,662, RMB6,026 and RMB8,138 (US$1,233) for the years ended December 31, 2008, 2009 and 2010, respectively.

(s) Advertising costs

Advertising costs are charged to expense in the period incurred and are included in selling expenses in the consolidated statements of income. The Group incurred advertising expenses totaling RMB64, RMB537 and RMB349 (US$53) for the years ended December 31, 2008, 2009 and 2010, respectively.

F-12

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(t) Research and development costs

Research and development costs are expensed as incurred.

(u) Income taxes

Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax loss carryforwards. Deferred income tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that some portion or all of the deferred income tax assets will not be realized. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates or laws is recognized in the statements of income in the period that the change in tax rates or tax laws is enacted.

The Group recognizes in the consolidated financial statements the impact of a tax position, if that position is more likely than not of being sustained upon examination, based on the technical merits of the position. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Group has elected to classify interest and penalties related to unrecognized tax benefits, if and when required, as part of income tax expense in the consolidated statements of income.

(v) Share-based compensation

The Group measures the costs of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award and recognizes the costs over the period the employee is required to provide service in exchange for the award, which generally is the vesting period. The estimate of the fair value of the equity award granted before the initial public offering (IPO) of the Company’s ordinary shares is determined based on consideration of both comparable valuation and discounted cash flow methods, taking into account the terms and conditions upon which the equity instrument was granted.

(w) Employee benefit plans

Pursuant to PRC regulations, the Company’s PRC subsidiaries are required to participate in various defined contribution plans organized by municipal and provincial governments for their employees. These entities are required to make contributions for each employee to these plans at rates ranging from 30% to 44% on a standard salary base determined by the local Social Security Bureau. Under these plans, certain pension, medical and other welfare benefits are provided to the employees. The Group’s PRC subsidiaries have no other obligation for the payment of employee benefits associated with these plans beyond the contributions described above. Employee benefits associated with these plans are expensed monthly as the related service is provided. The total amount of such contributions for the years ended December 31, 2008, 2009 and 2010 were RMB7,220, RMB11,656 and RMB13,114 (US$1,987), respectively.

(x) Earnings per share

Basic earnings per share is computed by dividing net income attributable to Chemspec International Limited shareholders by the weighted average number of ordinary shares outstanding during the year.

F-13

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

Diluted earnings per share is calculated by dividing net income attributable to Chemspec International Limited shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary shares and dilutive ordinary share equivalents outstanding during the year. Ordinary share equivalents consist of the ordinary shares issuable upon the exercise of outstanding share options (using the treasury stock method). Potential dilutive securities are not included in the calculation of diluted earnings per share if the effect is anti-dilutive.

(y) Segment reporting

The Group’s chief operating decision maker has been identified as its Chief Executive Officer. The Group has one operating segment, namely manufacturing of specialty chemicals. Geographic revenue information is presented in Note 18.

(z) Capitalized interest

The Group’s policy is to capitalize interest cost incurred on debt during the construction of major projects exceeding one year. A reconciliation of total interest cost to “Interest expense” as reported in the consolidated statements of income for years ended December 31, 2008, 2009 and 2010, is as follows:


	Year ended December 31
	2008		2009		2010		2010
	RMB		RMB		RMB		US$
Interest cost capitalized		2,244		1,116		334		51
Interest cost charged to income		2,746		2,149		80		12

Total interest expense		4,990		3,265		414		63

(aa) Fair value measurements

The Group applies the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Subtopic 820-10, Fair Value Measurements , or ASC Subtopic 820-10, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC Subtopic 820-10 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

FASB ASC Subtopic 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Group considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.

FASB ASC Subtopic 820-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC Subtopic 820-10 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

•

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date

F-14

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

•

Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

•

Level 3 inputs are unobservable inputs for the asset or liability

The level in the fair value hierarchy within which a fair measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety.

The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety.

The Group did not have any assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2009 and 2010.

(3) ACCOUNTS RECEIVABLE, NET

Accounts receivable are summarized as follows:


	As of December 31
	2009			2010		2010
	RMB			RMB		US$
Accounts receivable		94,700			137,873		20,890
Less: Allowance for doubtful accounts		(546	)		—		—

Accounts receivable, net		94,154			137,873		20,890

The following table presents the movement of the allowance for doubtful accounts:


	Year ended December 31
	2008			2009			2010			2010
	RMB			RMB			RMB			US$
Balance at the beginning of year		(723	)		(482	)		(546	)		(83	)
Additions charged to expense		(83	)		(64	)		—			—
Write-off of accounts receivable		—			—			465			71
Reversal credited to income		324			—			81			12

Balance at the end of year		(482	)		(546	)		—			—

As part of its ongoing control procedures, management monitors the creditworthiness of its customers to which it grants credit terms in the normal course of its business. Credit terms are normally ranging from 30 to 120 days from the date of billing.

F-15

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(4) INVENTORIES

Inventories consist of the following:


	As of December 31
	2009		2010		2010
	RMB		RMB		US$
Raw materials		91,375		147,275		22,314
Work in progress		92,380		178,540		27,052
Finished goods		87,679		144,617		21,912

		271,434		470,432		71,278

Write-down of finished goods were RMB1,090, RMB14,696 and RMB7,296 (US$1,105) during the years ended December 31, 2008, 2009 and 2010, respectively, which are included in cost of sales.

(5) PREPAYMENT AND OTHER RECEIVABLES

Prepayment and other receivables consist of the following:


	As of December 31
	2009		2010		2010
	RMB		RMB		US$
Prepayments to suppliers		819		17,849		2,704
Rental income receivable
—Related party (Note 19(a))		1,960		2,000		303
VAT recoverable		25,853		37,260		5,645
Others		10,106		16,340		2,476

		38,738		73,449		11,128

(6) PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment, net consists of the following:


	As of December 31
	2009			2010			2010
	RMB			RMB			US$
Buildings		281,195			342,819			51,942
Plant machinery		421,165			570,716			86,472
Office equipment		5,301			7,664			1,161
Motor vehicles		10,039			10,908			1,653
Construction in progress		63,075			92,609			14,032

Total property, plant and equipment		780,775			1,022,526			154,928
Less: Accumulated depreciation and amortization		(81,594	)		(151,128	)		(22,898	)

Total property, plant and equipment, net		699,181			871,398			132,030

F-16

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

As of December 31, 2010, certain buildings with an aggregate carrying value of RMB69,887 (US$10,589) and RMB5,532 (US$838) were pledged as collateral for bank borrowings and accounts payable to a supplier, respectively (certain buildings with an aggregate carrying value of RMB23,498 and RMB5,864 were pledged as collateral for bank borrowings and accounts payable to a supplier, respectively, as of December 31, 2009).

Depreciation and amortization expense on property, plant and equipment was recorded as follows:


	Year ended December 31
	2008		2009		2010		2009
	RMB		RMB		RMB		US$
Cost of sales		17,157		26,935		46,427		7,034
Research and development expenses		3,248		4,886		8,922		1,352
Selling expenses		37		26		112		17
General and administrative expenses		3,688		4,870		15,299		2,318
Other operating expenses		570		487		—		—

Total depreciation and amortization expense		24,700		37,204		70,760		10,721

(7) INVESTMENT IN AN AFFILIATE

The Group together with Central Glass Company Limited (“Central Glass”), a third party, established Central Glass Chemspec (“Central Glass Chemspec”) in April 2009. The Group contributed cash of US$1,644 (RMB11,225) and a land use right with a carrying value of RMB1,957 (US$287) and an estimated fair value of US$357 (RMB2,441) in exchange for a 40% equity ownership interest in Central Glass Chemspec. The Group recognized a gain of RMB290 in respect of the 60% portion of the excess of fair value over the carrying value of this land use right in accordance with FASB ASC Topic 845, Exchanges of a Nonfinancial Asset for a Noncontrolling Ownership Interest. Central Glass Chemspec is engaged in manufacturing and sales of chemical compounds in Zhejiang, PRC. This investment is accounted for under the equity method.

(8) LAND USE RIGHTS

Land use rights represent cost of the land use rights in respect of land located in the PRC. The Group acquired the land use rights for cash consideration of RMB17,517, RMB3,978 and RMB4,452 (US$675) for the years ended December 31, 2008, 2009 and 2010, respectively, to expand the Group’s existing manufacturing facilities. For the years ended December 31, 2008, 2009 and 2010, land use rights charged to the statements of income amounted to RMB998, RMB1,132 and RMB1,315 (US$199), respectively.

As of December 31, 2010, certain land use rights with an aggregate carrying value of RMB12,197 (US$1,848) and RMB848 (US$128) were pledged as collateral for bank borrowings and accounts payable to a supplier, respectively (certain land use rights with an aggregate carrying value of RMB3,241 and RMB868 were pledged as collateral for bank borrowings and accounts payable to a supplier, respectively, as of December 31, 2009).

(9) INCOME TAX

The Company and its subsidiaries file separate income tax returns.

Cayman Islands

Under the current laws of the Cayman Islands, the Group is not subject to income tax.

F-17

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

British Virgin Islands

Under the current laws of the British Virgin Islands, the Group is not subject to income tax. In addition, upon any payment of dividends by the Group, no British Virgin Islands withholding tax is imposed.

Hong Kong

No current income tax provisions were made for Hong Kong Profits Tax as the Group did not have assessable profits subject to Hong Kong Profits Tax during the years ended December 31, 2008, 2009 and 2010.

PRC

Shanghai ChemSpec, Taixing ChemSpec and Shanghai Wan Su were converted from domestic enterprises to foreign invested enterprises (“FIEs”) beginning in August 2006, October 2006 and September 2006, respectively. Prior to January 1, 2008, a production-oriented FIE could be entitled to a 2-year full exemption followed by a 3-year 50% exemption tax holiday (“tax holiday”). Taixing ChemSpec and Shanghai Wan Su qualified as production-oriented FIEs and were entitled to the tax holiday benefit beginning in 2007. As of December 31, 2007, there was an uncertainty regarding Shanghai ChemSpec’s qualification as a production-oriented FIE. In addition, Shanghai Qi Yue, being registered in the Pudong New Area, Shanghai, was subject to a reduced income tax rate of 15%.

On March 16, 2007, the PRC government enacted the new Enterprise Income Tax law (“new EIT law”), which changed the statutory income tax rate to 25%. The new EIT law was effective as of January 1, 2008. The new EIT law and its relevant regulations provide a 5-year transition period from its effective date for those companies which were entitled to a preferential lower tax rate under the then effective tax laws and regulations, as well as grandfathering tax holidays.

The Company’s PRC subsidiaries are subject to income tax at 25% from 2008 onwards, except for the followings:

(i)

Shanghai ChemSpec was converted into a FIE in August 2006 and was subject to income tax at 27%. Its tax returns were filed using this tax rate without any tax holiday benefit beginning in August 2006. Upon the receipt of the notification issued by the local tax bureau of Shanghai Putuo district in July 2008, Shanghai ChemSpec was entitled to a tax holiday retroactively from August 1, 2006 to December 31, 2010. As a result, Shanghai ChemSpec is subject to income tax at 12.5% from 2008 to 2010 and at 25% from 2011 onwards;

(ii)

Taixing ChemSpec and Shanghai Wan Su were exempt from income tax for 2007 and 2008, and are subject to income tax at 12.5% from 2009 to 2011 and at 25% from 2012 onwards;

(iii)

Shanghai Qi Yue is subject to income tax at 18%, 20%, 22%, 24% and 25% for 2008, 2009, 2010, 2011 and 2012 onwards, respectively;

(iv)

Jiangsu Wei Er was subject to income tax at 25% for 2008. It qualified as an “Advanced and New Technology Enterprise” under the new EIT law in 2009 and is entitled to the preferential income tax rate of 15% from 2009 to 2011. Thereafter, it is subject to income tax at 25%.

The new EIT law and its relevant regulations also impose a withholding tax at 10%, unless reduced by a tax treaty, for dividend distributions from earnings accumulated beginning on January 1, 2008. Undistributed

F-18

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

earnings generated prior to January 1, 2008 are exempt from such withholding tax. Under the China-HK tax arrangement, a qualified Hong Kong tax resident which is the “beneficial owner” and holds 25% or more of the equity interest in a PRC-resident enterprise is entitled to a reduced withholding rate of 5%.

The Company’s subsidiaries in the PRC are directly or indirectly held by one of the Group’s intermediate holding companies, Wisecon, a Hong Kong tax resident. On March 28, 2011, Shanghai Chemspec received approval from its tax authority in-charge confirming that the reduced withholding tax rate of 5% would be applied on its dividends to Wisecon effective from 2008 to 2010. Based upon the approval received and an assessment of the tax residency status of Wisecon and its ability to control its funds, management believes it is more likely than not that any dividends paid by the PRC subsidiaries from earnings generated beginning on January 1, 2008 will be subject to PRC withholding tax at 5%.

The income tax expense (benefit) attributable to income from operations, which is all derived from PRC sources, consists of:


	Year ended December 31
	2008			2009			2010		2010
	RMB			RMB			RMB		US$
Current income tax (benefit) expense		(48,264	)		29,482			38,183		5,785
Deferred income tax expense (benefit)		16,024			(644	)		816		124

		(32,240	)		28,838			38,999		5,909

Earnings (losses) before income taxes of the Group consist of the following:


	Year ended December 31
	2008			2009			2010			2010
	RMB			RMB			RMB			US$
PRC operations		302,677			222,799			266,116			40,321
Non-PRC operations		(18,249	)		(16,809	)		(891	)		(135	)

Total		284,428			205,990			265,225			40,186

F-19

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

The actual income tax expense (benefit) differed from the amounts computed by applying the statutory PRC income tax rate of 25% for the years ended December 31, 2008, 2009 and 2010 to earnings before income taxes as a result of the following:


	Year ended December 31
	2008			2009			2010			2010
	RMB			RMB			RMB			US$
Computed expected income tax expense		71,107			51,498			66,306			10,047
Increase (decrease) in income taxes resulting from:
Tax rate differential on PRC operations		(476	)		(1,472	)		4,009			607
Tax rate differential on Non-PRC operations		4,479			3,998			(147	)		(22	)
Non-deductible expenses Entertainment expenses		191			262			314			48
Penalty		8			—			—			—
Others		67			549			2,536			383
Additional deductible R&D expenses		(1,051	)		(3,381	)		(3,009	)		(456	)
Changes in valuation allowance		273			1,194			970			147
PRC dividend withholding tax on undistributed earnings of subsidiaries		13,851			2,219			3,515			533
Reinvestment tax refund(i)		(16,274	)		—			—			—
Income tax refund(ii)		(42,493	)		—			—			—
Tax holiday(iii)		(61,922	)		(26,029	)		(35,495	)		(5,378	)

Actual income tax (benefit) expense		(32,240	)		28,838			38,999			5,909

(i)

Amount of RMB16,274 for the year ended December 31, 2008 represents income tax refund received by Wisecon for making additional capital contribution to Shanghai ChemSpec in 2007. The tax refund is reported as a reduction of income tax expense in the consolidated statements of income and is recognized in the period when Wisecon received the approval from the state tax bureau of Shanghai Putuo District since government approval is required under the relevant PRC tax laws before an entity is entitled to the tax benefit.

(ii)

Amount of RMB42,493 for the year ended December 31, 2008 represents income tax refund received by Shanghai ChemSpec for the income tax paid for the period from August 1, 2006 to December 31, 2007. In 2007, Shanghai ChemSpec filed the application for the tax holiday, which was rejected by the tax bureau. Therefore, management believed that it was more likely than not that it would not be entitled to the tax holiday benefit, and Shanghai ChemSpec did not claim such benefit in its tax returns as well as in its financial statements until the formal approval from the tax bureau is obtained. In July 2008, the local tax bureau of Shanghai Putuo district notified Shanghai ChemSpec that it is entitled to an exemption from income tax retroactively for the period from August 1, 2006 to December 31, 2007 and a 50% reduction in the income tax in the subsequent three years. The tax refund was recorded as a reduction of income tax expense in the consolidated statements of income.

(iii)

Without the tax holiday, the Group’s basic and diluted earnings per share for the years ended December 31, 2008, 2009 and 2010 would have been reduced by RMB0.06, RMB0.01 and RMB0.02 (US$0.00), respectively.

F-20

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are presented below.


	As of December 31
	2009			2010			2010
	RMB			RMB			US$
Deferred income tax assets:
Write-down of inventories		2,629			1,597			242
Pre-operating expenses		119			—			—
Property, plant and equipment		300			—			—
Tax loss carryforwards		2,143			7,209			1,092

Total gross deferred income tax assets		5,191			8,806			1,334
Less: valuation allowance		(1,467	)		(2,437	)		(369	)

Net deferred income tax assets		3,724			6,369			965

Deferred income tax liabilities:
Property, plant and equipment		(186	)		(182	)		(27	)
Land use rights		(378	)		(362	)		(55	)
Intangible assets		(211	)		(178	)		(27	)
Capitalized interest expense		(1,210	)		(1,209	)		(183	)
Dividend withholding taxes for undistributed earnings of subsidiaries		(16,071	)		(19,586	)		(2,968	)

Total gross deferred income tax liabilities		(18,056	)		(21,517	)		(3,260	)

Net deferred income tax liabilities		(14,332	)		(15,148	)		(2,295	)

Classification on consolidated balance sheets:

Deferred income tax assets
—Current		3,424			6,369			965
—Non-current		300			—			—

Deferred income tax liabilities—Non-current		(18,056	)		(21,517	)		(3,260	)

The increase in the valuation allowance during the years ended December 31, 2008, 2009 and 2010 were RMB273, RMB1,194 and RMB970, respectively. The increase for each of 2009 and 2010 was mainly due to the allowance provided against deferred income tax assets of Kangpeng Nong Hua. As of December 31, 2010 and for the two years then ended, Kangpeng Nong Hua was in cumulative loss position.

As of December 31, 2010, no valuation allowance was provided against the deferred income tax assets of RMB4,772 recognized for Shanghai Qi Yue, Jiangsu Wei Er and Binhai Kangjie. Management considers the projected future taxable income in making this assessment. In order to fully utilize the deferred income tax assets, Shanghai Qi Yue, Jiangsu Wei Er and Binhai Kangjie will need to generate total future taxable income of approximately RMB4,754 and RMB23,755 prior to the expiration of the tax loss carryforwards in 2014 and 2015, respectively.

Based upon an assessment of the tax benefit of existing deductible temporary differences, the level of historical taxable income projections for future taxable income over the periods in which the deferred income tax assets are deductible or can be utilized and tax planning strategies, management believes it is more likely than not that the Group will realize the benefits of its deferred income tax assets, net of valuation allowances, as of December 31, 2009 and 2010. The amount of the deferred income tax assets considered realizable, however, could be reduced in the near term if estimates of future taxable income are reduced.

F-21

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

As of December 31, 2010, tax loss carryforwards amounted to RMB38,257 (US$5,797), of which RMB5,998 and RMB32,259 will expire if unused by the years ending December 2014 and 2015, respectively.

The Company has not provided for income taxes on accumulated earnings amounting RMB301,990 that are subject to the PRC dividend withholding tax as of December 31, 2010, since these earnings are intended to be permanently reinvested. The amount of unrecognized deferred income tax liability is approximately RMB15,100.

As of January 1, 2008 and for each of the years ended December 31, 2008, 2009 and 2010, the Group did not have any unrecognized tax benefits and accordingly no related interest and penalties have been recorded. The Group does not expect that the amount of unrecognized tax benefits will increase significantly within the next 12 months.

According to the PRC Tax Administration and Collection Law, the statute of limitation is three years if the underpayment of taxes is due to computation errors made by the taxpayer or the withholding agent. The statute of limitation is extended to five years under special circumstances, where the underpayment of taxes is more than RMB100 (US$15). In the case of transfer pricing issues, the statute of limitation is ten years. There is no statute of limitation in the case of tax evasion. Accordingly, the income tax returns of the Group’s operating subsidiaries in the PRC are open to examination by the PRC state and local tax authorities for the tax years beginning in 2005.

(10) BANK BORROWINGS


	As of December 31
	2009		2010		2010
	RMB		RMB		US$
Short-term secured bank borrowings		—		20,000		3,030

Long term secured bank borrowings, current portion		—		5,000		758

Long-term secured bank borrowings		10,000		—		—

As of December 31, 2009, the long-term bank borrowing of RMB5,000 of Shanghai Wan Su bore a weighted average interest rate at 5.13% per annum and the principal is due on December 30, 2011. Interest is payable on a quarterly basis. The long-term bank borrowing was secured by the Group’s buildings and land use rights with an aggregate carrying value of RMB22,424.

As of December 31, 2009, the long-term bank borrowing of RMB5,000 of Kangpeng Nong Hua bore a weighted average interest rate at 6.372% per annum and the principal is due on August 26, 2011. Interest is payable on a quarterly basis. The long-term bank borrowing was secured by the Group’s buildings and land use rights with an aggregate carrying value of RMB4,315. The loan was repaid in 2010.

As of December 31, 2010, the short-term bank borrowings of RMB20,000 (US$3,030) of Shanghai Wan Su bore a weighted average interest rate of 5.31% per annual and the principal is due on August 2011. Interest is payable on a quarterly basis.

As of December 31, 2010, the current portion of the long-term bank borrowings of RMB 5,000 (US$758) of Shanghai Wan Su bore a weighted average interest rate of 5.13% per annum and the principal is due on December 30, 2011. Interest is payable on a quarterly basis.

F-22

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

The above short-term and long-term bank borrowings were secured by the Group’s buildings and land use rights with an aggregate carrying value of RMB82,084 (US$12,437).

As of December 31, 2010, the Group has a credit facility amounting to RMB100,000, of which, RMB75,000 remain unused.

The bank borrowings or facilities contain no specific renewal terms or any requirement for the maintenance of financial covenants. The Group has traditionally negotiated the renewal of certain facilities shortly before they mature. However, no assurance can be made that the Group will be able to continue successfully re-negotiating the renewal of these facilities in the future.

(11) BILLS PAYABLE

As of December 31, 2010, bills payable of RMB50,929 (US$7,717) was secured by pledged bank deposits of the same amount and RMB 13,411 (US$2,032) was drawn down from the Group’s credit facility.

As of December 31, 2009, bills payable of RMB 37,919 was secured by pledged bank deposits of the same amount.

The Group has a total credit facility of RMB100,000 (US$15,152) for bills payable for which unused credit facility amounted to RMB86,589 (US$13,120) as of December 31, 2010. The Group has no credit facility for bills payable as of December 31, 2009.

(12) ACCRUED EXPENSES AND OTHER PAYABLES


	As of December 31
	2009		2010		2010
	RMB		RMB		US$
Payable for purchase of property, plant and equipment		118,174		129,323		19,595
VAT and other taxes payables		7,860		1,607		243
Accrued payroll		5,616		7,461		1,131
Receipts in advance		8,312		2,429		368
Accrued IPO costs		3,028		—		—
Payable for acquisition of noncontrolling interest in Jiangsu Wei Er		23,500		—		—
Payable for acquisition of Kangpeng Nong Hua		10,900		—		—
Others		5,876		7,418		1,124

		183,266		148,238		22,461

(13) ORDINARY SHARES

On June 24, 2009, the Company completed its IPO by issuing 379,680,000 ordinary shares, represented by 6,328,000 American Depositary Shares (“ADS”) for US$9.00 per ADS. In connection with the IPO, the Group received proceeds of US$48,228 (RMB329,432), net of related issuance costs. The ADSs are listed on the New York Stock Exchange. Each ADS represents sixty ordinary shares.

During November and December 2009, the Company repurchased 12,060,000 its ordinary shares for cash of US$1,192 (RMB8,134).

F-23

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

During September and October 2010, the Company repurchased 16,099,500 its ordinary shares for cash of US$1,637 (RMB10,953).

The repurchased shares were immediately retired in accordance with the laws of the Cayman Islands. The excess of cash consideration paid over par value of the ordinary shares was recorded as a reduction of additional paid-in capital in the consolidated statement of equity and comprehensive income for the years ended December 31, 2009 and 2010.

During 2010, 11,670,240 share options granted to executives and employees were exercised. The excess of cash consideration received over par value of the ordinary shares was recorded as an addition to additional paid-in capital in the consolidated statement of equity and comprehensive income for the year ended December 31, 2010.

(14) STATUTORY RESERVES

Under the PRC rules and regulations, the Company’s subsidiaries incorporated in the PRC are required to transfer 10% of the net profit, as determined in accordance with the relevant PRC laws and regulations, to a statutory surplus reserve annually until the reserve balance reaches 50% of the subsidiaries’ registered capital. The transfer to this reserve must be made before distribution of dividends to shareholders can be made. The statutory surplus reserve can be used to make good previous years’ losses, if any, and may be converted into share capital by the issue of new shares to shareholders in proportion to their existing share holdings or by increasing the par value of the shares currently held by the shareholders, provided that the balance of the statutory surplus reserve after such issue is not less than 25% of the registered capital.

The Company made appropriations to statutory reserves totaling RMB1,530, RMB17,585 and RMB22,398 (US$3,394), for the years ended December 31, 2008, 2009 and 2010, respectively.

(15) COMMITMENTS AND CONTINGENCIES

(a) Lease commitments

The Group has entered into operating lease agreements principally for its vehicles and certain equipment in the PRC. None of the leases includes contingent rentals. The initial terms of the lease agreements for vehicles and equipment are for one to two years.

Future minimum lease payments under non-cancellable operating leases as of December 31, 2010 are as follows:


	As of December 31, 2010
	RMB’000		USD’000
Within 1 year		331		50
1 to 2 years		75		12

		406		62

The Group’s rental expenses under operating leases amounted to RMB1,254, RMB1,518 and RMB789 (US$120) for the years ended December 31, 2008, 2009 and 2010 respectively.

F-24

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(b) Capital commitments

As of December 31, 2010, capital commitments for the purchase of property, plant and equipment approximated RMB41,956 (US$6,357).

(16) EARNINGS PER SHARE

The computation of basic and diluted earnings per share is as follows:


	Year ended December 31
	2008		2009		2010		2010
	RMB		RMB		RMB		US$
Numerator used in computing basic and diluted earnings per share		312,361		172,431		225,541		34,173

Shares (denominator):
Weighted average number of ordinary shares outstanding used in computing basic earnings per share		1,800,000,000		1,997,606,762		2,168,517,722		2,168,517,722

Plus incremental weighted average number of ordinary shares from assumed conversion of share options using the treasury stock method		2,742,035		—		1,111,634		1,111,634

Weighted average number of ordinary shares outstanding used in computing diluted earnings per share		1,802,742,035		1,997,606,762		2,169,629,356		2,169,629,356

Basic earnings per share		RMB 0.17		RMB 0.09		RMB 0.10	US$	0.02

Diluted earnings per share		RMB 0.17		RMB 0.09		RMB 0.10	US$	0.02

During the years ended December 31, 2008, 2009 and 2010, the Group’s potential dilutive shares outstanding consist of employee share options. In computing diluted earnings per share for the years ended December 31, 2008, 2009 and 2010, the dilutive effect of outstanding share options was computed by applying the treasury stock method based on the difference between the ordinary shares assumed to be issued upon the exercise of the share options and the number of shares assumed to be purchased at the average estimated fair value during the period. The Company excluded 13,652,500, 49,025,000 and 27,272,500 potential ordinary shares issuable upon exercise of employee share options in the calculation of diluted earnings per share for the year ended December 31, 2008, 2009 and 2010, as their effect would be anti-dilutive.

F-25

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(17) SHARE-BASED COMPENSATION

Share options

On January 1, 2008, the Board of Directors approved the adoption of the 2008 Share Incentive Plan (the “2008 Plan”) to provide additional incentives to the Company’s executives and employees. The Plan provides for the grant of options, restricted shares, and restricted share units. The Plan authorizes grants to purchase up to 180,000,000 ordinary shares. Share options granted become exercisable over four years. The Company is expected to issue new shares to satisfy share option exercises.

Under the 2008 Plan, the Company granted 13,555,000 unconditional share options and 13,555,000 conditional share options on January 1, 2008 and 22,700,000 unconditional share options and 900,000 conditional share options on June 30, 2008, respectively, to several of its executives and employees.

On May 7, 2010, the Board of Directors of the Company approved the grant of an aggregate of 24,497,500 unconditional share options. On the same date, the Company granted 12,277,500 unconditional share options in exchange for the 12,277,500 conditional share options previously granted under the 2008 Plan (“the Modification”). In addition, on the same date, the Company granted 12,220,000 share options to executives and employees who did not participate in the 2008 Plan.

The Modification was treated as an exchange of the original conditional share options award for the unconditional share options award at the date of modification. There was no significant difference between fair value of the new unconditional options and that of the original conditional option awards immediately before the modification.

Unconditional Share Options Awards

The unconditional share options granted in 2008 and 2010 have an exercise price of RMB0.55, vest over 4 to 5 years of continuous service, and expire in 10 years from the date of grant. The share options provide for accelerated vesting if there is a change in control (as defined in the 2008 Plan). Compensation cost is recognized over the requisite service period for each tranche based on a graded vesting schedule.

The fair value of each option award is estimated on the date of grant using a lattice option-pricing model based on the assumptions in the following table:


	For Unconditional Share Options Awards issued on January 1, 2008 and June 30, 2008		For Unconditional Share Options Awards issued on May 7, 2010
Expected volatility		35.50%~35.75%		41.69%
Expected dividend yield		1.7%		2.31%
Risk-free interest rate		4.02%~4.14%		4.15%
Expected term		10 years		10 years
Estimated fair value of underlying ordinary shares		RMB 1.70~RMB 1.77		RMB 1.03~RMB1.08

F-26

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

Prior to the IPO (since the Company did not have a trading history at the time the options were issued) and subsequent to the Company’s IPO (due to lack of sufficient historical trading record) the expected volatility was based on the historical volatilities of comparable publicly traded companies engaged in a similar industry.

The Company uses historical data to estimate employee termination within the valuation model.

Prior to the IPO, the estimated fair value of the underlying ordinary shares on each date of grant was determined by management based on a contemporaneous valuation conducted by an independent valuation firm, supplemented by the Company’s estimate of Enterprise Value (“EV”).

The Company’s EV was estimated using the discounted cash flows analysis (“income approach”). For the income approach, the Company’s terminal value projected cash flows that are based on five-year financial projections which were discounted to the respective valuation dates of January 1, 2008 and June 30, 2008 by the weighted average cost of capital (“WACC”) of 15.10% and 15.44%, respectively. The WACC used was the combined result of the changes in risk-free rate and industry average beta and company specific risks.

The estimated EV of the Company from the above calculation was then adjusted for a lack-of-marketability discount rate of 15% and 12% for the valuation date of January 1, 2008 and June 30, 2008, respectively, to reflect the fact that the Company was a private company at that time. The discounted EV was then allocated to the Company’s ordinary shares.

The fair value of the shares underlying the options on the date of grant subsequent to the IPO has been based on the closing price of the ordinary shares listed on the New York Stock Exchange for the trading day prior to the grant date.

A summary of share option activity during the years ended December 31, 2008, 2009 and 2010 is as follows:


	Number of options			Weighted average exercise price		Weighted average remaining contractual term		Aggregate intrinsic value
Outstanding as of December 31, 2007		—			—
Granted		36,255,000			RMB 0.55
Exercised		—			—
Forfeited		(632,500	)		RMB 0.55

Outstanding as of December 31, 2008		35,622,500			RMB 0.55
Granted		—			—
Exercised		—			—
Forfeited		(125,000	)		RMB 0.55

Outstanding as of December 31, 2009		35,497,500			RMB 0.55
Granted		24,497,500			RMB 0.55
Exercised		(11,670,240	)		RMB 0.55
Forfeited		(11,000,000	)		RMB 0.55

Outstanding as of December 31, 2010		37,324,760			RMB 0.55		8.57 years		RMB 10,100

Exercisable as of December 31, 2010		11,302,260			RMB 0.55		8.14 years		RMB 3,457

F-27

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

The weighted-average grant-date fair value of unconditional share options granted during the year ended December 31, 2008 and 2010 was RMB 1.24 and RMB 0.52 (US$0.08) per share, respectively. The total intrinsic value of options exercised during the year ended December 31, 2010 amounted to RMB3,186(US$ 483).

Share-based compensation under the Unconditional Share Option Awards was recorded as follows:


	As of December 31
	2008		2009		2010			2010
	RMB		RMB		RMB			US$
General and administrative expenses		10,806		11,781		(1,635	)		(248	)
Selling expenses		935		483		150			23
Research and development expenses		3,753		3,164		2,984			452

Total		15,494		15,428		1,499			227

As of December 31, 2010, there was RMB6,749 total unrecognized compensation cost related to non-vested share options under the Unconditional Share Options Awards. This cost is expected to be recognized over a weighted average period of approximately 3.5 years. RMB6,600 reversal of share-based compensation cost was recorded in 2010 in relation to forfeiture of unvested share options due to the resignation of certain employees and executives.

Conditional Share Options Awards

The Conditional Share Options Awards were granted at an exercise price equal to 88% of the fair market value of the Company’s shares on the respective vesting date. Such options vest over four years of continuous service with 25% of the options to be vested on each of the first, second, third and fourth anniversaries of the grant date and expire in 10 years. The vesting of share options under Conditional Share Options Awards is contingent upon the Group meeting revenue growth of at least 20% in the most recent fiscal year prior to each vesting date and the Group achieving a compounded annual growth rate in total revenues of at least 20% from the fiscal year 2007 through the most recent fiscal year prior to each vesting date. In addition, the Compensation Committee determines on its sole discretion that the grantee has met all employee performance criteria appropriate to merit the vesting of each tranche.

The fair value of each share option granted under the Conditional Share Options Awards was estimated on the date of grant using the same option pricing model used for share options granted under the Unconditional Share Options Awards and assumes the performance goals will be achieved. If such goals are not met, no compensation cost is recognized. The inputs used in estimating the fair value of share options granted under the Conditional Share Options Awards are the same as those noted in the table related to share options issued under the Unconditional Share Options Awards for expected volatility, expected dividends, and risk-free interest rate. The expected term for share options granted under the Conditional Share Options Awards was adjusted by an early exercise factor based on management’s estimates.

As the employees are required to provide the service to earn the award, but there has not been a mutual understanding of the terms of the award as to the exercise price until each vesting date of each tranche, the service inception date precedes the grant date. The fair value of the share option issued under Conditional Share Options Awards is remeasured at each reporting date using a lattice option-pricing model until the grant date occurs.

The Conditional Share Options Awards was cancelled by the Modification on May 7, 2010 as described above.

F-28

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

A summary of share options activity during the years ended December 31, 2008, 2009 and 2010 is as follows:


	Number of options			Weighted average exercise price		Weighted average remaining contractual term		Aggregate intrinsic value
Outstanding as of December 31, 2007		—			—
Granted		14,455,000			RMB 1.50
Exercised		—			—
Forfeited		(802,500	)		RMB 1.50

Outstanding as of December 31, 2008		13,652,500			RMB 1.50
Granted		—			—
Exercised		—			—
Forfeited		(125,000	)		RMB 1.50

Outstanding as of December 31, 2009		13,527,500			RMB 0.67
Granted		—			—
Exercised		—			—
Forfeited		(1,250,000	)		RMB0.67
Exchanged for Unconditional Share Options Awards		(12,277,500	)		RMB0.72

Outstanding and exercisable as of December 31, 2010		—			—		—		—

The weighted-average fair value of Conditional Share Options Awards granted during the year ended December 31, 2008 was RMB0.73 per share option. During the years ended December 31, 2008, 2009 and 2010, no options were exercised.

Share-based compensation under the Conditional Share Options Awards was recorded as follows:


	As of December 31
	2008		2009		2010		2010
	RMB		RMB		RMB		US$
General and administrative expenses		1,404		15		—		—
Selling expenses		275		—		—		—
Research and development expenses		744		—		—		—

Total		2,423		15		—		—

As of December 31, 2010, there was no unrecognized compensation cost related to non-vested share options under the Conditional Share Options Awards.

(18) SIGNIFICANT CONCENTRATIONS AND RISKS

All of the Group’s tangible long-lived assets are located in the PRC.

F-29

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

The Group’s revenues are derived from the following:


	Year ended December 31
	2008		2009		2010		2010
	RMB		RMB		RMB		US$
Commercialized projects		801,484		697,437		978,955		148,327
Pipeline projects		59,171		96,367		86,422		13,094
Sales of purchased goods		81,832		26,491		16,654		2,523

		942,487		820,295		1,082,031		163,944

Commercialized projects represent projects with sales of at least one metric ton per year of manufactured products while pipeline projects represent projects with sales of less than one metric ton per year of manufactured products. Sales of purchased goods represent sales of purchased chemicals to wholesalers or end users without any further processing of the chemicals.

Significant concentrations

The following summarizes the Group’s revenues, based on the geographic location of the customers:


	Year ended December 31
	2008					2009					2010
			%					%					%
	RMB		of sales			RMB		of sales			RMB		of sales			US$
PRC		483,380		51	%		362,191		44	%		523,505		49	%		79,319
Japan		165,962		18	%		233,627		28	%		337,568		31	%		51,147
Germany		231,299		25	%		160,490		20	%		164,252		15	%		24,887
United Kingdom		4,964		1	%		1,123		0	%		1,224		0	%		185
Others		56,882		5	%		62,864		8	%		55,482		5	%		8,406

		942,487		100	%		820,295		100	%		1,082,031		100	%		163,944

As a result of the Group deriving significant revenues from sales outside the PRC, the Group’s financial performance could be affected by events such as changes in foreign currency exchange rates, trade protection measures, changes in regional or worldwide economic or political conditions.

Management currently expects that the Group’s operating results will, for the foreseeable future, continue to depend on the sale of its compound chemical products to a relatively small number of customers. The Group’s business is affected by competition in the market for the products that many of the Group’s major customers sell, and any decline in their businesses could reduce purchase orders from these customers. These customers have sought, from time to time, to prospectively renegotiate the pricing terms of their current agreements with the Group or obtain more favorable terms upon renewal of the contracts. Any adverse revisions to the material terms of the Group’s agreements with its key customers could have a material adverse effect on its business and results of operations.

F-30

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

Sales to the major customers, which individually exceeded 10% of the total net revenues, are as follows:


	Year ended December 31
	2008					2009					2010
			%					%					%
	RMB		of sales			RMB		of sales			RMB		of sales			US$
Customer A		114,878		12	%		199,991		24	%		284,986		26	%		43,180
Customer B		333,128		35	%		188,710		23	%		352,597		33	%		53,424
Customer F		166,258		18	%		109,923		14	%		70,364		6	%		10,661

		614,264		65	%		498,624		61	%		707,947		65	%		107,265

Accounts receivable due from the major customers, which individually exceeded 10% of the total accounts receivable balances, are as follows:


	As of December 31
	2009					2010
			%					%
	RMB		of accounts receivable			RMB		of accounts receivable			US$
Customer A		16,854		18	%		661		1	%		100
Customer B		30,208		32	%		44,833		33	%		6,793
Customer E		12,886		14	%		14,189		10	%		2,150
Customer F		—		0	%		33,624		24	%		5,094

		59,948		64	%		93,307		68	%		14,137

Business and economic risks

The Group operates in a dynamic industry with limited operating history and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations or cash flows: advances and new trends in new technologies and industry standards; competition from other competitors; changes in certain strategic relationships or customers’ relationships; regulatory factors; the ability to obtain necessary financial and other resources at commercially viable terms; the ability to attract and retain employees necessary to support the Group’s growth and general risks associated with the industry.

The Group conducts its principal operations in the PRC and accordingly is subject to significant risks. These include risks associated with, among others, the political, economic, legal environment and social uncertainties in the PRC, government agencies’ influence over certain aspects of the Group’s operations and competition in the industry.

In addition, the ability to negotiate and implement specific business development projects in a timely and favorable manner may be impacted by political considerations unrelated to or beyond the control of the Group. Although the PRC government has been pursuing economic reform policies for the past two decades, no assurance can be given that the PRC government will continue to pursue such policies or that such policies may not be significantly altered. There is also no guarantee that the PRC government’s pursuit of economic reforms will be consistent or effective and as a result, changes in the rate or method of taxation and changes in state policies may have a negative impact on the Group’s operating results and financial position.

F-31

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(19) RELATED PARTY TRANSACTIONS


Name of party		Relationship

Dr. Yang, his wife Ms. Yuezhen Cha and his son Mr. Chongbo Yang (“the Yang Family”)		Majority shareholders

Dr. David Yunhung Tang		Principal shareholder (through June 24, 2009)

Mr. Xuhua Ren Huajing		Noncontrolling interest holder of Company

Mr. Yunxiang Wang		Noncontrolling interest holder of Binhai Kangjie (from April 15, 2009 through March 18, 2010)

Mr. Zhiyan Shen and Ms. Yunfen Fan		Noncontrolling interest holders of Kangpeng Nong Hua (from October 8, 2008 through November 9, 2009)

Mr. Wujun Yang, Mr. Yunlong Yuan, Mr. Weinian Qi and Ms. Yueping Cha		Management

Kangpeng Nong Hua		23.5% owned company by Dr. Yang (through October 8, 2008)

Kang Qi Investment Company (“Kang Qi”)		Majority shareholders’ company

Wise Lion Limited (“Wise Lion”)		Immediate holding company

Shanghai Ambiopharm Inc. (“Shanghai Ambiopharm”)		Majority shareholders’ company

Central Glass Chemspec		Affiliate

Central Glass		Controlling shareholder of Central Glass Chemspec

F-32

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

The principal related party transactions during the years ended December 31, 2008, 2009 and 2010 were as follows:


	Year ended December 31
	2008		2009		2010		2010
	RMB		RMB		RMB		US$
Sales of goods to:
Kangpeng Nong Hua		31,982		—		—		—
Central Glass		—		3,997		3,681		558

		31,982		3,997		3,681		558

Purchases of goods from:
Kangpeng Nong Hua		26,192		—		—		—

		26,192		—		—		—

Non-interest bearing advances to:
Kangpeng Nong Hua (Note (i))		28,400		—		—		—
Mr. Zhiyan Shen		2,500		—		—		—
Central Glass		—		64		—		—

		30,900		64		—		—

Non-interest bearing borrowings from:
Kangpeng Nong Hua (Note (ii))		14,400		—		—		—
Kang Qi (Note (iii))		6,000		6,000		—		—

		20,400		6,000		—		—

Jiangsu Wei Er’s non-interest bearing borrowings from:
Kangpeng Nong Hua (Note (iv))		49,347		—		—		—
Kang Qi (Note (iv))		5,000		—		—		—

		54,347		—		—		—

Kangpeng Nong Hua’s non-interest bearing borrowings from:
Kang Qi (Note (vi))		14,269		—		—		—
The Yang Family (Note (vi))		716		—		—		—
Mr. Zhiyan Shen (Note (vi))		239		—		—		—
Ms. Yunfen Fan (Note (vi))		3		—		—		—

		15,227		—		—		—

Lease income
Shanghai Ambiopharm (Note (v))		913		913		913		138

		913		913		913		138

Lease expense
Shanghai Ambiopharm (Note (v))		42		100		100		15

		42		100		100		15

Payments of expenses made on behalf of:
Shanghai Ambiopharm		—		356		277		42
Central Glass		—		336		—		—

		—		692		277		42

Payments of expenses made on behalf of the Group by:
Mr. Yunxiang Wang		—		674		—		—

		—		674		—		—

F-33

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

Amounts due from and due to related parties as of December 31, 2009 and 2010 were as follows:

(a) Prepayment and other receivables


	As of December 31
	2009		2010		2010
	RMB		RMB		US$
Shanghai Ambiopharm (Note(v))		1,960		2,000		303

		1,960		2,000		303

(b) Amounts due from related parties


	As of December 31
	2009		2010		2010
	RMB		RMB		US$
Payments made on behalf of:
Central Glass		64		—		—

		64		—		—

(c) Amounts due to related parties


	As of December 31
	2009		2010		2010
	RMB		RMB		US$
Non-interest bearing borrowings from:
The Yang Family		59		59		9
Kang Qi (Note (iii) and (vi))		9,500		5,500		833

Payable for acquisition of Kangpeng Nong Hua to:
Kang Qi		14,100		—		—

Total		23,659		5,559		842

Notes:

(i)	The Group made RMB28,400 non-interest bearing advances to Kangpeng Nong Hua to support its operating activities prior to October 8, 2008, the date Dr. Yang obtained control of Kangpeng Nong Hua (see Note 20(c)). The advances were repaid in full in May 2008.

(ii)	The borrowing was repaid in full in June 2008.

(iii)

During the years ended December 31, 2008 and 2009, the Group borrowed RMB6,000 and RMB6,000, respectively, which were non-interest bearing, from Kang Qi. The borrowings were repaid in full in April 2009.

(iv)

The Group acquired an 80% equity interest in Jiangsu Wei Er in February 2008 (See Note 20(a)). Jiangsu Wei Er borrowed RMB49,347 and RMB5,000, which were non-interest bearing, from Kangpeng Nong Hua and Kang Qi, respectively, prior to the acquisition. These non-interest bearing advances were recorded as liabilities assumed at the date of the acquisition. The advances from Kangpeng Nong Hua and Kang Qi were repaid in full as of December 31, 2008.

F-34

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(v)

The Group leased its plant and equipment to Shanghai Ambiopharm in 2008, 2009 and 2010. The carrying value of the plant and equipment amounted to RMB9,050 and RMB8,153 (US$1,235) as of December 31, 2009 and 2010, respectively. The initial lease term was two years and was renewed for an additional two-year period in June 2010. The annual lease receivable is RMB913 and Shanghai Ambiopharm paid RMB 873 in 2010.

The Group also leased certain equipment from Shanghai Ambiopharm. The initial lease term was two years starting from August 2008 and was renewed for an additional two-year period in June 2010. The annual lease payment is RMB100.

(vi)

The Group acquired 100% of the equity interest in Kangpeng Nong Hua in November 2009 for cash consideration of RMB25,000. Since the Company and Kangpeng Nong Hua were under the common control of Dr. Yang on the date of the acquisition, it was accounted for in a manner similar to a pooling-of-interests. Accordingly, the financial statements of Kangpeng Nong Hua were consolidated by the Company at their reported historical amounts and combined retrospectively to October 8, 2008, which is the earliest date that both entities were under common control (See Note 20 (c)).

Kangpeng Nong Hua borrowed RMB15,227, which were non-interest bearing, from related parties, prior to October 8, 2008. These non-interest bearing advances were recorded as liabilities assumed on October 8, 2008. RMB 2,958, RMB 2,769 and RMB 4,000 (US$ 606) was repaid in 2008, 2009 and 2010, respectively.

(20) ACQUISITIONS

(a) Acquisition of a subsidiary

On February 2, 2008, upon receiving regulatory approval, the Group completed its acquisition of an 80% equity interest in Jiangsu Wei Er from independent third parties for cash consideration of RMB4,000.

The acquisition of Jiangsu Wei Er was accounted for using the purchase method in accordance with FASB Statement No. 141, Business Combinations , (SFAS No. 141). The results of Jiangsu Wei Er’s operations have been included in the consolidated financial statements since that date. The principal activities of Jiangsu Wei Er are sales and manufacturing of chemical compounds. The excess over the fair value of the net assets acquired (goodwill) was mainly due to expected benefits from expansion of the Group’s production capacity and securing Jiangsu Wei Er’s existing product for the production of the Group’s advanced-technology new products. The goodwill is not deductible for tax purposes.

Management made estimates and judgments in determining the fair values of the assets acquired and liabilities assumed based on independent appraisal reports as well as its experience in valuation of similar assets and liabilities.

The allocation of the purchase price to 80% of the fair value of net assets of Jiangsu Wei Er on February 2, 2008 is as follows:


	RMB
Cash		5,004
Deferred income tax assets		1,181
Other current assets		11,710
Property, plant and equipment		41,509
Current liabilities		(58,334	)
Goodwill		2,930

Purchase price		4,000

F-35

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(b) Acquisition of additional equity interests in subsidiaries

Huajing Company

On March 25, 2008, Shanghai ChemSpec acquired an additional 20% equity interest in Huajing Company from the noncontrolling interest shareholder, which increased the Company’s equity interest from 60% to 80%, for cash consideration of RMB8,000. The consideration was paid in full in August 2008. The acquisition of the additional equity interests was accounted for using the purchase method in accordance with SFAS No. 141. The goodwill is not deductible for tax purposes.

Management makes estimates and judgments in determining the fair value of the assets acquired and liabilities assumed based on independent appraisal reports as well as its experience in valuation of similar assets and liabilities.

The allocation of the purchase price to 20% of the fair value of net assets of Huajing Company on March 25, 2008 is as follows:


	RMB
Cash		1,526
Other current assets		3,562
Property, plant and equipment		6,012
Current liabilities		(7,090	)
Non-current liabilities		(22	)
Goodwill		4,012

Purchase price		8,000

Jiangsu Wei Er

On November 5, 2009, the Group acquired the remaining 20% equity interest in Jiangsu Wei Er from the noncontrolling shareholder, which increased the Company’s equity interest from 80% to 100%, for cash consideration of RMB41,000. In accordance with FASB ASC Subtopic 810-10, Consolidation , which was effective for fiscal years beginning or after December 15, 2008, the excess of cash consideration over the carrying amount of the noncontrolling interest of RMB7,953 was recognized as a decrease in additional paid-in capital attributable to Chemspec International Limited shareholders in the statement of equity and comprehensive income for the year ended December 31, 2009.

Binhai Kangjie

On March 18, 2010, the Group acquired the remaining 8% equity interest in Binhai Kangjie from the noncontrolling shareholder, which increased the Company’s equity interest from 92% to 100%, for cash consideration of RMB2,800. In accordance with FASB ASC Subtopic 810-10, the excess of cash consideration over the carrying amount of the noncontrolling interest of RMB1,035 was recognized as a decrease in additional paid-in capital attributable to Chemspec International Limited shareholders in the statement of equity and comprehensive income for the year ended December 31, 2010.

F-36

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(c) Acquisition of a company under common control

On November 9, 2009, the Group acquired 100% of the equity interest of Kangpeng Nong Hua for cash consideration of RMB25,000. As Dr. Yang held more than 50% voting ownership interest of both the Company and Kangpeng Nong Hua at the date of the acquisition, it is considered a combination of entities under common control and has been accounted for in a manner similar to a pooling-of-interests. Accordingly, the financial statements of Kangpeng Nong Hua have been consolidated by the Company using their reported historical amounts and combined retrospectively to October 8, 2008, which is when Dr. Yang obtained control of Kangpeng Nong Hua by increasing his effective equity interest in Kangpeng Nong Hua to 51.7%.

The acquisition of 51.7% equity interest for consideration of RMB12,925 is recognized by reducing additional paid-in capital attributable to Chemspec International Limited shareholders by RMB8,616 and the excess of cash consideration over additional paid-in capital of RMB4,309 is recognized as a decrease to retained earnings.

In accordance with FASB ASC Subtopic 810-10, the excess of cash consideration of RMB12,075 over the carrying amount of the noncontrolling interest of RMB4,940 was recognized as a decrease to additional paid-in capital attributable to Chemspec International Limited shareholders in the consolidated statement of equity and comprehensive income for the year ended December 31, 2009.

(d) Changes in Chemspec International Limited’s ownership in subsidiaries

Effect of the changes in the Company’s ownership interest in its subsidiaries in net income attributable to Chemspec International Limited shareholders is as follows:


	Year ended December 31
	2008		2009			2010			2010
	RMB		RMB			RMB			US$
Net income attributable to Chemspec
International Limited Shareholders		312,361		172,431			225,541			34,173

Transfer to the noncontrolling interests

Decrease in Chemspec International Limited’s additional paid-in capital for purchase of:
—20% equity interest in Huajing Company		—		—			—			—
—20% equity interest in Jiangsu Wei Er		—		(33,047	)		—			—
—48.3% equity interest in Kangpeng Nong Hua		—		(7,135	)		—			—
—8% equity interest in Binhai Kangjie		—		—			(1,765	)		(267	)

Change from net income attributable to Chemspec International Limited shareholders and transfers to noncontrolling interests		312,361		132,249			223,776			33,906

(21) DIVIDENDS

Year ended December 31

2008

2009

2010

RMB

US$

Dividends declared by:

—the Company

—

44,460

6,735

Dividends per share

—

RMB 0.02

US$

0.00

F-37

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

Pursuant to a Board of Directors’ resolution passed dividends of USD$6,514 (RMB44,460) were declared and paid by the Company to its shareholders on March 7, 2010 and April 21, 2010, respectively.

(22) FINANCIAL INSTRUMENTS

The fair values of cash, pledged bank deposits, accounts receivable and payable, other receivables and payables, bills receivable and payable, short-term bank borrowings, and amounts due from/to related parties approximate their respective carrying amounts due to their short-term nature.

The following table summarizes the carrying amounts and the estimated fair values of the Group’s long-term bank borrowings:

December 31

2009

2010

Carrying
Amount

Fair
value

Carrying
amount

Fair
values

RMB

Long-term bank borrowings

10,000

9,978

5,000

4,944

(23) CHEMSPEC INTERNATIONAL LIMITED (PARENT COMPANY)

Relevant PRC laws and regulation permit the distribution of dividends by the Group’s PRC subsidiaries only out of their retained earnings, if any, as determined in accordance with the PRC accounting standards and regulations.

As a result of these PRC laws and regulations, the Group’s PRC subsidiaries are restricted in their abilities to distribute an aggregate amount of RMB670,400 (US$101,576) of their net assets to the Company, either in the form of dividends, loans or advances. Such amount consists of paid-up capital and statutory reserves as of December 31, 2010.

F-38

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

The following presents condensed parent company only financial information of Chemspec International Limited under U.S. GAAP as of December 31, 2009 and 2010 and the three-year periods ended December 31, 2010.

Condensed balance sheets as of December 31, 2009 and 2010


	As of December 31
	2009			2010			2010
	RMB			RMB			US$
Cash		103,070			17,104			2,592
Prepayment and other receivables		—			2,395			363
Amounts due from subsidiaries		237,883			256,410			38,849

Total current assets		340,953			275,909			41,804
Investment in subsidiaries		864,879			1,093,568			165,692

Total assets		1,205,832			1,369,477			207,496

Accrued expenses and other payables		3,028			—			—
Amounts due to subsidiaries		16,552			8,655			1,311

Total liabilities		19,580			8,655			1,311
Ordinary shares		21,686			21,649			3,280
Additional paid-in capital		364,098			360,995			54,696
Statutory reserves		63,422			85,820			13,003
Accumulated other comprehensive loss		(4,554	)		(9,610	)		(1,456	)
Retained earnings		741,600			901,968			136,662

Total shareholders’ equity		1,186,252			1,360,822			206,185

Total liabilities and shareholders’ equity		1,205,832			1,369,477			207,496

Condensed statements of income for the years ended December 31, 2008, 2009 and 2010


	Year ended December 31
	2008			2009			2010			2010
	RMB			RMB			RMB			US$
Selling expenses		(1,210	)		(483	)		(152	)		(23	)
General and administrative expenses		(12,211	)		(11,796	)		1,636			248
Research and development expenses		(4,496	)		(3,164	)		(2,983	)		(452	)
Interest income		—			75			36			5
Equity in earnings of the subsidiaries		330,278			187,799			227,004			34,395

Net income		312,361			172,431			225,541			34,173

F-39

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

Condensed cash flows for the years ended December 31, 2008, 2009 and 2010


	Year ended December 31
	2008			2009			2010			2010
	RMB			RMB			RMB			US$
Cash flows from operating activities
Net income		312,361			172,431			225,541			34,173
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Share-based compensation		17,917			15,443			1,499			227
Equity in earnings of the subsidiaries		(330,278	)		(187,799	)		(227,004	)		(34,395	)
Prepayment and other receivables		—			—			(2,395	)		(362	)

Net cash provided by (used in) operating activities		—			75			(2,359	)		(357	)

Cash flows from investing activities
Non-interest bearing advances to subsidiaries		—			(237,883	)		(22,998	)		(3,485	)

Net cash used in investing activities		—			(237,883	)		(22,998	)		(3,485	)

Cash flows from financing activities
Dividends paid		—			—			(44,460	)		(6,736	)
Proceeds from issuance of ordinary shares upon IPO		—			389,022			—			—
Issuance costs for ordinary shares upon IPO		—			(40,010	)		(3,028	)		(459	)
Proceeds from exercise of shares options		—			—			6,178			936
Repurchase of ordinary shares		—			(8,134	)		(10,953	)		(1,660	)
Repayment of non-interest bearing borrowings from subsidiaries		—			—			(7,761	)		(1,176	)

Net cash provided by (used in) financing activities		—			340,878			(60,024	)		(9,095	)

Effect of foreign currency exchange rate changes on cash		—			—			(585	)		(80	)

Net increase (decrease) in cash		—			103,070			(85,966	)		(13,025	)
Cash at beginning of year		—			—			103,070			15,617

Cash at end of year		—			103,070			17,104			2,592

(24) SUBSEQUENT EVENTS

(a) Going-private transactions

On March 21, 2011, the Company’s Board of Directors approved an agreement of merger with Halogen Mergersub Limited (“Mergersub”), a Cayman Islands exempted company which is jointly controlled by Dr. Yang and Primavera Capital Management Ltd. in response to the going private proposal letter issued by Dr. Yang on November 11, 2010. Under the terms of the agreement, Mergersub will be merged with and into the Company, with the Company being the surviving company and each ordinary share of the Company issued and outstanding immediately prior to the effective time of the merger will be cancelled in exchange for the right to receive US$0.135 (or US$ 8.1 per ADS) in cash without interest (less $0.05 per ADS cancellation fees payable to the ADS depositary), except for the ordinary shares beneficially owned by Dr. Yang, Mr. Yunlong Yuan and Mr. Weinian Qi, which will be cancelled without receiving any consideration. In addition, pursuant to the agreement of merger, the Company needs to comply with a number of covenants, and any breach of these covenants will result in termination of the agreement and the Company paying a termination fee of US$3,000 (RMB equivalent 19,800).

F-40

CHEMSPEC INTERNATIONAL LIMITED AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS—(CONTINUED)

(Amounts expressed in thousands, except share and per share data)

(b) Japan Earthquake and Tsunami in March 2011

On March 11, 2011, an earthquake with a magnitude of 9.0 occurred in Japan. The earthquake was followed by a tsunami which damaged multiple nuclear reactors at the Fukushima Daiichi Nuclear Power Station. These events have not had any impact on the Company’s consolidated financial statements for the year ended December 31, 2010. During the year ended December 31, 2008, 2009 and 2010, the Group’s sales to customers in Japan accounted for 18%, 28% and 31%, respectively, of the Group’s revenue. The Group currently does not have any physical presence in Japan. To date, the Group has not experienced any significant delay in customer orders or cash collection difficulties with its customers as a result of these March 11, 2011 events.

F-41

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Citigroup Prfd C (CPC) News

CPC Citigroup Prfd C

- Annual and Transition Report (foreign private issuer) (20-F)

20/06/2011 11:08am

Edgar (US Regulatory)